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Abstract 
Aims: Current treatment of colorectal cancer (CRC) liver metastases has a success 
rate of 50% 5-year survival, and recurrence rates of 50%. There is therefore still a 
need for a novel treatment modality. We aimed to examine the ability of JX-594 to 
preferentially replicate in and kill CRLM in vitro and ex vivo, and induce immune-
mediated tumour cytotoxicity by activation of natural killer (NK) cells. 
 
Methods: The Wyeth strain of vaccinia virus has been genetically manipulated to 
encode for granulocyte macrophage colony stimulating factor (JX-594-GM-CSF-
fLuc) and green fluorescent protein (JX-594-GM-CSF-GFP) in the disrupted 
thymidine kinase locus. Viability assays and Enzyme Linked Immunoabsorbent 
Assay (ELISA) was used to confirm tumour cell killing and production of 
inflammatory cytokines when CRC cell lines were infected with JX-594. Viral 
replication in vitro was investigated by plaque assay and using an ex vivo ‘tissue 
core’ method. Induction of the innate immune response was measured by 
upregulation of activatory markers on virus-treated-NK cells and monocytes by flow 
cytometry and anti-tumour cytotoxicity by chromium release.  
 
Results: JX-594 can directly lyse CRC cell lines, with greater lysis and replication 
(up to 250-fold) in cells with upregulated surface EGFR. JX-594 treatment resulted 
in substantial expression of GM-CSF and induction of inflammatory cytokines within 
the tumour microenvironment, and inhibition of anti-inflammatory and pro-
angiogenic cytokines. Ex vivo infection of CRLM with JX-594-GFP-GM-CSF 
resulted in tumour-specific GFP and GM-CSF expression. Treatment of NK cells 
with JX-594-GM-CSF led to activation, degranulation and increased cytotoxicity 
- v - 
against CRC cell targets. This was dependent on the presence of CD14+ve 
monocytes, which acquired an antigen-presenting phenotype 
(CD86+veCD11c+veClassIIDR+ve).  
 
Conclusions: JX-594 holds promise as a novel treatment modality for 
disseminated CRC. Direct tumour-specific lysis and transgene expression and the 
induction of tumour-specific innate immunity means that it may provide a two-
pronged attack against tumour cells whilst sparing normal tissue.  
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1 Introduction 
1.1 Cancer: Impact, tumourigenesis and interaction with the 
immune system 
1.1.1 Cancer: Impact of the disease 
Cancer is defined as a disease in which abnormal cells divide uncontrollably and 
spread. In the UK in 2009, there were 156,090 deaths from cancer. 28% of all 
deaths in the UK in 2007-2009 were due to cancer, which was higher than both 
coronary heart disease (by 69,000 deaths) and stroke (by 104,000 deaths) [1].  
 
1.1.2 Liver cancer 
1.1.2.1 Colorectal liver metastasis 
Colorectal cancer (CRC) is the third most common cancer in England; 13.6% of all 
registered cancer diagnoses in men and 11% in women, and 16,000 people die 
from colorectal cancer in the United Kingdom (UK) annually [2].  World-wide, an 
estimated 1.24 million new cases of colorectal carcinoma were diagnosed in 2008 
[3]. About 65% of all patients with CRC develop distant metastasis, the liver being 
the most common site (40%). Liver resection is the only modality shown to 
convincingly cure colorectal liver metastasis (CRLM), although newer ablative 
treatments are showing promise. Currently, due to newer surgical techniques [4] 
and imaging modalities and the introduction of more effective cytotoxic 
chemotherapy agents, the accepted 5-year survival rate is 50% [5] [6]. Although 
surgery remains the mainstay of potentially curative therapy, the role of systemic 
neo-adjuvant chemotherapy is increasing, with 5-fluorouracil (5-FU) plus leucovorin 
(LV) in combination with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) reported to 
facilitate resection rates of 9%-40% in initially unresectable disease [7]. A targeted 
- 3 - 
antibody with additional immunomodulatory properties, Cetuximab, is undergoing a 
major randomised trial in the UK. Cetuximab is a chimeric (mouse/human) 
monoclonal antibody that functions as an epidermal growth factor receptor (EGFR) 
inhibitor, in patients with Kirsten rat sarcoma (Kras) wild-type disease. The New 
EPOC trial (ISRCTN: 22944367) is a neo-adjuvant trial investigating the survival 
benefit of the addition of Cetuximab to standard chemotherapy regimes. 
 
1.1.2.2 Primary liver cancer (Hepatocellular carcinoma- HCC) 
HCC is within the top twenty most common cancers in the UK (18th). In 2009, 3,960 
people in the UK were diagnosed with liver cancer and in 2010 there were 3,789 
deaths from HCC. Almost two-thirds of cases of liver cancer occur in men [8]. 
Therapeutic options available include liver transplantation, surgical resection and 
local ablative therapies, but the prognosis of HCC remains poor due to high tumor 
recurrence rates. 50-80% of HCC express alpha-feto protein (AFP), and it is used 
as a marker for tumour diagnosis and follow-up. 
 
1.1.3 Mutation and tumourigenesis 
Cancer-causing agents can be broadly categorized into: oncogenic viruses, 
chemicals, and radiation. Oncogenic DNA viruses including Human Papilloma Virus 
(HPV), Epstein-Barr Virus (EBV), and Hepatitis B Virus (HBV) can integrate their 
DNA into the genome of the host, replicating and producing proteins that enable the 
virus to hijack the DNA synthesis machinery of the host cell. Two of these viral 
genes, E6 and E7, have the ability to act as oncogenes, and their encoded proteins 
can bind to two important tumour suppressor genes, p53 and retinoblastoma (RB) 
[9]. Only one human retrovirus, the human T-cell leukemia virus type I (HTLV-I), is 
linked to a human tumour (T-cell leukemia/lymphoma). Carcinogenic chemicals 
(mutagens) such as nitrogen mustard, benzoyl chloride, polycyclic aromatic 
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hydrocarbons etc. can target proto-oncogenes and tumour suppressor genes. 
Radiation with Ultraviolet-B (UV-B) rays have been linked to basal-cell carcinoma, 
squamous-cell carcinoma, and malignant melanoma of the skin. Ionising radiation 
has also been linked with tumourigenesis. Dramatic evidence of this has been seen 
in the consequences of atomic explosions in Japan at Hiroshima and Nagasaki in 
1945.  
 
During tumourigenesis, the cell becomes damaged due to a variety of mechanisms. 
These genetic and epigenetic changes participate in oncogenic intracellular 
pathways that promote proliferation and dissemination. Hanahan and Weinberg 
described classic hallmarks of cancer; self-sufficiency in growth signals, insensitivity 
to anti-growth signals, evading apoptosis, limitless replication potential, sustained 
angiogenesis, tissue invasion and metastasis [10, 11]. Several other hallmarks 
have been described; genetic instability, evasion of cell senescence, epigenetic 
alterations of cancer related-genes, RNA interference alterations in the expression 
of cancer related-genes, changes in glucose and glutamine metabolism, 
participation of cancer stem cells in cellular proliferation, stromal cell participation in 
the tumour's micro-environment, and changes in antigenic presentation and 
immunosuppression due to cytokines in the tumour's micro-environment [12]. 
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1.1.4 Cancer and the immune system 
1.1.4.1 The immune system 
The immune system serves to defend against infection, and consists of two 
fundamentally different arms. The innate response, which is the ‘first line defence’ 
against invading pathogens, is generally a non-specific response, and results in 
‘inflammation’ at the site of the pathogen regulated by a system of cytokines, 
prostaglandins, leukotrienes and complement proteins. The cellular component of 
the innate immune system comprises  phagocytes (macrophages, neutrophils, and 
dendritic cells), cells that release inflammatory mediators (mast cells, eosinophils, 
basophils), natural killer (NK) cells, NK-T cells and γδT cells [13]. NK cells contain 
cytotoxic granules contained in lysosymes that express perforin, which when 
binding to surface of tumour cells, make them permeable to the contained cytotoxic 
granules. NK cells are discussed in more detail in chapter 5. 
 
The adaptive (or acquired) immune response comes into play following an initial 
innate response, and creates immunological memory, leading to an enhanced 
response to subsequent encounters with that same pathogenic antigen. This 
process forms the basis of vaccination, whereby a low volume pathogenic trigger 
can lead to long lasting immunity. Cells of the adaptive immune response are 
specialised leukocytes, called lymphocytes. Derived from the hematopoietic stem 
cells in the bone marrow, the B cells (humoral response) and thymus-derived T 
cells (cell-mediated response) are the major types of lymphocyte. T cells are 
antigen-specific and proliferate in response to presentation of an antigen to the 
surface receptors of these cells by antigen-presenting cells (APC) such as dendritic 
cells (DC). This process occurs in secondary lymphoid tissue such as the lymph 
nodes and spleen [14]. 
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1.1.4.2 Immune cell ‘crosstalk’ 
A symbiotic relationship between NK cells and DCs has been demonstrated in 
recent years, both in the periphery and in lymphoid organs. Myeloid DCs support 
innate immunity by promoting the production of cytokines and enhancing the 
cytotoxicity of NK cells. In reply, NK cells also play immunoregulatory ‘helper’ 
functions and activate DCs, enhancing their ability to produce pro-inflammatory 
cytokines. NK cells also play a key role in polarizing a T helper (Th1) i.e. cytotoxic T 
lymphocyte (CTL), rather than antibody (Th2) response [15].  
 
1.1.4.3 Tumour associated antigens 
Many studies have demonstrated that cancer sera contain antibodies, which react 
with a unique group of autologous cellular antigens generally known as tumour-
associated antigens (TAAs). TAAs can be classified into 1) products of mutated 
oncogenes and tumor suppressor genes and 2) products of other mutated genes 
(e.g. oncogenic viral antigens, overexpressed/aberrantly expressed cellular 
proteins, oncofetal antigens and altered cell surface glycolipids and glycoproteins). 
By definition, these have to be produced by the tumour and not by the normal 
tissue. TAAs not only function as candidates for diagnostic tests, but also act as 
potential new targets for therapeutic intervention [16]. 
 
1.1.4.4 Tumour associated antigens in colorectal cancer 
In CRC, the most commonly identified TAA is Carcino-embryogenic antigen (CEA). 
Gold and Freedman [17] demonstrated the presence of antibodies to a component 
present in colonic cancer tumour when rabbits were immunised with an extract of 
the tumour. This was not observed in normal adult colon, but was present in the 
human gastrointestinal tract during embryogenesis, hence the term ‘Carcino-
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embryogenic antigen.’ This is a complex glycoprotein that is found in 50-80% of 
CRCs, and is used clinically for diagnosis and follow-up, but as it is not expressed 
in the early stages, its application in screening is limited.  
 
Using a TAA mini-array system, Liu et al. have identified several other TAAs in 
early CRC, including Imp1, p62, Koc, p53 and c-myc. Titres were significantly 
higher in sera of CRC patients versus healthy donors. Despite the high specificity, 
their clinical application may be hindered by poor sensitivity [18]. Babel et al. 
identified five further immunoreactive antigens in sera from patients with CRC; 
PIM1, MAPKAPK3, STK4, SRC, and FGFR4. Increased expression of these 
antigens was confirmed in CRC cell lines and colonic mucosa [19].  
 
Vascular Endothelial Growth Factor (VEGF) is involved in the growth and 
development of colorectal cancer. VEGF is expressed  at higher levels in tumors 
than in distant mucosa [20] and is correlated with poor prognosis [21]. Although not 
classically regarded as a TAA, anti-VEGF therapy (Avastin; bevacizumab) has 
played a role in the treatment of CRC [22]. Similarly, EGFR inhibitors such as 
cetuximab and panitumumab have recently shown activity in patients with CRLM 
whose tumors have wild-type Kras [23]. 
 
1.1.4.5 Tumour associated antigens in hepatocellular carcinoma 
Several vaccination strategies based on AFP as a TAA have been investigated for 
HCC immunotherapy. AFP-specific vaccination can significantly impair the growth 
of an autochthonous HCC [24]. In two conducted clinical trials, AFP-specific CTLs 
have been detected in blood after AFP peptide administration, however, this has 
not been correlated with an objective clinical response [25]. More recently, 
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vaccination using a Modified Vaccinia virus Ankara (MVA) which expressed 
membrane-bound AFP, induced a CD8+ T-cell response and elicited the production 
of AFP-specific antibodies. This was more effective than the secreted and 
intracellular versions of the AFP, hence concluding that the system of TAA delivery 
as a membrane-bound antigen induced a more effective response [26].  
 
1.1.4.6 The danger hypothesis 
Although the classical hypothesis of antigenic recognition of ‘self’ versus ‘non-self’ 
is well established, there are a number of phenomena which cannot be explained 
by this hypothesis. Matzinger proposed that “danger” signals are crucial to the 
generation of an effective immune response. This danger signal may be 
represented by pathogens, including viruses, and therefore oncolytic virotherapy 
might provide a potent immunological trigger; not only by releasing TAAs by tumour 
lysis, but also through a ‘danger signal’  [27].  
 
A range of danger signals has been proposed. Interestingly, Zhang et al. described 
the recognition of mitochondria as bacterial pathogens by the immune system; 
explained by the theory that these organelles are in fact ‘evolutionised’ bacteria. 
Thus, once released from the cell in abnormal conditions, they can initiate a 
‘danger’ response [28]. Mitochondria exemplify an inherent characteristic of a 
danger signal as they are not present extra-cellularly in normal physiological 
conditions. These intracellular danger signals are described as damage-associated 
molecular patterns (DAMPs) and they include other molecules such as adenosine 
tri-phosphate (ATP), nucleic acids, heat shock proteins (eg Hsp70), HMGB-1, S100 
calcium binding proteins, and the cytokine Interleukin (IL)- 1a. 
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Alternatively, danger signals may be pathogen-associated molecular patterns 
(PAMPs). These molecules are associated with pathogens, that are recognized by 
cells of the innate immune system by Toll-like receptors (TLRs) and other pattern 
recognition receptors (PRRs) such as helicase RIG-I. Both TLRs and helicase RIG-I 
are the major PRRs implicated in response to viral PAMPs. Bacterial 
Lipopolysaccharide (LPS), is a prime example of a PAMP; it is an endotoxin found 
on the cell membrane of a bacterium, recognised by TLR 4 [29]. 
 
1.1.4.7 The immunesurveillance hypothesis 
A theory proposed by Burnet in 1957 [30], hypothesised that immune cells 
constantly surveyed host tissue and could identify and destroy abnormal cells due 
to recognition of abnormal antigens on their  cell surface. Sceptics argued that the 
immune system would fail to recognise tumours due to antigenic similarity, and that 
tumours may still develop in immune-competent individuals. The 
immunosurveillance hypothesis was further challenged by the observation of a lack 
of increased tumour incidence in nude, athymic mice [31]. However, new studies in 
the 1990s explained this phenomenon by the demonstration of increased 
development of malignancy in NK-cell deficient mice [31-33]. Further studies have 
shown that deficiencies in Interferon (IFN)-γ and perforin increased susceptibility to 
both chemically induced and spontaneous tumours [34].  
 
1.1.4.8 The immuoediting hypothesis  
It eventually became recognised that immunosurveillance represents only part of 
the anti-tumour immunological response, hence the emergence of the 
‘Immuoediting Hypothesis.’ Cancer immunoediting is a process consisting of three 
phases; ‘Elimination’ (cancer immunosurveillance), ‘Equilibrium’ and ‘Escape’. The 
concept of elimination is similar to the classical theories of immunosurveillance, 
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initiated by a danger signal from the tumour, as described above [27]. Equilibrium is 
a period of ‘status quo’ whereby some surviving tumour cells at the end of the 
elimination phase go into a period of dormancy, which may be quite protracted [33]. 
This is exemplified by the demonstration of transmission of cancer from organ 
donors thought to be tumour-free for many years at the time of donation [35]. At this 
stage, the tumour cells could eventually be eradicated by the immune system, may 
remain permanently in the dormant phase, or undergo continued transformation 
and enter the ‘Escape’ phase. These escaping tumours represent naturally selected 
tumour variants that are less immunogenic. 
 
1.1.4.9 Evasion of the immune system 
The development of tumours may be seen as a failure of immunosurveillance; the 
continued mutagenic process in even the most immunogenic tumours may 
eventually overcome the immune system’s capacity. However, not all tumour cells 
are immunogenic, and thus do not initiate an immune response. This can be 
explained by several mechanisms. For example, there may be abnormal or 
disordered expression of cell surface proteins; the process of major 
histocompatibility class (MHC) I downregulation by tumours (which can reduce 
sensitivity to cytotoxic T cell-mediated lysis [36]); impaired binding of perforin [37]; 
and the downregulation of cytotoxic pathways such as the Fas and TRAIL (tumour 
necrosis factor-related apoptosis-inducing ligand), both of which have been 
implicated in cancer immune-therapy [38]. Tumour-derived Fas-ligand (FasL) may 
lead to the active killing of Fas-sensitive tumour-infiltrating lymphocytes (TILs) and 
metastatic colorectal cancer shows high levels of FasL expression [39, 40]. The 
evasion of innate attack by NK cells may be mediated by an increase of NK ligands 
in the tumour microenvironment. It has been observed in a wide variety of tumours 
that NKG2D-mediated (an activatory receptor on NK cells) tumour 
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immunosurveillance may be subverted the release of NKG2D ligands (NKG2DL) by 
the tumour [41].  
 
Another factor may be the solid nature of the tumour which may circumvent 
detection by T lymphocytes. It was observed in a sarcoma model that a single-cell 
suspension injected subcutaneously induced a strong cytotoxic T-Lymphocyte 
response, however the same tumour transferred as a solid fragment did not [42]. 
 
It must also be recognised that tumour cells arise from a body’s own tissue, and 
hence express ‘self’ antigens to which T-cells are tolerised, either centrally (in the 
thymus) or peripherally . Evidence suggests that the mechanisms of tolerance, by 
which the body prevents autoimmune disease, may lead to reduced anti-tumour 
immunity [43].  
 
1.1.4.10 Immunodeficiency  
An interesting demonstration of the protective role of the immune system lies in 
patients with immunodeficiency. Whether due to the acquired immune deficiency 
syndrome (AIDS) or iatrogenic immunosuppression in the immunosuppressed 
transplant patient,  there is a higher incidence of virus-associated cancer (Burkitt’s 
lymphoma; EBV), skin (Squamous-cell and Basal-cell carcinoma) and other 
cancers [44, 45]. 
 
1.1.4.11 Inflammation and cancer; “wounds that do not heal” 
Infection with a pathogen triggers an acute inflammatory response, which is 
mediated by the complement cascade, triggering the release of histamine and thus 
increased vascular permeability. Coupled with the up-regulation of adhesion 
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molecules on vascular endothelium and inflammatory mediators such as 
prostaglandins, leukotrienes and chemokines, inflammatory cells are recruited into 
the infected tissue. Injury, trauma or infection can initiate a systemic inflammatory 
response syndrome (SIRS).  
 
A paradox exists when discussing the role of inflammation in tumorigenesis. 
Virchow first observed the presence of leukocytes within tumours in the 19th century 
[46]. It is now accepted that an inflammatory microenvironment is an essential 
component of all tumours and that many somatic mutations leading to cancer are 
caused by chronic disease (obesity), pathogens (e.g. Helicobacter Pylori) and 
chemicals (e.g. tobacco) which can promote chronic inflammation. Once the tumour 
has developed, certain oncogenes can induce a pro-inflammatory tumour 
environment by expression of tumour-promoting chemokines and cytokines. In the 
case of HCC, IL-6 has been found to be a critical tumour-promoting cytokine [47]. 
As the tumour grows beyond its nutrient supply, the resulting necrosis can influence 
further pro-inflammatory mediators [46]. Dvorak et al. thus described tumours as 
‘wounds that do not heal’ [48]. 
 
Inflammation may serve to influence the host immune response. During 
chemotherapy, the ensuing inflammation due to induced necrotic death of cancer 
cells can lead to the production of DAMPs and can stimulate antigen presentation 
by tumour-infiltrating dendritic cells, which collectively can stimulate an anti-tumour 
response [46]. However, chemotherapy-induced anti-tumour immunity is only seen 
with certain agents (e.g. Oxaliplatin) [49]. Modulating this inflammatory response 
may be used to augment conventional chemotherapy [50].  
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1.1.4.12 Cancer immunotherapy 
The first report of cancer immunotherapy was William Coley’s description of using a 
bacterial infection to treat sarcomas in the 1890s, which he termed ‘Coley’s toxin’ 
[51]. His vaccine consisted of a combination of Streptococcus Pyogenes and 
Serratia Marcescens [52]. Coley asserted that induction of a fever was key to the 
success of his treatment, and in subsequent years it was demonstrated that fever is 
accompanied by enhanced leucocyte proliferation, maturation, and activation [53]. 
The description of microbial preparations used by William Coley has led to modern-
day therapies, and the Bacillus Calmette-Guerin (BCG) vaccine is a well-
established treatment used successfully in the treatment of superficial bladder 
cancer [54]. Although BCG therapy is not meant to induce a fever, but to cause a 
local cytokine storm with repeated administrations. 
 
The essence of cancer immunotherapy is the recruitment of the host’s immune 
system to identify and kill tumour cells, leading to a long-term memory response, 
preventing future recurrence. Immunotherapy strategies include antitumor 
monoclonal antibodies, cancer vaccines, adoptive transfer of ex vivo activated T 
cells and NK cells, and administration of antibodies or recombinant proteins that 
either co-stimulate immune cells or block immune inhibitory pathways. Unlike 
conventional cancer therapies, most immunotherapies are active and dynamic, 
capable of inducing immune memory [55].  
 
The potential use of OV to stimulate anti-tumour immunity is an interesting strategy 
as they have a direct cytotoxic effect along with the ability to activate host immunity, 
by exposure of TAA, induction of danger signals, and eventual recognition by 
immune effecter cells. Antitumoural immune responses may dictate the long-term 
therapeutic success of cancer treatment. 
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1.2 Oncolytic Viruses 
1.2.1 The evolution of oncolytic viruses 
Cancer therapy prior to the early twentieth century had only one modality, surgery, 
which only evolved following the advent of anaesthesia in 1846. Radiotherapy 
eventually contributed, once Roentgen discovered X-rays in 1895 [56]. 
Chemotherapy gained prominence after the introduction of aminopterin, a folic acid 
antagonist, by Farber et al [57]. Despite these advancements, we are still to find an 
absolute cure. The need for oncolytic viruses stems from the requirement for a 
novel mechanism of action that would not be cross-resistant with established 
therapy and would be effective in apoptosis-blocked cells. The first approval of an 
oncolytic virus was in November 2005, granted by Chinese regulators, for H101, a 
genetically modified adenovirus [58]. Prior to this, viruses had been pursued as 
anti-tumour therapy for a hundred years, however enthusiasm diminished, but has 
recently been revived over the past two decades [59].  
 
Biochemical analysis of viruses only progressed after the invention of the plaque 
assay in 1917, and it was only towards the end of the 20th century that viruses were 
employed for cancer therapy. Evolution has armed viruses with the ability to infect, 
replicate within and eventually lyse cells and consequently spread through tissues. 
Since the 1800s, there have been reports of transient cancer remissions following 
an episode of viral illness [59], and this led to further interest in the use of viruses 
as potential therapeutic agents [60]. In 1896, Dock described remission of 
“myelogenous leukaemia” after what was described as influenza infection – 
although this was years before the discovery that influenza was a virally-mediated 
disease [61]. In 1949, a clinical trial was undertaken in which 22 patients with 
Hodgkin’s disease were given sera and tissue samples from patients infected with 
the hepatitis virus [62]. In the UK, glandular fever serum was used for treatment of 
- 15 - 
acute leukaemia [63]. In 1974, Asada et al. used non-attenuated mumps virus in 
Japan to treat eighteen different types of tumour via various routes; intravenous, 
oral, per-rectal, topical and nasal inhalation [64]. This was perhaps a significant trial 
as 37 of 90 patients had complete tumour regression following therapy.       
 
Harnessing these viral characteristics/mechanisms for therapeutic potential was 
faced with one major challenge however; harm to normal cells alongside tumour 
cell destruction. Oncolytic viruses (OV) have the ability to specifically infect cancer 
cells and replicate within them. They can subsequently lyse these cells and spread 
to adjacent cancer [65-69]. They can also be targeted to cancer cells with activated 
genetic pathways and/or loss of tumour suppressor function [70]. OVs can induce 
activation of tumour-specific immune effector cells and be “armed” by expression of 
therapeutic transgene products [71]. These characteristics can be used to bypass 
some of the limitations of non-replicating viral therapeutics.  
 
Reovirus, for example, is a first-generation oncolytic virus, and has been 
extensively tested in clinical trials. Although it is safe and selective for cancer, little 
therapeutic potency has yet been observed in humans either through an 
intratumoural (IT) or intravenous (IV) delivery.  With the limitations of OV such as 
reovirus, new therapeutic agents with better anticancer properties, delivery and 
systemic spread are required. Poxviruses, such as vaccinia, were selected and 
armed with a gene encoding granulocyte-macrophage colony-stimulating factor 
(GM-CSF), to stimulate anti-tumoural immunity. Preclinical [72-75] and clinical [76, 
77] testing has shown these agents to be tumour selective and have a high degree 
of systemic efficacy. 
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1.2.2 Where did it all start: Smallpox 
The Poxviridae family is an enveloped double-stranded DNA virus, of which the 
orthopoxvirus subfamily includes vaccinia [78]. This family of viruses has notorious 
and impressive ancestry: the eradication of smallpox [79]. Anecdotes of inoculation 
against smallpox in China date back to the late 10th century. The procedure, 
infection with a variola virus, was widely practiced by the 16th century, during the 
Ming Dynasty [80]. In 1796 Dr Edward Jenner, in Berkeley, Gloucestershire, 
discovered that inoculating a person with material from a cowpox lesion could 
induce immunity to smallpox. Cowpox is a poxvirus in the same family as variola. 
He called this material ‘vaccine’, from the Latin root word vacca, (cow). This was a 
safer procedure than the Chinese method of variolation, which involved a risk of 
smallpox transmission. Vaccination was soon practiced all over the world. During 
the 19th century, the cowpox virus used for smallpox vaccination was replaced by 
vaccinia virus [81]. In 1922, it was discovered that the smallpox vaccine could 
inhibit the growth of tumours in mice and rats [59]. 
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1.3 Vaccinia Virus 
1.3.1 Viral structure, replication and life cycle 
Vaccinia is an enveloped, brick-shaped virion, which measures 250nm by 200nm, 
and has a 192-kb double-stranded DNA genome encoding over 200 polypeptides, 
of which approximately half are incorporated into virus particles. The unique 
characteristic of poxviruses is that the entire life cycle (transcription, genome 
replication, and virus assembly), occurs in the cytoplasm of the host cell. The large 
viral genome encodes for virtually all the enzymes required for these processes.  
The virus attaches to glycosaminoglycans (GAGs) on the host cell wall, and can 
either undergo membrane fusion or macropinocytosis. Membrane fusion leads to 
the release of the virus core into the cytoplasm. In some occasions, the fusion of 
the viral and host cell membranes triggers endocytosis and vesicular transport. 
Maturation of the transporting endosome eventually leads to fusion between 
endosome and virus membrane [82]. In the ‘early phase’ of replication, which 
begins 30 minutes post infection, early genes are transcribed in the cytoplasm by 
viral RNA polymerase. The viral core is completely uncoated by the time early 
expression ends, and the viral dsDNA is now free in the cytoplasm of the host cell.  
Approximately 100 minutes post-infection, the ‘intermediate phase’ genes are 
expressed, which initiate genomic DNA replication. In the ‘late phase’, which occurs 
140 min to 48 hours post-infection, all structural viral proteins are translated, and 
assembly of viral progeny begins with the first virion, the intracellular mature virus 
(IMV). 
 
Vaccinia virus produces four distinct virions throughout its life cycle; intracellular 
mature virus (IMV) (see figure 1-1), intracellular enveloped virus (IEV), cell-
associated enveloped virus (CEV) and extracellular enveloped virus (EEV) (see 
figure 1-2). Each virion has a different role in the viral life cycle. The IMV is the first 
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to be assembled, and is the abundant form of the virus. As the name suggests, it is 
retained intra-cellularly until lysis. It is covered in a surface membrane that displays 
surface tubules or surface filaments. IMV is a stable virion, which is capable of 
infective transmission between hosts. IEV is formed from the IMV virion by 
acquiring two additional membranes via wrapping in Golgi-derived cisternae. IEV is 
an intermediate to the CEV/EEV. Fusion of the outermost IEV membrane with the 
plasma membrane results in the formation of the CEV. This remains attached to the 
outside of the cell. EEV is formed from CEV that have been released from the cell. 
CEV induce the formation of actin tails that drive the virion away from the cell 
surface (see figure 1-3). It is these two virions that are responsible for spread of a 
poxvirus infection in culture and in infected animals [83, 84]. 
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Figure 1-1 Vaccinia structure: Intracellular Mature Virus 
The Intracellular Mature Virus (IMV) is the first viral particle to be assembled, and 
the most abundant form of the virus. It in covered in a surface membrane that 
displays surface proteins. This form of the virus is now capable of transmission 
between hosts. Ds; double stranded. 
 
 
 
 
Figure 1-2 Vaccinia structure: Extracellular Enveloped Virus 
Extracellular Enveloped virus (EEV) is formed by gaining additional membranes as 
the IMV wraps in Golgi-derived cisternae, and then fuses with the plasma 
membrane, forming first the Cellular Enveloped virus (CEV) which then dissociates 
to form the EEV. 
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Figure 1-3 Vaccinia replication and activation of the immune system 
Vaccinia enters a tumour cell by binding onto surface receptors (GAGs). Tumour 
cells have an activated EGF pathway, and have high levels of Thymidine kinase 
(TK) which supports viral replication. Early proteins can inactivate the host cell’s 
anti-viral interferon response and  provide further signals to the EGFR. Following 
formation of viral progeny, the cell is lysed and virus particles are released, and can 
infect nearby cells. The lysis of the cell releases pro-inflammatory cytokines, tumour 
associated antigens and danger signals- this, coupled with the GM-CSF production 
from engineered forms of the virus (JX-594), can lead to recruitment of immune 
effector cells and further immune-mediated tumour cell lysis. 
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1.3.2 Why does vaccinia work? 
Vaccinia and other poxviruses present an ideal platform for development as 
oncolytic agents. They are able to replicate and lyse cells rapidly, with the first viral 
particles secreted within 8 hours of infection [85]. Poxviruses have a broad tumour 
tropism. ‘Tropism’ refers to the way in which different viruses/pathogens have 
evolved to preferentially target specific host species, or specific cell types within 
those species. They infect cells through several membrane fusion pathways [86, 
87] and inherently target tumour cells, as the cancer cell infrastructure is similar to 
that of virally infected host cells; blocked apoptotic pathways, deregulated cell cycle 
control and immune evasion [88]. Furthermore, most human cancers show 
activation of the epidermal growth factor (EGF) – Ras signalling pathway, which has 
been associated with vaccinia replication and spread [89]. Vaccinia also produces 
an EGF homologue, called Vaccinia Growth Factor (VGF) that is produced during 
the early phase of viral replication, which can bind EGFR, thereby priming the cell 
for enhanced viral proliferation [90] [91]. Wali et al. demonstrated that vaccinia 
decreases the number of cells in G1 and increases the number of cells in the S and 
G2M phases of the cell cycle.  They also showed that vaccinia can regulate altered 
expression of p53 and p27 proteins, which can influence the cell cycle. P53 was 
found to initially up-regulate and then down-regulate in response to vaccinia 
infection [92].  
 
Once within the cell, replication takes place in mini-nuclear structures in the 
cytoplasm, and hence vaccinia does not integrate into the host DNA, and some 
forms have the ability to envelope themselves in host cell-derived proteins [93]. 
Therefore, each virus particle is capable of infecting a tumour cell and generate 
progeny capable of spreading to other cells, remaining largely undetected as they 
move through the tumour microenvironment or bloodstream, achieving higher levels 
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of viral delivery [74, 94]. Viral therapy can employ a variety of targeting 
mechanisms; therefore different tumour phenotypic properties can be targeted with 
different viral strains [95]. Furthermore, vaccinia viruses are able to accommodate 
large quantities of foreign DNA [96], allowing for insertion of various genes resulting 
in different mechanisms of anti-tumour therapy. The vaccinia genome expresses 
several genes, including anti-apoptotic and immunomodulatory genes, and deletion 
of several individual, or a combination, of these genes can improve efficacy of the 
virus [97, 98] and recruit the immune system; recombinant vaccinia containing 
certain co-stimulatory molecules (B7-1/ICAM-1/LFA-3) can induce CD4+ and CD8+ 
T-cell hyperstimulation [99]. 
 
Vaccinia has been shown, in preclinical and clinical models, to induce vascular 
collapse within tumours. This phenomenon is mediated by neutrophil infiltration into 
the tumour, induced by chemokines and cytokines, which eventually results in 
intravascular thrombosis and avascular necrosis. Vaccinia strains are also capable 
of infecting tumour-associated endothelial cells, destroying these cells and leading 
to vascular collapse [100] [101]. On the other hand, Weibel et al. [102] showed 
extensive malignant-cell specific necrosis, whilst the vasculature remained 
functional and infection-free, using breast tumour xenografts in nude mice, following 
6 weeks of recombinant vaccinia (GLV-1h658) infection. However, viral colonization 
did result in hyper-permeability of the tumour vasculature, and there was an 
increase in the expression of genes involved in endothelial cell/leukocyte 
interactions, which would result in peri-vascular inflammation. This was confirmed 
by immunohistochemical analysis which showed infiltration of MHCII positive cells 
into infected tumours, which was not observed in immunosuppressed mice, which 
still showed similar levels of tumour necrosis and enhanced viral spreading.  
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1.3.3 JX-594 
A new therapeutic class of oncolytic poxvirus has recently been developed that 
combines targeted and armed approaches for treating cancer. Developed from the 
Wyeth strain, JX-594 is a targeted and transgene-armed oncolytic poxvirus. It has 
been modified by the insertion of human GM-CSF and LacZ genes (encoding for β-
gal) into the viral TK gene (see figure 1-4) [72, 103, 104]. JX-594 is designed to 
selectively replicate in, and destroy, cancer cells with cell-cycle abnormalities and 
epidermal growth factor receptor (EGFR)-ras pathway activation [89]. Direct 
oncolysis plus granulocyte-macrophage colony-stimulating factor (GM-CSF) 
expression also stimulates shutdown of tumour vasculature and antitumoral 
immunity [77].  
 
Recently, JX-594 has shown promise as an i.v.-delivered, targeted virotherapeutic. 
Using an immunocompetent liver tumour rabbit model (with reproducible time-
dependant metastases) and a carcinogen-induced rat tumour model, Kim et al. 
showed complete response against both the intrahepatic tumours and the 
pulmonary metastases. Tumor-specific virus replication and gene expression, 
systemically detectable levels of hGM-CSF, and tumor-infiltrating CTLs were also 
demonstrated [72]. 
 
1.3.4 Deletion of thymidine kinase 
Thymidine kinase (TK) is an E2F- responsive gene and drives JX-594 replication in 
cancer cells that have cell cycle abnormalities. The deletion of the TK gene means 
that viral replication is reliant on cellular TK expression, which is expressed in 
abundance in the majority of cancers [105]. The TK disruption is also important in 
the context of viral toxicity. The TK-deletion virus is less likely to infect healthy 
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organs and nervous tissue, and is quickly cleared from these, but replicates 
efficiently in tumour tissue [103].  
 
Figure 1-4 Schematic of the generation of JX-594, with the insertion of the 
GM-CSF and LacZ genes into the TK gene.  
The top fragment represents the 5.1-kb “J” fragment, where the TK gene resides. 
Homologous recombination into the TK gene using the pSC65 vector, into which 
the GM-CSF gene has been inserted, disrupts the TK gene. The LacZ gene, 
encoding for β-galactodase, is inserted as well. Figure from Mastrangelo et al [106]. 
In the virus strains used in experiments in this work, the β-Galactodase expression 
is substituted by either fLuc or GFP. 
 
 
 
 
 
 
 
 
 
 
 
 
regression of an established syngeneic renal cell cancer
in mice launched many clinical trials, the av ilable
results of which were recently reviewed.4 Some tumor
regressions have been noted primarily in patients with
melanoma.
Although studies in murine models and early cli ical
data support the hypothesis that enrichment of the
cytokine milieu at the immunization site can result in
tumor rejection/regression, the use of in vivo gene
transfer techniques in the clinic is severely limited by the
requirement that an autologous tumor be available,
removed, grown in tissue culture, transfected with the
gene(s) of interest, etc. We propose that this cumber-
some procedure can be circumvented by the use of a
recombinant virus (RV) to insert genes of interest into
tumors in vivo so that cytokines are produced in situ,
thereby enhancing tumor immunogenicity and the acqui-
sition of antitumor immunity.
We report here on the use of vaccinia virus (VV) as a
vector for the transfer and expression of GM-CSF
cDNA to melanoma cells in vivo by direct intratumoral
(i.t.) injection. Toxicity was minimal with twice-weekly
injections of escalating doses of RV. Reporter gene
(!-galactosidase (!-gal)) expression and passenger cyto-
kine gene (GM-CSF) function could be maintained over
a protracted period despite the presence of antivaccinia
antibody (Ab). Most often, injected metastases re-
gressed; in some patients uninjected lesions regressed
as well.
MATERIALS AND METHODS
Vaccinia/GM-CSF RV
Human GM-CSF-producing vaccinia recombinant was gener-
ated using standard techniques.5,6 The wild-type (wt) virus
used in the preparation of the recombinant was derived from
the New York City Board of Health strain of vaccinia (Centers
for Disease Control, Atlanta, Ga). The full-length cDNA for
GM-CSF was obtained fro the Am ican Type Culture
Collection (Manassas, Va) (pCSF-1, no. 39754). The pSC65
vector used for generation of RV was provided by Dr. Bernard
Moss (National Institute of Allergy and Infectious Diseases,
Bethesda, Md). The GM-CSF gene was cloned first into the
EcoRI site of pBluescript II SK (Stratagene, La Joll , Calif)
and subsequently into the SalI and BglII sites of pSC65. This
plasmid was then transfected by calcium phosphate precipita-
tion into CV-1 monkey kidney cells that had been infected 2
hours previously with a low multiplicity of non-RV. The
plasmid is designed to facilitate homologous recombination
into the vaccinia thymidine kinase (TK) gene (Fig 1). Recom-
binants were selected in 143B (human osteosarcoma, TK-
negative) cells in the presence of 5-bromo-2!-deoxyuridine.
The !-gal gene was included in the plasmid as a reporter gene.
Following three rounds of selection, the virus was plaqued to
confirm that a pure recombinant stock had been obtained.
Southern blot analysis of HindIII-digested DNA from purified
virus confirmed that the plasmid had recombined in the
intended location. Northern blot analysis of cells infected with
the recombinant in the presence of cycloheximide showed a
mRNA species that hybridized strongly with the 32P-labeled
GM-CSF DNA extracted from the original pCSF-1 plasmid.
The size ("1 kilobase (kb)) was as predicted. Western blot
analysis using polyclonal rabbit anti-human GM-CSF from
Genzyme (Cambridge, Mass) demonstrated a heavily stained
band at "24 kDa in supernatants of vaccinia/GM-CSF-in-
fected cells, matching the molecular mass of mature GM-CSF.
An assay for biological activity was performed with the GM-
CSF-dependent Mo7e cell line using recombinant GM-CSF as
a standard. The infection of 106 143B cells (with a multiplicity
of 10 plaque-forming units (PFU)/cell) generated "105 U of
GM-CSF or 0.1 U/cell (Fig 2). (By comparison, "2 # 107 U
are administered systemically daily for the treatment of neu-
tropenia.) By these criteria, the virus was judged to be the
desired product.
Figure 1. Schematic of the strategy
for generating the GM-CSF-ex-
pressing VV recombinant. The top
fragment represents the 5.1-kb “J”
fragment resulting from a HindIII di-
gest of the VV genome. The vaccinia
TK gene resides on this fragment.
Homologous recombination into the
TK gene using the pSC65 vector,
into which the GM-CSF gene has
been inserted, disrupts the TK gene
and is predicted to replace the
5.1-kb fragment with two fragments
of "1.6 and 8.2 kb. The !-gal gene,
which is used to distinguish true
recombinants from spontaneous TK
mutants, is inserted as well.
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1.3.5 Double-deleted vaccinia virus 
Vaccinia-growth factor (VGF) is an epidermal growth factor (EGF)-like glycoprotein 
encoded by vaccinia, consisting of 77 amino-acids. VGF is expressed in the early 
phase of the virus replicative cycle and is secreted into the extra-cellular 
environment. VGF is reported to be important as a mitogen, to stimulate the growth 
of vaccinia-infected cells and support viral replication [107, 108]. Deletion of the TK 
gene or VGF genes significantly decreases pathogenecity compared with wild-type 
(WT) virus, with decreased viral replication in resting cells [109, 110]. McCart et al. 
reported the construction of a vaccinia virus with deletion of both the TK and VGF 
portion of the genome - vvDD (figure 1-5) [73]. They theorised that the combined 
effect of both deletions would mean that replication would occur only in actively 
dividing cells (those that have high TK, and those that do not require VGF-
stimulation to divide), thus improving tumour selectivity. In resting murine NIH3T3 
cells, in vitro infection with vvDD yielded reduced viral recovery compared to WT, 
TK-ve or VGF-ve, whereas similar viral recovery was seen in actively dividing cells. In 
an in vivo mouse model, intra-peritoneal vvDD was safer than WT, TK-ve or VGF-ve 
strains, with significantly less virus recovered from brain, but more in bone-marrow 
(though not statistically significant). A similar amount was recovered from tumour, 
and vvDD-injected mice lived for longer (>100 days) than the WT (6 days), TK-ve (17 
days) or VGF-ve (29 days) group.  
 
Lun et al. have used a vvDD in combination with rapamycin and cyclophosphamide 
to treat malignant gliomas in vitro and in vivo. Systemic delivery targeted solitary 
and multifocal intracranial tumors and prolonged survival of immunocompetent rats. 
Viral replication was enhanced by combination therapy with rapamycin or 
cyclophosphamide and further prolonged survival [111]. 
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Currently, a phase I dose-escalation trial of a vvDD administered by IT or IV 
injection is currently in progress, but not recruiting (ClinicalTrials.gov Identifier: 
NCT00574977). 
 
 
 
 
Figure 1-5. The double deletion vaccinia virus (vvDD).  
The TK locus of parenteral vaccinia (vSC20) is disrupted by insertion of eGFP 
which is under the control of a synthetic early/late promoter (Pse/l). The VGF sites 
within Inverted terminal repeats (ITR) are disrupted by insertion of the LacZ gene. 
Adapted from McCart et al [73].  
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1.3.6 Histone deacetylase inhibitors (HDACi) 
HDACi decrease interferon production, and can dampen cellular innate immune 
responses. MacTavish et al. used Trichostatin A (TSA, a HDACi) in combination 
with vvDD in vitro, in murine 4T1 breast cancer cells,  and demonstrated enhanced 
vvDD-associated GFP expression. Similarly, in a syngeneic lung metastasis mouse 
model injected intravenously with melanoma cells, followed by intraperitoneal TSA 
and/or intravenous vvDD, they demonstrated a further therapeutic benefit of the 
dual therapy when compared to either TSA or vvDD alone . 
 
1.3.7 Pro-inflammatory cytokines  
The vaccinia genetic backbone can be easily manipulated to ‘arm’ the virus with 
pro-inflammatory cytokines. This presents a platform for targeted inflammation at 
the site of the tumour, without causing a generalised systemic response. One of the 
most effective demonstrations of this was in athymic mice bearing a human tumour 
which were injected with the Copenhagen vaccinia strain which harboured cDNA for 
IL-6. Infective vaccinia particles were found to efficiently infect tumour cells, sparing 
liver, spleen, brain and bone marrow, with detectable IL-6 in the serum. Similarly, in 
euthymic mice, vaccinia expressing IL-2 reduced growth rate of 50% of tumours 
and complete rejection in 17% [112]. Concurrently, it was found that organs such as 
liver, spleen, brain and bone marrow showed barely detectable levels or no signs at 
all of virus infection.  
 
Li et al. in Pittsburgh, hypothesized that combinations of immunotherapy and 
oncolytic viral therapy may be used to produce improved anticancer effects. To 
demonstrate this, they used a vvDD backbone to create vvCCL5, which expresses 
a murine chemokine CCL5 (RANTES; regulated upon activation, normal T-cell 
expressed and secreted). They used a mouse model, which had subcutaneously 
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implanted MC38 (murine, colonic adenocarcinoma). When compared to vvDD, 
vvCCL5 showed increased persistence and enhanced therapeutic effect, and was 
also found to be more actively cleared from normal tissue. The therapeutic effect 
also correlated with increased immune cell infiltration into the tumour [113]. 
 
1.3.8 JX-963 
In 2007, Thorne et al. [74] described the design of a new systemically effective 
virotherapeutic (JX-963). Using the Western Reserve (WR) strain of vaccinia, a 
highly potent poxvirus strain, they engineered a vvDD that expressed human GM-
CSF. Significant cancer selectivity of JX-963 was demonstrated in vitro in human 
tumor cell lines, in vivo in tumor-bearing rabbits, and in primary human surgical 
samples ex vivo. JX-963 was compared with vvDD to assess the potential of GM-
CSF expression, and with JX-594, to compare the WR strain versus the Wyeth 
strain backbone. They showed that at 1 x 109 pfu, there were significant antitumor 
effects, and inhibition of the outgrowth of microscopic lung metastases, compared 
to vvDD and JX-594. There was also an increased amount of blood GM-CSF in the 
JX-963 treated model, which indicated increased replication of the WR strain 
backbone.  
 
More recently (2010), the JX-963 strain of vaccinia has been investigated by Lee et 
al, using an immunocompetent, orthotopic and spontaneously metastasizing rabbit 
liver cancer model [114]. Antitumoral efficacy against primary and metastatic 
tumour foci was evaluated by serial chest and abdominal computerised tomography 
(CT) scanning, and there was significant reduction in primary tumour mass, and 
liver and lung metastases. Replication of virus was observed in all tumour tissue, 
despite rising neutralizing antibodies to JX-963 from day 5-18. Following 
intravenous administration of JX-963, GM-CSF was detected in tumour-burdened 
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rabbits, but not in controls, indicting that viral replication and GM-CSF production 
was tumour-specific. GM-CSF production at 24 hours was also higher for JX-963 as 
compared to vvDD. Splenocytes were isolated before and after injection of JX-963, 
which confirmed a significant increase in tumour-targeting CTLs. A significant 
improvement in median survival was also observed, along with prevention of weight 
loss, and no significant organ toxicity was noted. 
 
1.3.9 B18R protein and the development of JX-795 
Interferons (IFNs) are a class of cytokine that are important in the host antiviral 
response, and play a major role in the treatment of hepatitis C. IFNs are so-named 
as they ‘interfere’ with viral replication within cells and allow communication 
between cells to trigger the immune system to eradicate pathogens and tumours. 
Thus, the IFN antiviral defence mechanism presents a barrier to OV therapy. OV-
related cancer selectivity is partly due to IFN-mediated inhibition of viral replication 
in normal tissues, whereas replication and oncolysis proceeds unhindered in 
tumour cells with defects in IFN responses. Vaccinia has evolved to expresses a 
protein, B18R, which acts as a ‘decoy’ receptor to bind type I IFNs (see figure 1-3), 
preventing binding onto the cell-surface which would initiate the host protein kinase-
R (PKR) mediated anti-viral response. B18R deletion increases the median lethal 
dose (LD50) of vaccinia by 3-logs [98] and integration of B18R into a Herpes 
simplex virus (HSV) has been shown to improve replication and enhance killing 
ability against otherwise resistant cell lines [115]. 
 
Kirn et al. hypothesised that IFN expression from vaccinia would increase anti-
cancer effects, and reduce toxicity to normal tissue with intact interferon pathways. 
In order to do this, using a WR backbone, the B18R locus was disrupted, and 
murine IFNβ was cloned for expression from the 7.5 early/late promoter in a similar 
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fashion to GM-CSF expression from JX-594. This virus was termed JX-795. This 
WR B18R deletion mutant demonstrated IFN-dependent cancer selectivity and 
efficacy in vitro, and tumour targeting and efficacy in mouse models in vivo, which 
was further enhanced by the addition of IFNβ [116]. 
 
1.3.10 Suicide genes to direct chemotherapy 
Bacterial and yeast cytosine deaminase (CDase) have been well characterised as 
an enzyme–prodrug system that converts 5-fluorocytosine (5-FC; a non-toxic anti-
fungal agent) to its highly toxic derivate 5-fluorouracil (5-FU), which is a 
chemotherapeutic agent capable of inhibiting DNA and RNA synthesis and 
interfering with DNA repair. Using a vaccinia virus carrying the bacterial and yeast 
CDase genes, directed expression of CDase enzyme in tumours has been 
achieved [117, 118]. Follope et al. used a TK-deleted vaccinia virus (Copenhagen 
strain) that expressed the fusion suicide gene FCU1 (vvDD-FCU1). Intratumoral 
inoculation of this virus, along with IV prodrug 5-FC, resulted in statistically 
significant reductions in the growth of subcutaneous human colon cancer in nude 
mice compared with control 5-FU alone. They also demonstrated a reduction in 
tumour volume in nude mice bearing orthotopic liver metastasis of a human colon 
cancer, following intravenous delivery of VV-FCU1 and 5-FC. [119].   
 
1.3.11  Oncolysate: active specific immunotherapy 
In 1992, Scoggin et al. observed antitumor effects with vaccinia virus infected tumor 
cell lysate in animal models, and therefore established a adjuvant 
immunotherapeutic clinical trial in patients with melanoma using vaccinia virus 
infected melanoma oncolysate (VMO). Preliminary clinical trials showed minimal 
side effects and moderate responses. Postimmune sera contained melanoma-
specific antibodies. In August 1985, a Phase II clinical trial was initiated and 19 of 
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39 patients with stage II  disease had a disease-free mean survival time of 24.6 
months ( which was statistically significant compared with historical controls) [120].  
 
This eventually resulted in a randomized, double-blind, multicenter phase III trial 
(across 11 centers), initiated in June 1988. 217 patients with stage 3 melanoma 
were recruited. The VMO was prepared by using 4 tested melanoma cell lines 
infected with Vaccinia virus. Following incubation, the infected cells were lysed by 
sonication and the nucleus-free lysate was obtained. This VMO was then injected 
once a week for 13 weeks and then once every 2 weeks for a total of 12 months, or 
until recurrence. This trial showed no statistically significant increase in either 
disease-free interval (DFI) (p = 0.61) or overall survival (OS) (p = 0.79) of patients 
treated with VMO (n = 104) compared with Vaccinia virus alone (n = 113). Although 
a subset of patients (Male, aged 44-57, with 1-5 nodes) had significant 
improvement in survival. [121]. It was suggested that the VMO trial may have 
shown an enhanced efficiency if compared to a no-treatment observation control 
arm [122]. 
 
Published in 2002, another large (N= 675) phase III, unblinded, multicenter trial, 
conducted by Hersey et al. showed a non-significant trend towards overall survival 
improvement after a vaccinia melanoma cell lysate (VMCL) treatment (intention-to-
treat analysis; 59.6% vs 55.1% at 5 years). In this trial, patients with stages IIB and 
III melanoma received intradermal injections of VMCL over a 2-year period at 
reducing dose frequency, and were followed up for a median of 8 years [123]. 
 
Tanaka et al. in 1994 published results of a study of vaccinia colon oncolysate 
(VCO). In this case, oncolysate was prepared with VV engineered to express 
interleukin-2 (IL-2) (IL-2VCO) in combination with recombinant IFNα. This was 
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studied in a syngeneic murine CC-36 colon hepatic metastasis model. This showed 
an improvement in survival compared with controls, consistent with a reduction in 
hepatic metastases (mean liver weight), and induction of cytolytic T-cell activity. It 
was suggested IL-2VV could be used as a substitute for recombinant IL-2 in 
cytokine-augmented active specific immunotherapy [124]. 
 
1.3.12  GLONC-1 virus 
Another strain of vaccinia has been used as a backbone to construct an OV; the 
Lister strain from the Institute of Viral preparations (LIVP). The OV, termed GLV-
1h68 carries a Renilla luciferase-green fluorescent protein (GFP) fusion cassette at 
the F14.5L locus, and the TK locus (J2R) is disrupted by insertion of a β-
galactosidase cassette. Robust GLV-1h68 transgene expression was found 
following infection of four human sarcoma cell lines with >80% cytotoxicity at an 
multiplicity of infection (MOI) of 5. In a human sarcoma cell-line xenograft model in 
mice, IT injection of GLV-1h68 resulted in localised viral-luciferase activity, with no 
spread to adjacent normal tissue. There was near-complete tumour regression over 
a 28-day period without observed cytotoxicity [125]. A similar virus, GLV-1h153 was 
found to infect, replicate in, and kill triple-negative breast cancer cell-lines in vitro. In 
an in vivo orthotopic murine model with reliable metastases from a mammary fat 
pad xenograft, IT and IV injection both resulted in a 90% reduction in tumour 
volume compared to control mice, and all harvested tumours and metastases 
showed no evidence of residual malignant metastatic cells [126]. 
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1.4 Clinical trials with JX-594 
Table 1.1 summarises all human clinical trials performed to date using JX-594 
therapy in multiple tumours. 
 
1.4.1 Metastatic prostate cancer 
It has been previously shown that prostate-specific antigen (PSA)-specific CTLs 
could be generated that lyse PSA-expressing prostate cancer cells [127]. Vaccinia 
has been used as a potential vector for presentation of the PSA antigen and 
thereby inducing specific cellular immunity.  
 
In 2002, Gulley et al. conducted a phase I trial of recombinant vaccinia prostate 
specific antigen (rV-PSA) in 42 patients with advanced metastatic prostate cancer. 
Vaccinia virus containing the gene for PSA was  delivered by two routes: dermal 
scarification and subcutaneous injection, given three times, at 4-week intervals. 
Results showed no significant treatment-related toxicity apart from local reaction at 
the injection site. There was an increase in the proportion of PSA-specific T cells, 
and these were shown to lyse tumour cells in vitro. They did not demonstrate any 
objective tumour response. They postulated that this was due to a combination of 
the advanced nature of the disease in the patient population (and thus impaired 
immune functional status) and relative lack of potency of this vaccine regimen 
required for an immune response [128]. 
 
Similar results were seen in a study by Alren et al. in 2007. In this study a 
recombinant vaccinia virus with transgenes for PSA and a triad of co-stimulatory 
molecules (B7.1, ICAM-1, and LFA-3) was utilised as a priming vaccine. This was 
followed by a boost vaccination with a recombinant fowlpox virus. Some grade 2 
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toxicity was seen with higher doses. Viable vaccinia was seen using plaque assay 
at the site swab of 1 of 4 patients analyzed, and PSA-specific immune responses 
were seen in 4 of 6 patients [129]. In 2010, Kantoff et al. performed a randomized, 
controlled, and blinded phase II trial of the same treatment strategy in 122 patients 
(therapy: control; 82:40). They found that progression-free survival was similar in 
both treatment and control arms, but at three years, overall survival was longer by a 
median of 8.5 months in the treatment group [130]. 
 
Most recently, a vaccine based on a modified vaccinia Ankara virus combined with 
the oncofetal antigen 5T4 has been developed (TroVax), which has been used for 
the treatment of castration-resistant prostate cancer. The 5T4 TAA is highly 
expressed in a large number of carcinomas, including prostate cancer, but rarely in 
healthy tissue. Disease progression was monitored by PSA measurements every 4 
weeks and CT and bone scans every 8 weeks. All 24 patients mounted a significant 
5T4-specific immune response. All patients experienced disease progression, and 1 
year follow-up, 16 patients remained alive. There were no objective clinical 
responses on CT or bone scans [131]. 
 
1.4.2 Colorectal cancer 
Similarly, TroVax has been used in colorectal cancer, which was the first trial of 
TroVax. This dose-escalation study showed that TroVax was safe and well-
tolerated [132]. In 2012, a phase IIa trial of neo-adjuvant IV and IT JX-594 injection 
in patients with colorectal liver cancer trial was terminated early due to logistic 
concerns rather than adverse events. Currently, JX-594 is being investigated in a 
phase I/IIa dose-escalation trial, administered by multiple IV infusions 
(ClinicalTrials.gov Identifier:NCT01469611) or multiple IV infusions followed by IT 
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boosts, in combination with Irinotecan (ClinicalTrials.gov Identifier: NCT01394939) 
in patients with metastatic, refractory colorectal carcinoma . 
 
1.4.3 Melanoma 
Several early-phase and proof-of-concept clinical trials in humans have been 
performed. In 1999, a phase I, dose escalation pilot JX-594 trial conducted by 
Mastrangelo et al., investigated IT therapy in cutaneous melanoma. Seven patients 
with surgically incurable and metastatic cutaneous melanoma received twice-
weekly IT injections of escalating doses for 6 weeks. Immunological responses and 
virus-derived GM-CSF were seen in all patients. There was tumour response at the 
site of the injection in 5 patients, of which 4 had regression in non-injected dermal 
lesions. Importantly, JX-594 was safe, and the maximum-tolerated dose (MTD) was 
not reached [106]. In 2011, Hwang et al. described a mechanistic proof-of-concept 
trial in 10 patients with previously treated metastatic melanoma. JX-594 was 
delivered intratumourally, and β-Galactosidase (a different trnasgene) was 
expressed in tumour, in all patients, and an increase in GM-CSF-responsive white 
cell subsets was also seen. Despite the presence of neutralising antibodies (NAb) 
against JX-594 after initial treatment, replication was also observed in non-injected 
tumours. Using the Response Evaluation Criteria in Solid Tumours (RECIST) 
criteria, stable disease was demonstrated in all 5 evaluated patients, and 3 patients 
had stable disease in non-injected tumours. JX-594 was well tolerated, and all 
patients reported only grade 1 or 2 toxicity, with grade 3 toxicity in 1 patient only 
(anaemia) [133]. 
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1.4.4 Primary and secondary liver tumours 
In South Korea, a phase I trial by Park et al. in 2008 showed that IT injection of JX-
594 into primary or metastatic liver tumours was generally well-tolerated and had 
anti-tumoral effects against several refractory tumours. 14 patients with liver tumour 
(both primary and metastatic from colorectal, lung and melanoma) were recruited 
into the trial and injected with varying doses of JX-594 every 3 weeks; 1x108 
plaque-forming units (pfu), 3x108 pfu, 1x109 pfu, or 3x109 pfu. An average of 3.4 
cycles was given. All patients experienced flu-like symptoms and 4 had dose-
related thrombocytopenia, 2 patients had hyperbilirubinaemia. The maximum 
tolerated dose was 1x109 pfu. In 10 assessed patients, tumour responses were 
observed in injected and non-injected tumours, and according to RECIST criteria 3 
patients had partial response, 6 had stable disease, and 1 had progressive disease. 
 
Heo et al. treated three HCC patients who had progressive disease following JX-
594 treatment, with sorafenib (a small molecule inhibitor of B-raf and vascular 
endothelial growth factor receptor). All three patients showed rapid and marked 
tumour necrosis, and had objective responses according to Choi and Response 
Evaluation Criteria in Solid Tumors (RECIST) criteria, which occurred as early as 
2.5 weeks following sorafenib initiation; comparative responses had not been 
observed in patients with HCC treated with sorafeib alone in the same unit [134]. 
These observations clearly pave the way for combination studies using vaccinia or 
other oncolytic viruses with established small molecule inhibitors as well as 
standard chemotherapeutic agents. 
 
In a more recent phase II trial in 2013, Heo et al. infused low-dose (108 pfu) or high-
dose (109 pfu) JX-594 by image-guided IT injection (3 doses; days 1, 15 and 29) in 
30 patients with HCC [135]. Most had had previous locoregional treatment, and 
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some had progressed despite systemic therapy. This trial was halted due to 
significant survival in the high-dose group. The intrahepatic mRECIST disease 
control rate at week 8 was 46% overall with no difference between dose-groups, 
with objective mRECIST responses and decreased tumor perfusion and contrast 
enhancement in both injected and noninjected tumors. GM-CSF expression was 
detectable by day 5 in more than 60% of patients. Induction of antitumoral immunity 
was demonstrated by assessing antibody-mediated complement-dependent 
cytotoxicity (CDC) in patients’ serum, and 11/16 (69%) patients developed CDC 
against at least one of four HCC cell lines. Cellular immunity was also 
demonstrated by the induction of CTLs against vaccinia peptides. Patients’ survival 
was significantly related to dose (median survival of 14.1 months compared to 6.7 
months on the high and low dose, respectively). 
 
1.4.5 HBV-associated HCC 
In this phase I study (part of the same cohort as Park et al. [77]), Liu et al. showed 
that JX-594 demonstrates anti-tumoural, anti-vascular and anti-HBV activities in 
patients with HCC [76]. Three patients with advanced refractory HBV-associated 
HCC received 4-8 cycles of intratumoral administration of JX-594. Treatment 
response was evaluated clinically using CT, positron emission tomography (PET)-
CT, and tumour markers (AFP). Treatment was well tolerated in all 3 patients and 
showed tumour responses based on RECIST and Choi criteria, and two patients 
showed a reduction in tumour markers. Response in distant metastases was also 
demonstrated; one patient developed a metastasis in the neck, and following four 
cycles of intra-tumoural JX-594, there was a 76% decrease in metabolic activity on 
PET-CT and  a 98% reduction in AFP.  
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JX-594 replication was also demonstrated; initially detectable 15 minutes after the 
injection and eventually cleared with a half life of 15-30 minutes. Interestingly, JX-
594 was detectable once again from days 5-8, despite the development of 
neutralizing antibodies, suggestive of viral replication. Dissemination to non-injected 
tumour sites was also demonstrated. GM-CSF was detectable at 3 hours and up to 
22 days in one patient. On day 3, consistent with the initiation of viral replication, 
there was ten-fold increase in white blood cells. At 3 hours, induction of IL-4, IL-6 
and IL-10, TNF-α and interferon-γ was observed. There was a sustained reduction 
in serum VEGF levels in two patients, suggesting tumour vascular disruption.   
 
In addition to the anti-tumour response, there was  a reduction in HBV DNA 
concentrations (70-91%) in all three patients, which rose again once extra-hepatic 
metastases developed. Interestingly, further successful treatment of the metastases 
was associated with a further fall in HBV DNA, suggesting that tumour cells are a 
source of HBV genomes. 
 
1.4.6 Intravenous JX-594 in multiple tumours 
A further pivotal early-phase trial by Breitbach et al. treated 23 patients (of which 22 
were evaluable) with intravenous JX594; lung, colorectal, melanoma, thyroid, 
pancreatic, ovarian, mesothelioma, leiomyosarcoma and gastric cancers were all 
targeted. This study showed that JX-594 selectively infects, replicates and 
expresses transgene products in cancer, but not normal tissue. Disease control was 
seen in 13 of these patients by RECIST criteria [136]. 
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Virus  
Author, Year 
Phase 
Patient population 
and modality of viral 
delivery 
Outcome and important 
findings 
Toxicity 
JX-594 
Mastangelo et 
al., October 
1999 
Phase I dose-
escalation trial 
N= 7; surgically 
incurable cutaneous 
melanoma, re-
vacciniated with WT 
Vaccinia. 
 
Intratumoural injection 
104 - 8x107 pfu/session 
2/7 Complete remission 
(with one patient having 
remission of un-injected 
lesions) 
3/7 Mixed response 
2/7 No response 
All patients developed an 
anti-vaccinia humoral 
response, yet β-Gal 
transgene expressed in all 
patients in tumour. 
Local 
inflammation 
at site of 
injection  
Grade 1 flu-
like symptoms 
 
JX-594 
Park et al. June 
2008 
Phase I dose 
escalation trial 
N= 14; refractory 
primary (3) or 
secondary (11) liver 
tumours, heavily pre-
treated 
 
Intratumoural 108 - 
3x109 pfu every 3 
weeks. MTD found to 
be 1 x 109 pfu 
4/6 patients at MTD had 
GM-CSF related increase in 
neutrophil count 
RECIST criteria;  
3/10 Partial response 
6/10 Stable disease 
1/10 Progressive disease 
CHOI criteria; 
8/14 showed decrease in 
HU (6/8 > 30% decrease) 
14/14 grade 
1–3 flu-like 
symptoms 
4/14 transient 
grade 1–3 
dose-related 
thrombocytop
enia.  
2/14 Grade 3 
hyperbilirubina
emia at max 
dose (3 x109 
pfu). 
JX-594 
Lui et al., July 
2008 
 
(Same cohort as 
above, Park et 
al.) 
 
N=3, advanced, 
surgically unresectable 
hepatitis B virus (HBV) 
-associated HCC. All 
failed previous 
treatment. 
Intratumoral Inj. 3 x108 
– 3 x 109 pfu/cycle 
3/3 showed objective 
response on RECIST 
criteria, including the 
extrahepatic disease on 
N=1/1.  
N =2/3 had reductions on 
serum VEGF 
N=3/3 had significant 
reductions in HBV DNA  
Following acute clearance 
after 15 minutes, a second 
wave on replication-
dependant genomes were 
detected in serum, despite 
neutralising antibodies. 
Transient flu-
like symptoms 
JX-594 + 
Sorafenib 
Heo et al., Jun 
2011 
Phase II 
N=3 HCC, failed 
response on 
intratumoural Inj. of JX-
594 and subsequent 
Sorafenib treatment 
N=1 metastatic RCC, 
intratumoural JX-595 
followed by sunitinib 
 
3/3 had response based on 
RECIST and CHOI criteria 
 
 
CHOI tumour responses in 
liver and abomen following 
JX-594 and complete whole 
body tumour response after 
sunitinib by CT.  
No liver 
toxicity 
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Virus  
Author, Year 
Phase 
Patient Population 
and modality of viral 
delivery 
Outcome and important 
findings 
Toxicity 
JX-594 
Breitbach et al., 
September 2011 
Phase I dose-
escalation trial) 
23 patients; 
Lung (NSCLC) (N=5) 
Colorectal (N=6) 
Melanoma (N=4) 
Thyroid (N=1) 
Pancreatic (N=1) 
Ovarian (N=2) 
Mesothelioma (N=1) 
Leiomyosarcoma (N=1) 
Gastric (N=1) 
 
Intravenous delivery; 
1x105 – 3x107 pfu/kg) 
Disease Control in: 
3/5 
3/6 
2/4 
1/4 
0/1 
2/2 
1/1 
1/1 
0/1 
JX-594 selectively infects, 
replicates, ,and expresses 
transgene products in 
cancer tissue. 
Grade 1 and 2 
flu-like 
symptoms 
only 
JX-594 
Hwang et al., 
October 2011 
Mechanistic 
proof-of-concept 
trial 
10 patients; previously 
treated stage IV 
Melanoma 
 
Intratumoural delivery; 
108 pfu/cycle 
β-Gal transgene expressed 
in all patients in tumour 
Increase in GM-CSF 
responsive WCC subsets 
(60%) 
Replication seen in non-
injected tumour (at day 5) 
All patients developed NAb 
titres. 
RECIST criteria; stable in 
5/5 injected tumours and in 
3/5 non-injected tumours 
Grade 1 flu-
like 
symptoms. 
Grade 3 in 
N=1 
(anaemia) 
 
JX-594 
 
Heo et al., 
January 2013 
 
Phase II trial 
30 patients; 22 had 
loco-regional treatment 
and 18 were virally-
associated 
 
IT delivery; 3 cycles of 
low-dose (108 pfu) or 
high dose (109 pfu) 
Intrahepatic mRECIST 
criteria; 46% overall 
disease control rate at 
week 8  
 
Modified Choi response; 
62% overall 
GM-CSF (69% of high-dose 
patients) and β –Gal 
antibodies (75% of high-
dose patients).   
Complement-dependent 
cytotoxicity in 1/16 
Survival; 14.1 months in 
low-dose and 6.7 months in 
high-dose 
Grade 3 in 
N=5 (low-dose 
and high-
dose) and 
Grade 4 in 
N=1 (high-
dose) 
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Table 1-1  Summary of JX-594 trials 
Table above summarises the trails published to date investigating the clinical 
effectiveness of JX-594. NSCLC = non-small cell lung cancer, NAb = neutralising 
antibody. RECIST = Response Evaluation Criteria in Solid Tumors, MTD = 
maximum tolerable dose, HU=Hounsfield units, pfu = plaque forming units. 
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1.5 Other oncolytic viruses 
1.5.1 Adenovirus 
Adenoviruses were the first class of OV used in clinical trials in humans. Tumour 
specificity was enhanced via a number of mechanisms, including deletion of viral 
E1B, which leads to ubiquitinylation of p53, targeting it for degradation, thereby 
theoretically limiting viral replication to p53 deficient malignant cells. Onyx015 was 
developed in 1996 and a related virus gained a licence in China for use in 
combination with chemotherapy for head and neck cancer [65]. However, interest in 
Onyx015 dissipated thereafter due to the lack of significant therapeutic effect on 
testing in larger trials. More recently, a tumour-specific replicating adenovirus hTert-
Ad (human telomerase reverse transcriptase promoter-regulated adenovirus) was 
investigated in the treatment of HCC in combination with bortezomib. In a mouse 
model with subcutaneous HCC implantation, bortezomib and hTert-Ad were found 
to trigger complementary unfolded protein response (UPR) pathways and 
negatively interfere with important recovery checkpoints, resulting in enhanced 
endoplasmic reticulum stress induced apoptosis and improved oncolysis in vivo 
[137]. 
 
1.5.2 Newcastle Disease Virus 
Newcastle disease virus (NDV) is an avian pathogen, and transmission to humans 
(for example in poultry processing plants) can cause mild conjunctivitis and 
influenza-like symptoms, but poses otherwise no major hazard to human health 
[138]. It displays tumour specific killing due to tumour specific defects in the IFN-
mediated antiviral response. It has been investigated in vivo and in vitro in 
combination with another OV, reovirus, leading to improved cytotoxicity and 
simultaneous replication of both viruses [139].  A naturally attenuated, non-
engineered NDV, PV701 has been investigated in phase I clinical trials. IV-
administration led to flu-like symptoms and fatigue, which was then improved by a 
- 43 - 
desensitisation regimen [140, 141]. There have been three phase I trials of 114 
patients using IV administration of PV701, and in the most recent, out of 19 
patients, 6 responses were observed [142].  
 
1.5.3 Vesicular Stomatitis Virus 
Vesicular stomatitis virus (VSV) is an enveloped, nonsegmented, negative-strand 
RNA virus of the Rhabdoviridae family. VSV is a pathogen of livestock, with human 
crossover being relatively rare and subclinical in presentation. Similar to other OV, 
VSV replicates in tumour cells due to a defect in the interferon anti-viral response 
pathway. VSV is a promising OV for clinical use, due to a lack of pre-existing 
immunity in humans, its small, easily manipulated genome, relative independence 
of a receptor and cytoplasmic replication (hence no host-cell transformation). A 
phase I trial is underway [107, 143]. 
 
1.5.4 Herpes Simplex Virus 
The most clinically advanced oncolytic virus, based on herpes simplex virus 1, is 
called OncoVEX (now renamed T-Vec), and is an oncolytic HSV encoding GM-CSF 
to enhance anti-tumour immune responses. In a recently published phase II trial of 
intra-tumoural injection of OncoVEX in advanced melanoma [144], 13 of 50 patients 
achieved a radiological response, including 8 with a complete response. OncoVEX 
is currently undergoing phase III trial testing in melanoma. The first completed 
phase III clinical trial with an oncolytic virus, using an intratumoural T-Vec treatment 
in melanoma, has just been reported to have met its primary endpoint of durable 
response rate.  
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1.5.5 Measles Virus 
Measles Virus (MV) has also been tested in the clinical setting. The  Edmonston-
Zagreb (MV-Edm) lineage has been used as a live attenuated vaccine [145], and 
preferentially infects malignant cells, which overexpress a measles virus receptor, 
CD46. MV-CEA is an engineered strain of MV-Edm, which expresses the soluble 
biomarker CEA, thus allowing in vivo monitoring of viral replication. A phase I trial of 
MV-CEA has has been completed in recurrent ovarian cancer resistant to paclitaxel 
and platinum chemotherapy [146]. Five of the 21 patients had significant decreases 
in CA125 levels, indicating a biochemical response to therapy. 
 
1.5.6 Reovirus 
Reovirus (Respiratory Enteric Orphan Virus) has no known clinical syndrome in 
humans. It is a naturally occurring, ubiquitous virus, and most of the population 
have been exposed to it in childhood, and hence carry neutralising antibodies. It 
was thought to infect Ras-activated malignant cells due to their inability to mount an 
RNA-activated protein kinase (PKR) response, although this theory has been 
challenged. An activated Ras signalling pathway is prevalent in the majority of solid 
malignancies, including 80-90% of pancreatic cancers, 40-50% of colorectal 
cancers and 50% of thyroid cancers. Early phase trials of both local and systemic 
Reolysin® (Oncolytics Biotech Inc) have demonstrated some significant promise in 
patients with metastatic cancers including those of the pancreas, lung and 
malignant melanoma. The safety profile of this treatment is excellent and it is 
generally well tolerated [147]. Reovirus is safe and tumour-specific following 
intravenous delivery in patients with colorectal liver metastases [148]. In this study, 
delivery of reovirus to tumour was demonstrated despite the presence of 
neutralising antibodies (NAb); replication-competent reovirus was recovered from 
blood cells but not plasma, suggesting that transport by immune cells could protect 
virus from systemic neutralisation. A phase III trial is currently underway using 
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Reolysin® in combination with Paclitaxel and Carboplatin in platinum-refractory 
head and neck cancers (Clinical trials.gov indentifier: NCT01166542). 
Our laboratory has considerable experience with reovirus, and hence this is used 
as a positive control in some of the experiments described in this thesis, in order to 
understand and measure the response of vaccinia virus.   
 
1.6 Obstacles to oncolytic viral therapy  
Vaccinia strains and other pox viruses have been used in various clinical trials for 
treatment of established cancers [149-151], but their efficacy has been limited. This 
may be due to several factors; the local immunosuppressive nature of the tumour 
microenvironment, immune editing (escape of tumour populations that do not 
express target antigens), failure to cross the endothelial barrier during intravenous 
delivery, and the host anti-viral response.  
 
Tumours evade the immune system by mechanisms such as down-
regulating/modifying various components of the antigen presenting machinery 
resulting in loss of MHC-I antigen presentation [152], and the induction of immune 
tolerance via release of soluble immunosuppressive factors, such as transforming 
growth factor beta (TGF-β), indoleamine 2,3-dioxygenase (IDO), VEGF, IL-10 and 
prostaglandin E2 (PGE2). These immunosuppressive cytokines, along with immune-
suppressive cell populations present in the tumour microenvironment, can prevent 
the successful eradication of tumour cells. Therefore, reversing this tumour-induced 
immune tolerance will be critical to generating effective anti-tumour immunity. OV, 
as potent viral immune danger signals, have the potential to reverse this 
suppressive tumour microenvironment, facilitating the generation of an anti-tumour 
response. 
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Systemic delivery is the ideal route of administration to allow dissemination of OV to 
distant metastases. However, even in a previously un-exposed host, there are 
obstacles to overcome. The delivery of virus to tumour sites may be impeded by the 
development of NAbs and sequestering by the reticuloendothelial system and 
complement components. Even once delivery to a tumour site has been achieved, 
crossing the endothelial barrier to ensure adequate penetration into tumours may 
be yet another obstacle. Various strategies to overcome these limitations have 
been investigated; reducing anti-viral responses by immunosuppression, inhibiting 
viral clearance by coating viruses in antigenically inert polymers, overcoming 
specific anti-viral immunity by serotype switching, and ‘hiding’ OVs from NAbs with 
the use of cell based delivery strategies. Cells that traffic to tumours and that are 
permissive to viral replication have therefore been utilised as ‘Trojan horses’ to 
deliver OV direct to the tumour [153]; these carriers include stem cells 
(mesenchymal, adipose, neuronal and endothelial cells), immune cells (cytokine-
induced killer (CIK) cells, DC, monocytes and T cells) and irradiated tumour cells.  
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1.7 Aim of study 
To investigate the potential oncolytic and immune-stimulatory effects of vaccinia 
virus on liver cancer by testing; (i) direct tumour lysis, (ii) replication in tumour cell 
lines and fresh tissue, (iii) immune-stimulatory effects and (iv) development of an ex 
vivo tissue system for a more clinically relevant translational model. 
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Chapter 2  
 
Materials and Methods 
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2 Materials and Methods 
2.1 Chemicals 
All chemicals and reagents were Molecular Biology Grade. 
2.2 Cell culture 
2.2.1 Cell lines 
Colorectal cell lines, purchased from American Type Culture Collection (ATCC), 
were cryopreserved in 90% foetal calf serum (FCS) supplemented with 10% (v/v) 
dimethyl sulphoxide (DMSO) (Fisher Chemical, Loughborough, UK), in liquid 
nitrogen. CRC cell lines used were ; HCT116, LoVo, SW480 and SW620. The latter 
two are cell lines were derived from the same patient; SW480 from the primary 
tumour and SW620 from the metastatic tumour. Other cell lines used include; K562 
(human chronic myeloid leukaemia) and Vero (kidney epithelial cells extracted from 
an African green monkey). See Appendix A for further details of cell lines. 
 
2.2.2 Cell culture method 
Cell culture was performed under aseptic conditions in NuAire Class II 
Microbiological Safety Cabinets (NuAire, Plymouth, USA). Sterility was maintained 
by laminar flow, and pre- and post-use cleaning with 2% Virkon (Dupont, Suffolk, 
UK) followed by 70% Ethanol. All cell lines and primary cultures were grown in 
either Dulbecco’s Modified Eagle’s Medium (DMEM) or Roswell Park Memorial 
Institute (RPMI) 1640 (both Gibco, NY, USA), supplemented with 10% (v/v) heat 
inactivated (30 minutes at 560C) FCS.  
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Cell lines were stored in 10% DMSO in 1.2ml cryotubes (Nunc, NY, USA) in liquid 
nitrogen. Cell recovery from frozen was performed by rapid thawing in a water bath 
at 370C, then dilution with 10x excess fresh media and centrifugation (Eppendorf 
centrifuge 5810R, 400g, 5 minutes) to harvest cells and remove otherwise toxic 
DMSO. Maintenance of cell lines was performed in vented plastic tissue culture 
flasks (Corning Costar, Amsterdam, The Netherlands) (75cm2, 150cm2), in a Sanyo 
CO2 incubator at 370C. Adherent cells are then harvested when near-confluent by 
washing with phosphate buffered saline (PBS) (Sigma, Dorset, UK) (with or without 
supplementation with Ethylenediaminetetraacetic acid (EDTA)), followed by 
Trypsin-EDTA (10x Stock solution (Sigma) diluted 10:1 in Hanks’ Buffered Salt 
Solution (HBSS) (Sigma)). Cells were then harvested in media and  centrifuged in a 
50ml Falcon tube (Corning), and viable cell counts were obtained using a Nikon 
Eclipse TS100 microscope, using tryptan blue (Sigma) exclusion and an Improved 
Neubauer haemocytometer (Weber Scientific, NJ, USA) [154]. 
 
2.3  Isolation of peripheral blood mononuclear cells (PBMC) from 
fresh blood 
PBMCs were isolated from fresh whole blood using density gradient separation. 
Peripheral blood was collected from healthy donors or patients with identified liver 
pathology in accordance with local guidelines and appropriate precautions.  Written, 
informed consent was obtained from all patients in accordance with local 
institutional ethics review and approval. Blood was first diluted 2:1 with HBSS and 
30 mls then layered over 15 mls Lymphoprep© (Axis Shield, Oslo, Norway) in 50 ml 
Falcon tubes. Tubes were centrifuged at 800g for 25 minutes at RT with no brake, 
and the interface PBMC layer collected using a Pasteur pipette (Alpha laboratories 
Ltd. Hampshire, UK). Cells were washed in 50 ml of HBSS and centrifuged at 400 g 
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for 10 minutes at RT. Cells were washed again in 50 ml HBSS and pelleted by 
further centrifugation at 400 g for 5 minutes at RT and supernatant discarded. 
PBMCs were maintained in culture at 2x106 cells/ml of culture medium (RPMI + 
10% FCS) for all future experiments. 
 
2.4  Cell separation of PBMC population using magnetic-
activated cell sorting (MACS) bead selection 
Fresh PBMCs were isolated from whole blood as described in section 2.3. To 
separate CD14–ve cells, PBMCs were centrifuged, pelleted and re-suspended in 80 
µL/107 cells of MACS buffer (PBS+1% (v/v) FCS+ 2mM EDTA). 30 µL of CD14 
Microbeads (Miltenyi Biotec Ltd., Surrey, UK) per 107 cells was added and 
incubated at 4oC for 15 minutes  and then washed in 2 ml MACS buffer. Cells were 
pelleted by centrifugation and re-suspended in 500 µL MACS buffer, and passed 
over a MACS LS separation column mounted on a magnetic board (both Miltenyi 
Biotec Ltd.) and unbound cells (CD14-ve) collected by washing with 1 ml MACS 
buffer (repeated three times). The remaining CD14+ve cells are collected by flushing 
out the retained cells in the MACS LS column using the supplied plunger, away 
from the magnetic board. NK cells were isolated in a similar fashion, by incubating 
first with an NK Cell Biotin-Antibody cocktail at 20 µL/107 cells for 10 minutes at 4oC 
and then 40 µL/107 cells of NK Cell Microbead Cocktail for 15 mins at 4oC (both 
Miltenyi Biotec Ltd.) and collecting the unbound cells. 
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2.5 Vaccinia virus (JX-594) 
Varying genetically modified strains related to clinical JX-594 were provided by The 
Centre for Innovative Cancer Research, Ottawa Hospital, Canada, courtesy of John 
Bell laboratories, Dr. Fabrice Le Boef and Jennerex Therapeutics. These included 
JX-594-GM-CSF-fLuc (here onwards referred to as ‘JX-594-GM-CSF’), JX-594-GM-
CSF-eGFP (here onwards referred to as JX-594-GFP) and JX-594-YFP (which 
does not express GM-CSF). The insertion of the gene encoding for GM-CSF under 
an early/late promoter has clinical relevance, but along with GFP, can be used as a 
surrogate marker to make assessments of cellular entry and replication of the virus 
using flow cytometry, Enzyme-Linked Immunoabsorbent Assay (ELISA) and 
confocal microscopy (described later in sections 2.7, 2.10 and 2.15 respectively). 
 
2.6 JX-594 infection of cells and tissue 
Human CRC cell lines were harvested when near-confluent from tissue culture 
flasks and 2 x 105 cells seeded into a 6-well plate in 3mls of DMEM + 10% FCS. As 
described later in section 2.13, tissue cores and slices were placed in ‘fresh tissue 
culture medium.’ Serial dilutions of JX-594 were prepared in DMEM, and once cells 
were adherent, JX-594 was added to the culture medium at titres of 0, 0.01, 0.1, 1 
and 10 pfu/cell. In the case of tissue cores/sections, a standard dosage of 106 and 
107 pfu of virus was used. Following infection for defined time points, supernatant 
+/- cells can be collected and stored for later experiments. Cells/Tissue were fixed 
in 1% paraformaldehyde (PFA) (Adams Healthcare, Leeds, UK) for further 
processing/experiments. 
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2.7 Flow Cytometry 
2.7.1 Background 
Cytometry is a process by which physical and/or chemical characteristics of single 
cells can be measured. Flow cytometry has evolved to incorporate the use of 
multiple fluorochromes to effectively identify and isolate subset populations in a 
mixed-cell sample. Flow cytometers work using four closely related systems. The 
fluidic system transports cells from a suspension into a stream of a single column of 
cells through the cytometer into an illumination system, where a laser beam is 
applied onto each cell in turn. The resulting light scattering and fluorescence from a 
fluorescently labeled cell is collected, filtered and converted into electrical signals 
by the optical and electronics system (see figure 2-1). The processing system 
utilises specialised software to save acquired data and to analyse the resulting 
information, which is heavily graphically oriented (see figure 5-2). Two standard 
modalities of graphical representation are used: one-parameter histograms give 
information of mean fluorescence and distributional statistics and may be 
superimposed to show a ‘shift’ in the fluorescence of cells exposed to different 
treatment conditions; and two-parameter box plots, which are important for 
identifying cells of interest based on size  and density and by expression of cell 
surface markers. Experience and pattern-recognition are an important part of flow 
cytometric analysis [155].  
 
2.7.2 Method 
PBMCs treated for specified time intervals with virus were harvested into 15 ml 
Falcon tubes (Corning) and centrifuged at 400g for 5 minutes, supernatant was 
collected and stored at -800C for later use. Cells were re-suspended in 200 µL per 
1x106 cells of FACS buffer (Sterile PBS, 1% FCS, 0.1% Sodium Azide). 
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Approximately 5 x 105 - 1 x 106 cells (in 100 – 200 µL) were then transferred into 
FACS tubes that have been previously loaded with 3 - 10 µL fluorescent antibodies 
(see table 2.2). Cells were incubated with antibody for 20 minutes in the dark at RT, 
and subsequently washed with 2mls of FACS buffer and pelleted by centrifugation 
at 400g for 5 minutes. The excess FACS buffer was decanted and the cells re-
suspended in 300 µL of 1% PFA for acquisition and analysis at a later date. 
Analysis was then performed using a FACSCalibur machine and BD CellQuest© 
Pro software (v4.0.1) (both Becton-Dickinson, Oxford, UK). 
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Figure 2-1. Flow cytometry 
A mixed population of fluorochrome-labelled cells in suspension is streamlined into 
a single column of cells in a ‘flow cell’. A laser beam (480nm) is applied onto each 
cell in turn, and its light emitting properties used to determine its physical and 
chemical properties. Photodiode electrodes (  ) analyse the emitted light and 
convert it into an electric signal. The identity of each cell can be determined by cell 
mass (FSC; forward scatter) and cell density (SSC; side scatter). Labelled with 
fluorescent antibodies, each cell will emit a light signal(s) of a particular 
wavelength(s). A system of dircroic interference filters will reflect emitted light of a 
particular wavelength onto a photodiode electrode (FL1=530nm, FL2=585nm, 
FL3=670nm, FL4=661nm), and this will be acquired and analysed using specialised 
software. 
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Target antigen Significance Flourochrome Volume Source 
Isotype Mix Control FITC, PE, 
PerCP 
2 µl Dako 
Cytomation 
CD3 T-cell Marker PerCP 3 µl BD Biosciences 
CD56 PE 2 µl Abd Serotec 
CD56 
Marker on NK cells and 
a subset of activated T-
cells (NK-T cells) FITC 10 µl BD Biosciences 
CD69 PE 5 µl BD Biosciences 
CD69 
Early Activation 
marker, and signal-
transmitting receptor FITC 10 µl BD Biosciences 
NKG2D Activation receptor on 
NK cells and T-cells 
PE 3 µl BD Biosciences 
DNAM-1 Activation marker PE 3 µl BD Biosciences 
NKp30 PE 3 µl BD Biosciences 
NKp44 PE 3 µl BD Biosciences 
NKp46 
Natural cytotoxicity 
receptors, expressed 
exclusively on NK cells, 
play a major role in NK-
mediated killing 
PE 3 µl BD Biosciences 
CD107 Marker of NK/T-cell 
cytotoxicity due to 
degranulation 
FITC 5 µl BD Biosciences 
CD80 Marker on activated B 
cells and monocytes. 
Provides a 
costimulatory signal for 
T cell activation and 
survival. 
PE 5 µl BD Biosciences 
CD86 Expressed on antigen-
presenting cells that 
provides a 
costimulatory signal for 
T cell activation and 
survival 
PE 5 µl BD Biosciences 
CD11c PE 5 µl BD Biosciences 
Class II DR 
expressed in antigen 
presenting cells (APC: 
B lymphocytes, 
dendritic cells, 
macrophages)  
PE 5 µl BD Biosciences 
CD14 Expressed on 
monocytes.  
FITC 5 µl BD Biosciences 
CEA Marker of colorectal 
carcinoma. 
FITC 5 µl BD Biosciences 
EGFR Receptor for epidermal 
growth factor. 
Stimulates cell growth 
and differentiation. 
PE 5 µl BD Biosciences 
Table 2-1 Antibodies used for cell-surface phenotyping 
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2.8 Cell viability 
2.8.1 Microculture tetrazolium test (MTT) 
2.8.1.1 MTT background 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), is a yellow 
tetrazole that is reduced to purple in living cells. A solubilisation solution e.g. DMSO 
is required to turn the insoluble purple product into a soluble, coloured solution. The 
absorbance can then be measured at a certain wavelength by a spectrophotometer, 
hence giving the level of cell viability due to active reductase enzymes [156]. 
 
2.8.1.2 MTT method 
8 x 103 cells/well were seeded into each well of a 96-well plate (Costar) and 
incubated overnight at 370C to adhere. Serial dilutions of the virus were made and 
added to each well in triplicate, from 10 pfu/cell to 1 x 10-6 pfu/cell, with an un-
infected control, and cells were incubated at 370c overnight. At specified time 
points, 20µL MTT (Sigma) was added to medium for 4 hours at 370C and then 
medium containing dead cells was removed. 150 µL DMSO was added to solubilise 
the cells and optical density was measured using a Multiskan EX plate reader 
(Thermo Fisher Scientific, Northumberland, UK) at wavelength 550nm using Ascent 
software (v 2.6, Thermo Fisher Scientific). The fluorescence output in sample wells 
was then compared to the un-infected control, and a relative fluorescence was 
calculated. 
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2.8.2 Cell viability assessment using a Live/Dead® fluorescent dye kit 
The Live/Dead® reactive dye can permeate the compromised membranes of dead 
cells and react with free amines both on the cell surface and in the interior, resulting 
in intense fluorescent staining. In viable cells, only the cell-surface amines will react 
with the dye, resulting in relatively dim staining. Following infection with escalating 
doses of JX-594 for specified time points in 6-well plates, cells were harvested, 
washed in PBS and placed in FACS tubes (BD Falcon) and centrifuged at 400g for 
5 minutes. 1 µL of Live/Dead fluorescent dye (PE) (Invitrogen, Paisely, UK) was 
added to the suspended cell pellet for 20 minutes at room temperature (RT). 
Following a final wash in PBS, and fixation in 1% PFA, acquisition and analysis was 
then performed using a FACSCalibur machine (Becton-Dickinson, Oxford, UK) 
using BD CellQuest© Pro software (v4.0.1), with the percentage of dead cells being 
determined as those that showed higher PE fluorescence. 
 
2.8.3 Intracellular active caspase-3 production 
2.8.3.1 Background 
Caspase-3 is a member of the Cysteine-aspartic acid protease (Caspase) family. 
The activation of caspase-3 plays a key role in the execution phase of apoptosis. 
Caspases exist as inactive proenzymes that undergo proteolytic processing by self-
proteolysis and/or cleavage by another protease, to produce two subunits that 
dimerise to form the active enzyme, active caspase-3. 
 
2.8.3.2 Method 
SW480 and SW620 cells were seeded into 6-well plates (2x105 cells in 3 mls 
culture medium). Following a 4-hour period to facilitate adherence of the cells, they 
were treated with 0, 0.1, 1 and 10 pfu/cell JX-594. Similarly, PBMCs were 
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suspended in culture medium at 2x106/ml in 6-well plates and treated with JX-594 
at 0, 0.1 and 1 pfu/cell. 
 
Following treatment over specified time-points, cells were harvested into FACS 
tubes, pelleted and fixed in 1% PFA. Active caspase-3 production was measured 
using a PE-conjugated Active Caspase-3 Apoptosis Kit (BD Pharmigen, Oxford, 
UK). Briefly, fixed cells were incubated for 20 minutes on ice with a 
Cytofix/Cytoperm™ solution at a volume of 0.5 ml/1x106 cells. Cells were 
centrifuged at 400g for 5 minutes at RT to remove excess buffer, washed in the 
Perm/Wash™ buffer at a volume of 0.5ml/1x106 cells and pelleted. Cells were 
incubated with a PE-conjugated Active Caspase-3 antibody diluted in Perm/Wash™ 
buffer for 30 minutes at RT. Cells were then washed with 1 ml Perm/Wash™ buffer, 
pelleted, and re-suspended in 500 µL Perm/Wash™ buffer. Cells were analysed 
immediately using a FACS Calibur flow cytometer (described in section 2.17). 
 
2.9 JX-594 replication  
2.9.1 Plaque assay background 
In order to determine the quantity of infectious virus particles, a procedure known 
as a plaque assay may be adopted. This technique was first developed for use in 
animal virology by Renato Dulbecco in 1952 [157]. 10-fold dilutions of a virus stock 
are prepared and 0.1ml aliquots are inoculated onto susceptible cell monolayers, 
and left to incubate. The cells are then covered with an overlay medium; a thick, 
nutrient-containing medium, that restricts spread of the virus to defined ‘plaques’ 
and aids to keep the cells stable. The originally infected cells will eventually lyse 
and release viral progeny, which is restricted to neighbouring cells by the overlay 
medium. Eventually, each virus particle produces a circular zone of infected/dead 
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cells; a ‘plaque.’ The plaque eventually becomes large enough to be visible to the 
naked eye. Surrounding living cells can be stained with a dye (e.g. methylene blue) 
to provide a contrast. The subsequent titre of a virus stock can be calculated in 
plaque-forming units (pfu) per ml. Each dilution of virus is plated in duplicate, and 
only those plates that have between 10 to 100 plaques are counted (for accuracy). 
The concentration of sample and stock virus used is determined by the formula 
below;  
 
# plaques     =    pfu/ml 
   d x V 
 
where d = dilution factor and V = volume of diluted virus added to the well  
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Figure 2-2 Illustration of viral plaques 
Figure a) shows a photomicrograph at 40x magnification of a vaccinia viral plaque 
on Vero cells. There is a central area of cells that have been killed by the virus. The 
overlay medium restricts each plaque-forming unit to a single plaque, minimising 
merging of plaques, hence allowing the quantification of the total number of 
infectious viral plaques. Figures b) and c) show duplicate wells demonstrating viral 
plaques following serial dilutions on a background of Vero cells dyed with 
methylene blue, fixed in 1% PFA. 
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2.9.2 Plaque assay method 
2.9.2.1 Sample preparation; CRC cell lines 
7.5 x 104 cells (SW480 and SW620) were adhered to a 24-well plate in 1 ml of 
medium at 370C for 4 hours. JX-594 was then added to the medium and incubated 
for various time points at 370C. Cells and supernatant were then harvested and 
subjected to three rounds of freeze-thaw; methanol/dry ice followed by a block-
heater at 370C (Grant Instruments, Cambridgeshire, UK). These were then stored at 
-800C until required. 
 
2.9.2.2 Sample preparation; PBMCs 
PBMCs were cultured at 2x106/ml in RPMI + 10% FCS and cell suspension 
including media harvested and frozen following 24 hour and 48 hour incubation with 
JX-594 at 0.1 pfu/cell in a 6-well plate. Samples were subjected to three cycles of 
freeze/thaw prior to plaque assay. 
 
2.9.2.3 Plaque assay 
Vero cells, which are susceptible to Vaccinia, were cultured in vented plastic tissue 
culture flasks (150 cm2), in a Sanyo CO2 incubator at 370C. Near-confluent cells 
were harvested and seeded at 2 x 105 in 6-well plates in 2ml DMEM + 10% FCS for 
4 hours to allow cells to adhere. Samples and reference stock virus sample 
dilutions were prepared by serial dilutions in DMEM, resulting in logarithmic 
dilutions ranging from 10-2 to 10-11.  
 
Medium was removed from the adherent Vero cells and replaced with 500 µL of 
serum-free medium and 100 µL of the diluted sample or stock virus (in duplicate 
wells) and incubated at 370C for a further 4 hours. The media containing the 
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sample/stock virus was then taken off and 2 mls of overlay medium (2:1 ratio of 
DMEM + 10% FCS and 1.6% (w/v) of carboxymethylcellulose (CMC)) was added to 
each well. Cells were then incubated at 370C for 3 days. 
 
Following this incubation, the excess media:CMC solution was removed and the 
cells were washed with PBS, and fixed with 0.5 ml 1% glutaraldehyde for 10 mins at 
RT. Following removal of the fixative solution, the cells were stained with 0.5 mls 
1% methylene blue (in 50% ETOH) for 3 minutes at RT and washed to remove the 
excess dye. Plaques were counted using a light box to aide visualisation and the 
average of duplicate wells was used to calculate viral titre using the formula 
described above. 
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2.10 ELISA (Enzyme-Linked Immunoabsorbent Assay) 
Flat bottomed 96 well Maxisorp© plates (Nunc) were coated with pre-optimized 
dilutions of capture antibodies (see table 2-2) diluted in coating buffer (100 mM 
NaHCO3 in ddH20) or PBS. These were then wrapped in cling-film and foil and 
incubated at 40C, overnight. Plates were then washed three times with PBS-Tween 
(0.05% Tween (Sigma) in PBS) using a plate washer (Skan Washer 300, Molecular 
devices, Berkshire, UK) and 200 µL of blocking solution (PBS + 10% FCS) was 
then added for 2 hours at RT. Plates were then washed a further 3 times with 
PBS/Tween. 200 µL of recombinant protein standards (at known concentrations) 
were added to the top three wells (in triplicate), and serial dilution were made to 
create a ‘standard curve.’ In order to prevent drying, the remainder of the wells 
were filled with 20 µL of medium, and the stored supernatants were thawed and 80 
µL added to the remainder of the wells, also in triplicate. This dilution was corrected 
for in the final algorithm. Following an overnight incubation at 40C, plates were 
washed six times in PBS/Tween and 100 µL of biotinylated detection antibody (see 
table) were added at appropriate dilutions in blocking solution for 2 hours, at RT. 
Following another 6 washes with PBS/Tween, 100 µL of Extravidin-alkaline 
phosphatase conjugate (Sigma), diluted 1:5000 with PBS/Tween was added for 1 
hour at room temperature. Plates were then washed again three times with 
PBS/Tween and three times with ddH2O. 100 µL of substrate solution was then 
added (p-nitrophenyl phosphate 1 mg/ml (Sigma) in 0.2 M TRIS Buffer (Sigma)) per 
well. Plates were left in the dark to develop for 30-180 minutes and placed in a 
multiskan EX plate reader (Thermo Fisher Scientific) at wavelength 450 nM to 
determine optical densities. Optical densities for each sample well are converted to 
a quantity of protein (pg/ml) by extrapolating from the standard curve. 
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Antibody Capture Detection Standard (top 
concentration) 
Type Source 
GM-CSF 1:500 1:1000 2000 pg/ml Mouse Anti-
human 
Mabtech 
IL-2 1:250 1:500 5000 pg/ml Mouse Anti-
human 
BD 
Biosciences 
IL-6 1:500 1:500 2000 pg/ml Rat Anti-human BD 
Biosciences 
IL-8 1:500 1:500 500 pg/ml Mouse Anti-
human 
BD 
Biosciences 
IL-10 1:500 1:1000 2000 pg/ml Rat Anti-human BD 
Biosciences 
IL-28 1:180 1:180 8000 pg/ml Mouse Anti-
human 
R&D Systems 
IL-29 1:180 1:180 4000 pg/ml Mouse Anti-
human 
R&D Systems 
TNFα 1:1000 1:1000 2000 pg/ml Mouse Anti-
human 
BD 
Biosciences 
VEGF 1:500 1:250 2000 pg/ml Mouse Anti-
human 
R&D Systems 
IFNα 1:250 1:500 5000 pg/ml Mouse Anti-
human 
Mabtech 
IFNγ 1:250 1:500 10,000 pg/ml Mouse Anti-
human 
BD 
Biosciences 
RANTES 
(CCL5) 
1:250 1:500 1000 pg/ml Mouse Anti-
human 
R&D Systems 
/ Mabtech 
Table 2-2 Antibodies and Standards used in ELISA 
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2.11 Interferon β ELISA 
IFNβ production was measured using the VerikineTM Human IFN Beta ELISA Kit 
(PBL Interferon source, NJ, USA). Pre-coated 96-well plates were supplied in the kit 
and 50 µL of sample supernatants were added in duplicate, along with serial 
dilutions of recombinant protein standards. Following a 1 hour incubation at RT, 
plates were washed three times with the supplied Wash Buffer in a trough and 100 
µL of the supplied detection antibody (diluted in the Concentrate Diluent) was 
added and incubated for 1 hour at RT. Following a further three washes in Wash 
Buffer, 100 µL of diluted Horseradish peroxidase (HRP) was added, incubated for 1 
hour and washed again with Wash Buffer. 100 µL of the supplied TMB substrate 
was added and developed in the dark for 15 minutes, following which 100 µL stop 
solution was added, and optical densities read using the Multiscan EX plate reader 
at a wavelength of 405 nm. Optical densities for each sample well are converted to 
a quantity of protein (pg/ml) by extrapolating from the standard curve. 
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2.12 Assessment of NK cell activity 
2.12.1  NK cell CD107 degranulation assay 
Degranulation of NK cells within a mixed PBMC population was determined by cell-
surface expression of CD107. PBMCs were isolated and cultured overnight in RPMI 
+ 10% FCS with 0, 0.1 and 1 pfu/cell JX-594. These ‘effector cells’ were then 
cultured in FACS tubes at a 10:1 effector:target ratio with SW480, SW620 or K562 
‘targets’ in a total volume of 400 µL at 37oC for 1 hour, along with 5 µL each of anti-
CD107a and anti-CD107b FITC antibodies (BD Biosciences). K562 served as a 
positive control. Following a one-hour incubation, 3 µL of 10 µg/ml Brefeldin A 
(Sigma) was added and incubation continued at 37oC for a further 4 hours. Cells 
were washed in FACS buffer and pelleted by centrifugation at 400g for 5 minutes at 
RT. 3 µL anti-CD3 PerCP and 2 µL anti-CD56 PE antibodies were added to each 
FACS tube, and incubated at RT for 20 minutes. Cells were pelleted by 
centrifugation and fixed with 300 µL 1% PFA and stored at 4oC prior to acquisition 
by flow cytometry.  
 
2.12.2 51Chromium release assay 
The cytotoxicity of NK cells within a mixed PBMC population was analysed using 
the 51Chromium (51Cr) release assay. PBMCs were isolated and cultured overnight 
in RPMI + 10% FCS with 0, 0.01, 0.1 and 1 pfu/cell JX-594. SW480 and SW620 
tumour target cells were harvested, washed and pelleted by centrifugation and 
incubated with 100 µL of 51Chromium at 37oC for 1 hour in a 50 ml Falcon tube, 
taking appropriate radioactive substance handling precautions. Effector cells 
(PBMCs) with or without overnight pre-treatment with JX-594 were harvested, 
washed and pelleted and re-suspended in lymphocyte culture medium at 5x106/ml. 
1x106 effector cells (200 µL) were pipetted into the top wells of a 96-well round-
bottomed plate (NUNC Thermo Scientific, Roskilde, Denmark) in triplicate, and 
diluted serially downwards to obtain effector: target ratios of  100:1, 50:1, 25:1 and 
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12.5:1. Following labelling, target cells were washed three times with 50 ml HBSS 
and re-suspended in lymphocyte culture medium at 5x104 cells/ml. 5x103 target 
cells (in 100 µL, making a total of 200 µL in each well) were added to each well. A 
separate plate containing no effectors was set up with 1% (v/v) Triton X in 
lymphocyte culture medium and media alone to determine maximum and 
spontaneous 51Cr release respectively. Triton X will lyse the target cells, providing a 
positive reference point for maximal 51Cr release. The plates were incubated at 
37oC for 4 hours, centrifuged at 400g for 5 minutes at RT and 50 µL of supernatant 
from each well was transferred into a Luma scintillation plate (Perkin Elmer, 
Warrington, Cheshire) and left to dry overnight. 51Cr release was determined using 
a liquid 1450 Microbeta scintillation and luminescence counter (Wallack Betajet 
System, Perkin Elmer). The results are expressed as percent tumour lysis using the 
formula: 
 
% lysis =  100 x (sample cpm – spontaneous cpm)  
(maximum cpm – spontaneous cpm) 
 
Where cpm = counts per minute as determined by the scintillation and 
luminescence counter. 
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2.13 Fresh liver tissue culture 
Liver cancer tissue and accompanying normal liver tissue was obtained from freshly 
resected liver specimens immediately following surgical resection in a sterile 
environment in the operating theatre. Written, informed consent was obtained in 
accordance with institutional ethics review and approval. Tissue was placed in 
‘fresh tissue culture medium’ for transfer; DMEM + 10% FCS with 1% Antibiotic 
Antimycotic Solution (10,000 units Penicillin, 10mg Streptomycin and 25µg 
Amphoterecin B (Sigma)). Tissue slices were made using a precision-cutting 
microtone (Leica, VT1000S), using 5x5 mm cubes of tissue embedded in 3% Agar. 
Slices were immediately placed in 2mls of the above described ‘fresh tissue culture 
medium’ in 6-well plates (Costar). Tissue cores were made using a Tru-Cut® biopsy 
needle (CareFusion, Surrey, UK), resulting in cores of 1mm diameter and 15mm 
length. In order to facilitate standardisation of tissue conditions, as well as optimal 
surface area for viral exposure, these 15mm cores were then divided into three 
5mm-length cores and placed into three separate wells. Tissue cores were 
maintained in flat-bottomed 12-well plates (Costar), with 3 cores in each well in 1ml 
of ‘fresh tissue culture medium’ for up to 96 hours. 
  
2.13.1 Validation of technique; Alamer blue 
In order to ensure that these tissue cores can be used as a true ‘ex vivo’ system, it 
was vital to ensure that the tissue retained steady metabolic activity for the duration 
of the incubation. AlamarBlue®  is a proven indicator of cell viability [158, 159] and 
uses the natural reducing power of living cells to reduce resazurin (a blue, nontoxic, 
nonfluorescent cell permeable compound) to a fluorescent molecule, resorufin, 
which produces a bright red fluorescence. Viable cells continuously convert 
resazurin to resorufin, thereby generating a quantitative measure of viability.  
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During tissue processing, separate cores of tissue were obtained for assessment of 
tissue viability. This assay was initially performed as described in the literature; 
wells containing three 5 mm cores of tissue in ‘fresh tissue culture medium’ were 
set up. At specified time points 25 µL of AlamerBlue® dye (Invitrogen) was added 
to each well, and left to incubate for 1 hour at 37oC, and 100 µL was pipetted in 
triplicate into a 96-well Microtitre plate (Greiner Bio One, Stonehouse, UK). The 
fluorescence from each well was measured using a fluorescence plate reader using 
530nm excitation and 590nm emission filters. The same cores were used for the 
entire duration of the experiment, with fresh media replenished at each time point 
up to 120 hours.  
 
In the second experimental condition, four wells containing three cores each were 
set up (once for each time point), with no replenishing of media. This mimicked the 
experimental conditions applied to all future experiments, and hence was more 
representative of the viability of the tissue cores following 96 hours of viral 
treatment.  
 
2.14 Isolation of liver- and tumour- derived mononuclear cells 
Freshly resected CRLM tumour and normal liver tissue was obtained from patients 
undergoing liver resection as detailed in section 2.13. Tissue was placed in a 
100mmx20mm petri dish (Corning Inc., NY, USA) and disaggregated manually 
using a standard disposable surgical scalpel (Swann-Morton, Sheffield, UK), with or 
without 10 ml of 0.5 mg/ml Collagenase II (Lorne laboratories, Reading, UK). The 
resulting tissue was then passed through a 70 µm cell strainer (BD Biosciences) 
and debris removed by washing with 50 ml HBSS and centrifugation at 400 g for 5 
minutes at RT. The resulting pellet was then either cultured in ‘tissue culture 
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medium’ and treated directly with JX-594-GM-CSF or a further density gradient 
separation step was performed. In the latter case, the pellet was re-suspended in 
30 ml HBSS and layered over 15 ml of Lymphoprep© in a 50 ml Falcon tube and 
centrifuged at 800g for 25 minutes at RT with no brake. Liver mononuclear cells 
(LMCs) and tumour mononuclear cells (TMCs) were collected from the interface 
layer using a Pasteur pipette, washed with HBSS, centrifuged, and cultured at 
2x106 cells/ml of culture medium (RPMI + 10% FCS + 1% Antibiotic Antimycotic 
Solution). 
 
2.15 Confocal laser scanning microscopy (CLSM) 
2.15.1  Background 
Although a standard fluorescent microscope would suffice to detect the 
fluorescence emission, the advantage of CLSM is that it enables the acquisition of 
high-resolution images which can be taken from selected depths within tissue, a 
process known as ‘optical sectioning’. Reconstructed images can be displayed as 
three-dimensional images and the process of ‘Z-stacking’ achieves this by taking 
images at pre-set planes. Hence, fluorescence present at both the surface and 
within the tissue can be detected at equal intensity.  
 
A laser beam is focussed onto the tissue via an objective lens, and any scattered 
and reflected laser light (as well as any inherent fluorescent light) is then re-
collected by the objective lens. A system of mirrors separates off some portion of 
light into the detection apparatus, via a filter, which selectively passes fluorescent 
wavelengths into a photodetection device. Separate images of various fluorescent 
wavelengths can be achieved and combined (see figure 4-1). In order to provide a 
focal contrast for CLSM lens, and to provide a demonstration of the tissue 
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architecture, a nucleic acid stain is used prior to microscopy. 4',6-diamidino-2-
phenylindole (DAPI) is a fluorescent stain that binds strongly to A-T rich regions in 
DNA. In order to ensure penetration of the dye, particularly in live cells, it may be 
diluted in 0.1% Triton X.  
 
2.15.2 Method 
At specified time points following infection of the tissue slices/cores with JX-594-
GFP, supernatant was harvested, and the tissue fixed in 1% PFA. Prior to CLSM, 
nuclear staining was performed with DAPI (Invitrogen); 1% DAPI diluted in 0.1% 
Triton X (diluted in PBS) at RT for 45 minutes. The stain was washed off with PBS 
and the tissue re-suspended in 1% PFA. CLSM was preformed using a Nikon A1 
Confocal Laser Scanning Microscope (Nikon, Tokyo, Japan). Settings for the lasers 
(DAPI, FITC) were kept as standard throughout all experiments. DAPI; HV: 110, 
Offset: -110, FITC; HV: 90, Offset: -17.  
 
2.16 Statistical Analysis 
Continuous data is graphically presented as mean + standard deviation (SD). P 
values were calculated using paired student’s t-test with two-tailed distribution and 
the one-way or two-way Analysis of Variants (ANOVA) test with Bonferroni's 
multiple comparison post-hoc test. p<0.05 was regarded as significant. Statistics 
were performed using Graphpad Prism for Mac (v 5.0b, Graphpad Software, Inc). 
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Chapter 3 
 
Results: JX-594 can replicate in and kill tumour 
cells and trigger inflammatory changes in the 
tumour microenvironment 
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3 JX-594 can kill tumour cells and trigger inflammatory 
changes in the tumour microenvironment 
3.1 Introduction 
The infection of a tumour cell by JX-594 leads to a series of events that eventually 
results in tumour cell death. The complexity of the viral genome is not fully 
understood, however several favourable attributes have been demonstrated which 
result in tumour-specific toxicity, as described in detail in section 1.3. As previously 
discussed, associated with viral killing is the potential induction of an inflammatory 
tumour microenvironment, which promotes the recruitment of immune cells and 
may result in the subsequent induction of anti-tumour memory. This chapter 
describes studies to investigate the direct cytotoxicity of JX-594 against CRC cell 
lines, and the induction of a cytokine/chemokine response. Cytokines/chemokines 
analysed and a summary of their functions are outlined in table 3-1. 
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Table 3-1 Cytokines/chemokines involved in the inflammatory response 
Table shows the cytokines/chemokines involved in the inflammatory response that 
are studied in this chapter. 
 
 
Cytokine/ 
Chemokine 
Main Source Function 
IL-6 Th2 T-cells and 
macrophages 
Activation of lymphocytes, differentiation of 
B cells, stimulating production of acute-
phase proteins 
IL-8 T-cells and macrophages Chemotaxis of neutrophils, basophils and T 
cells 
IL-10 Monocytes and lymphocytes Inhibiting synthesis of pro-inflammatory 
cytokines, and impairs proliferation of 
lymphocytes 
CCL5 CD8+ T cells Chemotactic for T cells, eosinophils, and 
basophils, and recruits leukocytes into 
inflammatory sites. 
VEGF Rapidly differentiating cells Stimulates vasculogenesis and 
angiogenesis 
GM-CSF T-cells, macrophages, NK 
cells, and B-cells 
Promotion of the growth of granulocytes 
and macrophages 
IFNα 
IFNβ 
Virally infected cells, NK 
cells, B-cells and T-cells, 
pDCs (maximal IFNα), 
macrophages, fibroblasts, 
endothelial cells, osteoblasts 
 
Resistance to virus, and activation of 
lymphocytes with NK and T cell phenotype. 
Resistance to virus 
IL-28 Virally infected cells Induces an anti-viral state in response to 
viral particles 
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3.2 JX-594 infection results in tumour cell death 
To investigate the direct lytic potential of JX-594 in an in vitro system, the 
cytotoxicity of JX-594 against tumour cell lines was investigated. The CRC cell lines 
HCT116, LoVo, SW480 and SW620 were infected with JX-594-GM-CSF, at 
concentrations of 0, 0.1, 1 and 10 pfu/cell for 24, 48, 72 and 96 hours. At specified 
time points, cells were harvested and percentage cell viability was determined using 
MTT and a Live/Dead® discrimination kit. Figure 3-1 illustrates tumour cell viability 
following JX-594 infection as demonstrated by the MTT assay. All cell lines were 
susceptible to JX-594 induced death, although a variation in sensitivity was evident, 
with the HCT116 and SW620 cell lines being more resistant to the lytic effects of 
the virus than LoVo and SW480. In HCT116 cells, a significant decrease in viability 
was only evident after 96 hours p.i., and only with 10pfu/cell JX-594. In SW620 
cells, significant decrease in viability was evident after 72 hours p.i., and again, only 
following 10pfu/cell JX-594 treatment. In contrast to HCT116 and SW620 cells, 
LoVo cells showed a significant reduction in metabolic activity by MTT assay by 48 
hours, and following treatment with 10 pfu/cell. By 96 hours of treatment, a 
reduction in viability was observed with both 1 pfu/cell and 10 pfu/cell treatment. 
SW480 cells showed similar susceptibility to LoVo cells. 
 
To confirm that loss of metabolic activity was a result of cell death, the Live/Dead® 
assay was performed (figure 3-2). In HCT116 cells, a significant (p<0.05) reduction 
in viability compared to untreated cells was evident only after 72 hours of treatment, 
and only with 10pfu/cell JX-594. There was a significant difference in viability of 
HCT116 cells treated with 1 and 10 pfu/cell JX-594 at 96 hours post-infection (p.i.). 
In SW620 cells, a similar pattern was observed, with significant reduction in viability 
following treatment with only 10 pfu/cell JX-594 for at least 72 hours. In contrast to 
HCT116 and SW620, significant reduction in viability of LoVo cells compared to 
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untreated control was observed by 72 hours and 96 hours p.i., with both 1 pfu/cell 
and 10 pfu/cell treatment, with a significant improvement in killing with escalating 
doses of virus (1 pfu/cell vs 10 pfu/cell). SW480 cells showed similar susceptibility 
to LoVo cells; following 96 hours of treatment, a reduction in viability was observed 
with both 1 pfu/cell and 10 pfu/cell JX-594. The cytopathic effect of JX-594 on 
SW480 and SW620 cells is depicted in photomicrographs in figure 3-3. It is 
interesting to note that HCT116 and SW620 cell lines were less susceptible to viral 
killing, and these were observed to grow more rapidly in culture compared to LoVo 
and SW480 cell lines, as observed by the differing split ratios required when 
passaging these cells in culture. 
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Figure 3-1. Susceptibility of CRC cell lines to JX-594-mediated death by MTT 
assay 
CRC cell lines a) HCT116 b) LoVo, c) SW480 and d) SW620 were seeded at 8 x 
103 cells per well in a 96-well plate  and infected with JX-594 at concentrations of 0, 
0.1, 1 and 10 pfu/cell overnight. At appropriate time points post infection, MTT was 
added for 4 hours and DMSO used to solubilise the cells. Absorbance was 
measured and % viability was calculated relative to untreated cells. All experiments 
were performed in triplicate (N=3), and bars show the mean + SD. * indicate 
significant reduction in viability; *p<0.05, ** p<0.01, ***p<0.001. 
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Figure 3-2. Susceptibility of CRC cell lines to JX-594-mediated death by 
Live/Dead® assay 
CRC cell lines a) HCT116 b) LoVo, c) SW480 and d) SW620 were seeded at 2 x 
105 cells per well in a 6-well plate and infected with JX-594 at concentrations of 0, 
0.1, 1 and 10 pfu/cell. Cells were subsequently harvested and stained with a red 
fluorescent dye (Live/Dead® kit) and fixed. Fluorescence, and hence the viability, of 
the cells was evaluated by flow cytometry. All experiments were performed in 
triplicate (N=3) and bars show the mean + SD. * indicate significant reduction in 
viability; *p<0.05, ** p<0.005, ***p<0.001. 
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Figure 3-3. JX-594 kills and retards proliferation of CRC cell lines 
SW480 and SW620 cells were seeded at 2 x 105 cells in a 6-well plate, and were 
treated with 0pfu and 1pfu/cell JX-594 and photos were taken at 24 and 96 hours at 
40x magnification, against white light. SW480s were split at a 1:4 ratio and SW620s 
at a 1:6 ratio to achieve confluence within 3 days in culture. 
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3.3 JX-594 Activates Caspase-3 in CRC Cell Lines 
To investigate the mechanism by which JX-594 kills CRC cell lines, SW480 and 
SW620 cells were infected with varying concentrations of JX-594-GM-CSF (0, 0.01, 
0.1 and 1 pfu/cell) for 24, 48, 72 and 96 hours, and expression of active Caspase-3 
was determined by flow cytometry using an Active Caspase-3 Apoptosis Kit 
(section 2.8.3). Figure 3-4 demonstrates that an increase in 1) the percentage of 
cells expressing active caspase-3 (a and c) and 2) the mean fluorescence intensity 
(b and d) was observed in both cell lines, with an average of 65% of SW480 cells 
and 35% of SW620 cells expressing active caspase-3 by 96 hours, following 
treatment with 1 pfu/cell JX-594. Hence, the results indicate that JX-594 induces 
cell death by activation of caspase-3 and apoptosis mediated pathways. In keeping 
with the susceptibility to viral killing, SW480 cells expressed more active caspase-3, 
and hence higher levels of apoptosis. 
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Figure 3-4. JX-594 activates Caspase-3 in CRC cell lines 
SW480 (a and b) and SW620 (c and d) CRC cell lines were seeded at 2 x 105 in 6-
well plates and treated with JX-594 at 0, 0.01, 0.1, and 1 pfu/cell for 24, 48, 72 and 
96 hours. Cells were harvested and active caspase-3 production measured using a 
PE-conjugated Active Caspase-3 Apoptosis Kit and flow cytometry. All experiments 
were performed in triplicate (N=3) and error bars show the mean + SD. Data is 
expressed as % cells expressing active caspase-3 (a and c) and mean 
fluorescence intensity (b and d) of PE anti-caspase-3 fluorophore as detected by 
flow cytometry. 
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3.4 Vaccinia replicates effectively in tumour cell lines 
3.4.1 JX-594 replication demonstrated by plaque assay 
To examine viral replication, SW480 and SW620 CRC cell lines were infected with 
0.1 pfu/cell and 1 pfu/cell JX-594. Initially, samples were harvested at four time 
points post infection (24, 48, 72 and 96 hours) and fold increase in viral replication 
over time as demonstrated by plaque assay is shown in Figure 3-5. JX-594 
replicated in SW480 and SW620, with an increased replication efficiency in the 
more susceptible cell line, SW480, compared to the more rapidly diving cell line, 
SW620. Increased replication was seen in the samples infected with 0.1 pfu/cell 
compared with 1 pfu/cell. A time-dependant increase in viral replication was 
observed with 0.1 pfu. In contrast, a reduction in fold replication at 96 hours was 
observed in samples infected with 1 pfu/cell. As the most efficient fold-replication 
was noted to be following infection with 0.1pfu/cell of JX-594, the remainder of 
experiments (total N=5) were performed in these conditions.  As depicted in figure 
3-6, these data confirm an improved replication efficiency in the SW480 cells (mean 
216-fold), compared to SW620 (150-fold) correlating with the increased cytotoxicity 
observed in SW480 cells. 
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Figure 3-5 JX-594 Replication in SW480 and SW620 cells at 1 and 0.1pfu/cell 
2 x 105 SW480 (a and b) and SW620 (c and d) cells were adhered onto a 6-well 
plate with tissue culture medium. 0.1 pfu/cell (a and c) or 1 pfu/cell (b and d) of JX-
594 was added and cells and supernatant harvested at specified time points, and 
frozen, and subjected to 3 rounds of freeze/thaw. A plaque assay was used to 
asses fold replication. Figure shows the results of a single experiment.  
 
Figure 3-6 JX-594 replication at 0.1pfu/cell at 72 hours 
SW480 and SW620 cell lines were infected with JX594 at 0.1 pfu/cell for 72 hours. 
Cells and supernatant were harvested and subjected to 3 rounds of freeze/thaw. 
Plaque assay was used to determine virus concentration and hence fold replication 
compared with input virus. Data is presented as mean fold replication + SD. 
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3.4.2 Enhanced surface expression of EGFR in SW480 cells may 
explain enhanced replication 
Amongst a plethora of yet-to-be fully-characterised proteins, the vaccinia genome 
encodes for VGF, which is an EGF analogue. The early-phase production of VGF 
from JX-594 will bind to EGFR and enhance the environment of the cell for vaccinia 
replication. To examine the potential mechanisms behind enhanced JX-594 
replication in SW480 cells, the surface expression of EGFR was determined. 2 x 
105 SW480 and SW620 cells were maintained in culture medium up to 96 hours 
and harvested and incubated with an EGFR-PE antibody for 20 minutes. Figure 3-7 
shows that EGFR is expressed on the surface of SW480 cells, but not SW620 cells. 
Hence, in SW480 cells it is possible that VGF binding to EGFR may facilitate 
increased JX-594 replication in these cells. 
 
Figure 3-7. EGFR expression in SW480 and SW620 cells 
2 x 105 SW480 and SW620 cells were cultured in 6-well plates for 96 hours in 
culture medium. Cells were harvested and surface expression of EGFR determined 
by flow cytometry using an EGFR-PE antibody.  
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3.4.3 JX-594 replication demonstrated by Green Fluorescent Protein 
(GFP) expression 
The insertion of GFP into the disrupted TK locus of the vaccinia genome may be 
exploited to examine the potential replication efficiency of the virus. GFP is 
expressed under the control of an early/late promoter, hence small quantities of 
GFP may be transcribed as the virus enters the cell and takes over the cell 
machinery, and further transcription may take place at the late stage of viral 
replication. In order to further examine and understand JX-594 replication, SW480 
and SW620 cells were treated with varying concentrations of JX-594-GFP; 0, 0.01, 
0.1 and 1 pfu/cell for 24 - 96 hours. At specified time points, cells were harvested 
and fixed in 1% PFA, and GFP expression examined by flow cytometry (FITC). A 
viral dose- and time-dependant increase in GFP production was seen as shown in 
figure 3-8. Flow cytometry reveals earlier GFP expression in SW480, which is 
similar to the findings of the plaque assay where, following 1 pfu/cell JX-594 
infection, plaques were visible at 24 hours in the SW480 samples (figure 3-5 b), and 
only at 48 hours in the SW620 samples (figure 3-5 d). In both cell lines, following 72 
hours infection with JX-594-GFP, the % cells positive for GFP expression 
plateaued, and thus figures 3-8 c) and d) depict a comparison of both cells lines at 
72 hours p.i. There is an increase in the mean fluorescence and hence the quantity 
of GFP protein expression in SW480 cells (significant increase at 1 pfu/cell 
treatment) compared to SW620 cells, potentially inferring an increased number of 
replicating viral particles. 
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Figure 3-8 JX-594 replication in CRC cell lines as demonstrated by GFP 
expression  
Figure demonstrates an increase in GFP expression as % cells expressing GFP (a, 
b and c) and the geometric mean of the fluorescence intensity (d) in SW480 (a) and 
SW620 cells (b). For comparison, GFP expression as % positive cells (c) and 
geometric mean (d) at 72 hours in both cell lines is plotted. 2 x 105 cells were 
adhered onto a 6-well plate in 2ml of medium and infected with JX-594-GFP and 
cells harvested, pelleted and fixed with 1% PFA at specified time points. The 
fluorescence intensity (FITC) was determined by FACS analysis. All experiments 
were performed in triplicate (N=3) and bars show the mean + SD. * indicate 
significant increase in viability; *p<0.05, **p<0.01, ***p<0.0001  
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3.4.4 GFP demonstration by confocal laser scanning microscopy  
CLSM allows further demonstration of the replication ability of JX-594 as inferred by 
GFP production. Figure 3-9 shows GFP production in SW480 (a) and SW620 (b) 
CRC cell lines respectively. This further demonstrates the difference in replication 
due to the quantity of green fluorescence in the cells in the photographed field. At 
both 24 and 48 hours p.i., increased GFP expression is seen in the SW480 cells 
(figure 4-4 a) as compared to SW620 (figure 4-4 b). By 72 hours (SW480) and 96 
hours (SW620) the images also show the resulting death of the tumour cells. The 
substantial increase in GFP fluorescence between 48 and 72 hours is in keeping 
with the replication cycle of the virus as detailed in section 1.3, and is the point in 
which viral progeny will escape from the lysed cell and begin to infect surrounding 
cells. 
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Figure 3-9. CLSM images showing GFP expression by JX-594-GFP replicating 
in SW620 CRC cell line 
(Figure on previous page) 2 x 105 SW480 and SW620 cells were adhered onto a 6-
well plate and infected with JX-594-GFP at 0, 0.01, 0.1 and 1 pfu/cell. At specified 
time points, growth medium was removed and cells were fixed in 1% PFA and 
photographed using confocal laser scanning microscopy with dual phase to depict 
tumour cells and GFP. 
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3.5 The induction of an inflammatory tumour microenvironment 
by JX-594; cytokine and chemokine profiles. 
Once the ability of JX-594 to kill CRC cell lines by apoptosis had been determined, 
the induction of virally-expressed and other chemokines and cytokines by infected 
tumour cells was investigated. GM-CSF is cytokine that stimulates stem cells to 
produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes. It 
also serves as a chemotactic cytokine (chemokine), attracting immune cells. 
HCT116, LoVo, SW480 and SW620 CRC cell lines were infected with varying 
concentrations of JX-594-GM-CSF, at concentrations of 0, 0.01, 0.1, 1 and 10 
pfu/cell for 24, 48, 72 and 96 hours. At specified time points, cell-free supernatant 
was collected and expression of GM-CSF from virally-infected cell lines was 
determined by ELISA. GM-CSF was expressed in a dose/time responsive manner 
(see Figure 3-10), with significant increase from untreated controls by 48 hours p.i. 
in all four cell lines. At 72 hours, similar quantities of GM-CSF were detected in all 
four cell lines (~2000 pg/ml).  By 96 hours p.i., there was a reduction in GM-CSF 
production at 10 pfu/cell JX-594, with a significant decrease in GM-CSF production 
following treatment with 10 pfu/cell JX-594 compared to 0.01 pfu/cell (SW480) and 
0.1 pfu/cell (HCT116). 
 
Vascular endothelial growth factor (VEGF) is a signal protein produced by cells that 
stimulates the growth of new vessels (vasculogenesis) and the propagation of 
existing vessels (angiogenesis), and is expressed early in the progression of 
colorectal cancer [160]. The faster growing HCT116 and SW620 cell lines produced 
higher levels of VEGF in culture by 96 hours (untreated control); 1395 pg/ml and 
1249 pg/ml respectively. Figure 3-11 illustrates that JX-594 treatment induced a 
significant down-regulation of VEGF production from all four cell lines following 96 
hours of treatment.  
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Figure 3-10. GM-CSF production in CRC cell lines treated with JX-594 
CRC cell lines, HCT116 (a), LOVO (b), SW480 (c) and SW620 (d) were seeded at 
2 x 105 in 6-well plates and treated with JX-594 at 0, 0.01, 0.1, 1 and 10 pfu/cell for 
24, 48, 72 and 96 hours. Supernatant was collected and GM-CSF production 
measured by ELISA. All experiments were performed in triplicate (N=3) and bars 
show the mean + SD. * indicate significant increase/decrease in GM-CSF; *p<0.05, 
** p<0.001, ***p<0.0001 (only relevant statistics bars are included).  
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Figure 3-11. VEGF production in CRC cell lines treated with JX-594  
CRC cell lines, HCT116 (a), LOVO (b), SW480 (c) and SW620 (d) were seeded at 
2 x 105 in 6-well plates and treated with JX-594 at 0, 0.01, 0.1, 1 and 10 pfu/cell for 
24, 48, 72 and 96 hours. Supernatants were collected and VEGF production 
determined by ELISA. All experiments were performed in triplicate (N=3) and bars 
show the mean + SD. * indicate significant decrease in VEGF levels; *p<0.05, ** 
p<0.01, ***p<0.005. 
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To assess the induction of a pro-inflammatory tumour micro-environment, IL-6, IL-8, 
IL-10, CCL5, IFNα, IFNβ and IL-28β production by JX594-infected CRC cell lines 
was investigated. IL-6 is a pro-inflammatory cytokine and IL-10 is considered to be 
immunosuppressive, as it inhibits synthesis of pro-inflammatory cytokines, immune 
priming and T-cell proliferation [161]. IL-6 was produced from all four CRC cell 
lines, with no significant increase/decrease with time in the untreated controls. 
There was a general increase in IL-6 in the supernatants of all four CRC cell lines 
following treatment with JX-594 (data not shown), a finding which was more 
pronounced in the HCT116 and SW480 cell lines; however, a statistically significant 
increase was only evident in these cell lines following treatment with 10 pfu/cell of 
JX-594 for 48 hours.  
 
IL-10 was produced by all four CRC cell lines in the absence of JX-594, with a 
general increase seen in the LoVo, SW480 and SW620 cell lines with time (see 
Figure 3-12 for SW480 and SW620 data). Only the SW480 cell line showed a 
significant increase in IL-10 production in culture with time in the untreated cells, 
and there was a significant decrease with JX-594 treatment compared to untreated 
control at 72 hours p.i. (vs 1 and 10 pfu/cell) and 96 hours p.i. (vs 0.01, 0.1, 1 and 
10 pfu/cell). In the SW620 cell line, JX-594 treatment only induced significant 
reduction in IL-10 in the supernatant following 96 hours of treatment (0 vs 10 
pfu/cell). 
 
CCL5 (Regulated on Activation, Normal T Cell Expressed and Secreted; RANTES) 
is chemotactic for T cells, eosinophils, and basophils, and recruits these leukocytes 
into inflammatory sites; it also induces the proliferation and activation of certain NK 
cells. There was no dose/time response observed following JX-594 treatment of all 
four CRC cell lines with JX-594 (data not shown). Similarly to CCL5, there was no 
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observed dose/time response in the production of IFNα, IFNβ, or IL-28β from CRC 
cell lines following treatment with JX-594 (data not shown). IFNα and IFNβ are type I 
interferons and IL-28β is a type III interferon; these are all involved in the immune 
defence against viruses. As type I interferons may be produced early in response to 
viral infection, supernatants were also collected at 6 hours p.i., but again no 
induction of interferons by JX-594 was seen (see table 3-2). 
 
JX-594 treatment of the four CRC cell lines resulted in a variable IL-8 response 
(see figure 3-13). In the more aggressive cell lines, HCT and SW620, there was an 
increase in IL-8 production in the supernantant of the untreated cells with time, and 
after 96 hours of treatment, there was a dose-dependant decrease in IL-8, which 
was only significant in HCT116 cells (0 vs 10 pfu/cell and 0.01 vs 10 pfu/cell). The 
converse was true for the LoVo cell line – after 96 hours of JX-594 treatment, there 
was a significant increase in IL-8 production with up to a dose of 1 pfu/cell, following 
which there was a significant decrease with 10 pfu/cell treatment. 
 
Overall, JX-594 treatment of CRC was observed to result in a pro-inflammatory and 
anti-angiogenic tumour microenvironments, with an increase in GM-CSF and IL-6 
and a decrease in IL-10 and VEGF (see table 3-2 for data summary). 
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Figure 3-12. IL-10 production in CRC cell lines treated with JX-594  
CRC cell lines, SW480 (a) and SW620 (b) were seeded at 2 x 105 in 6-well plates 
and treated with JX-594 at 0, 0.01, 0.1, and 1 pfu/cell for 24, 48, 72 and 96 hours. 
Supernatant was collected and IL-10 production measured by ELISA. All 
experiments were performed in triplicate (N=3) and bars show the mean + SD. * 
indicate significant increase/decrease in IL-10 production; *p<0.05, ** p<0.005, 
***p<0.0001. 
 
 
 
Figure 3-13. IL-8 production in CRC cell lines treated with JX-594 
CRC cell lines, HCT (a), LOVO (b), SW480 (c) and SW620 (d) were seeded at 2 x 
105 in 6-well plates and treated with JX-594 at 0, 0.01, 0.1, and 1 pfu/cell for 24, 48, 
72 and 96 hours. Supernatants were collected and IL-8 production measured by 
ELISA. All experiments were performed in triplicate (N=3) and bars show the mean 
+ SD. * indicate significant increase/decrease in IL-8 production (p<0.05) 
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 Effect upon infection of CRC cell lines with JX-594 
 Early (< 48 hours) Late (48 – 96 hours) 
GM-CSF !* !* (dose dependant decrease 
at 96 hours) 
VEGF "# $* 
IL-6 !* ! 
IL-8 "# $(HCT, SW620) !(LoVo) 
IL-10 $ (SW480, SW620) $*(SW480, SW620) 
IL-28 "# "# 
CCL5 
(RANTES) 
"# "# 
IFNα¶  "# - 
IFNβ¶ "# - 
 
Table 3-2. Summary of cytokine and chemokine profile following treatment of 
CRC cell lines with JX594 
Table summarises the overall cytokine profile of CRC cell lines infected with JX-
594. All experiments were carried out in triplicate. 
* Significant (p<0.05) 
¶ Supernatant also collected at 6 hours 
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3.6 Discussion 
In the development of an anti-cancer therapy, the primary outcome is that of direct 
tumour cell lysis. The results displayed in this chapter demonstrate the ability of JX-
594 to kill tumour cell lines. There was an observed variability in the growth patterns 
and sensitivity of the CRC cell lines investigated; both HCT116 and SW620 cell 
lines were observed to grow more rapidly in culture compared to LoVo and SW480 
cell lines, and were less susceptible to viral killing. This is particularly interesting in 
the context of the SW480 and SW620 cell lines, which are derived from the same 
patient (51-yr old Caucasian male); SW480 from the primary tumour and SW620 
from a secondary lymph node metastatic deposit. Interestingly, there were 
observed differences in cell viability using the MTT and Live/Dead® assay, which 
assess different mechanisms of the loss of cell viability; loss of metabolic activity by 
the MTT assay and loss of cell membrane integrity (presumably, at the point of viral 
exit from the cell) by the Live/Dead® assay. Both cell lines were found to 
significantly lose membrane integrity by 72 hours (Live/Dead® assay) which 
conforms with the life cycle and host-cell interaction of JX-594; however, the slower 
proliferating cell line (SW480) demonstrated a significant reduction in metabolic 
activity (MTT) by 48 hours, which was earlier than the faster growing SW620 cell 
line, which had significant reduction in viability by 72 hours only. The likely 
explanation of this difference is that in the SW620 cell line, the non-virally infected 
cells proliferate faster, maintaining a larger number of viable cells with preserved 
metabolism, leading to a higher metabolic activity of the cell population as a whole.  
 
Similar results have been published in the literature. Lun et al. showed that JX-594 
was effective against killing of malignant glioma cell lines, with about 10% viability 
in four out of five cell lines by 72 hours at an MOI of 10 [162]. In addition to this, 
they also demonstrated greater efficacy and broader spectrum of activity of JX-594 
- 99 - 
versus other oncolytic viruses such as VSV and Reovirus. Heo et al. demonstrated 
JX-594 mediated killing in HCC cell lines HepG2, SNU423, SNU475, SNU449, and 
PLC/PRF/5 [134]. Similarly, and more recently, Parato et al. demonstrated effective 
JX-594 mediated killing against a wide panel of tumour cell lines; colorectal, 
ovarian, kidney, breast, brain, prostate, non-small cell lung cancers, melanoma and 
leukaemia. They reported ED50 (the initial virus MOI to achieve 50% cell killing 
compared to untreated control) after 72 hours of treatment in SW620 and HCT116 
cell lines to be approximately 1 pfu/cell for both. This is marginally higher than the 
levels of killing presented in this chapter. In the same study, they also demonstrated 
killing of tumour initiating cells (TICs) of colorectal and lung origin [163]. This is a 
significant finding, as TICs are notorious for resistance to many conventional cancer 
therapies [164]. 
 
As discussed in section 3.3, the activation of caspase-3 following JX-594 infection 
demonstrates that JX-594 promotes apoptosis. Caspases are involved in the 
transduction of a ‘kill’ signal, and ultimately in the destruction of various cellular 
protein targets [165]. Liskova et al. used a WR vaccinia strain to infect HeLa G 
(human cervical carcinoma) and BSC-40 (African green monkey kidney cells). 
Using a cell-based flow cytometric assay, they showed a activation of caspase-2, 3 
and 4 in both cell lines after JX-594 treatment, which was inhibited following 
treatment with a pan-caspase inhibitor (Z-VAD) [166]. However, they also argue 
that, although vaccinia can initiate the apoptotic program, apoptosis was not 
completed and switched into necrosis, as there was no observed vaccinia-induced 
cleavage of poly ADP-ribose polymerase (PARP), another classical hallmark of 
apoptosis [167]. The loss of membrane integrity as demonstrated by the 
Live/Dead® assay, may suggest the development of necrosis, however, in vitro, 
apoptotic cells will proceed to ‘late apoptosis’, alternatively referred to as 
‘secondary necrosis’. Although activation of the executioner caspase-3 was evident, 
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the mechanism of viral exit from the cell following replication by exocytosis or 
membrane disruption [168] suggests a double-pronged attack by JX-594 (apoptosis 
and necrosis), which is important in the initiation of an inflammatory reaction. In 
vivo, apoptotic cells would not release their cellular constituents into the 
surrounding interstitial tissue as they are quickly phagocytosed by surrounding 
immune cells [169]. In contrast, the disruption of the membrane by viral exit may 
result in shedding of danger signals, and tumour associated antigens which can 
bolster an adaptive anti-tumour immune response. 
 
The cytotoxic effects of other oncolytic viruses against CRC cell lines have been 
studied in vitro. Kooby et al. demonstrated cell survival ranging between 10 - 75% 
after 96 hours of treatment with G207, a multi-mutated herpes virus, against a panel 
of 5 CRC cell lines; C18, C29, C85, C86 and HCT8 [170]. Using a vesicular 
stomatitis virus (M51R), Stewart et al. demonstrated 20% viability of HCT116 cells 
following 48 hours of treatment at an MOI of 1, and in LoVo cells, 80% viability 
[171]. Adair et al. demonstrated reovirus induced cytotoxicity in a panel of four CRC 
cell lines; LoVo, LS174T, SW480 and SW620, and showed  significant death 
compared to untreated control following 24 hours treatment with 1 pfu/cell. By 72 
hours, >80% killing was evident in SW480 and Lovo cell lines, and 40% death in 
SW620 [172]. Thus, in comparison to other OVs, JX-594 may have a slower, 
steadier cytotoxicity rather than a rapidly-ablative tumour cell destruction as 
demonstrated by these studies.  
 
The slower JX-594-mediated cytotoxicity detailed in this chapter may have 
beneficial consequences. It allows time for the induction of an inflammatory process 
and immunogenic activation of the tumour microenvironment, allowing for induction 
of therapeutically beneficial cytokines, some of which may be chemo-attractant to 
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immune effector cells. The steady tumour killing induced by JX-594 is particularly 
beneficial in the context of virally-encoded proteins such as GM-CSF. The results in 
section 3.4 show that maximal GM-CSF production occurred at 96 hours, and this 
decreased at higher doses of virus, when less viable cells were available for viral 
replication and hence cytokine production. Hence, a slower death may allow for 
greater production of replication-dependant virally-encoded proteins, further 
supporting JX-594 as a vector for optimal therapy.  
 
The differences in susceptibility of the SW480 and SW620 cell lines may be 
explained by the ability of JX-594 to replicate within these tumour cell lines. Plaque 
assays have shown replication to be more efficient in the SW480 cell line. This may 
be explained by the difference in tumour cell biology of SW480 and SW620 
affecting the ability of JX-594 to either infect or replicate within these tumour cells. 
The finding of surface EGFR expression on SW480 cells may explain the 
susceptibility of this cell line to viral killing and replication. This variable expression 
of EGFR has also been published by Dahan et al.; no EGFR expression was 
detected in SW620 cells, while SW480 cells showed an EGFR-positive expression 
by immunoblot.  However, both cell lines are K-Ras mutant [173]. Parato et al. have 
demonstrated that killing of lung and colon tumour initiating cell lines by JX-594 (JX-
594-GFP+/β-gal−) is dependant on replicative ability, which is in turn dependent on 
EGFR/Ras/MAPK (mitogen-activated protein kinase) pathway signalling. SW620 
and HCT116 CRC cell lines (both K-Ras mutant) were pre-treated for 2 hours with 
U0126, an inhibitor specific for extracellular signal-regulated kinase (ERK) (a MAPK 
that is rapidly phosporylated following EGFR activation) prior to treatment with 
0.1pfu/cell, and they found U0126 inhibited JX-594-GFP+/β-gal− replication [163]. 
Langammer et al. have also demonstrated that an EGFR inhibitor, Gefitinib (Iressa), 
can impair poxvirus spreading [174]. Thus, EGFR expression by tumour cells may 
make them more susceptible to JX-594 treatment, and enhancing the EGFR 
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pathway may augment replication of JX-594, which is mechanistically important, as 
direct JX-594 mediated killing is dependant on replication. 
 
Exploiting the GFP early/late promoter gene in JX-594-GFP provides an adjunct to 
the plaque assay in demonstrating and understanding replication of JX-594 in CRC 
cell lines. In the plaque assay technique, no plaque-forming viral progeny were 
present in the in vitro samples by 24 hours, but flow cytometry and CLSM of CRC 
cell lines revealed GFP expression at 24 hours, in keeping with the recognition that 
the early steps of vaccinia replication have already begun at this stage [175]. The 
finding of early GFP expression with no demonstrable replication is explained by 
the temporal fashion of the expression of the vaccinia genome; immediately after 
entry into the host cell, mRNA is synthesised by enzymes packed within the virus 
core. Hence, early-phase genomic expression occurs independently of replication 
and is not prevented by either inhibitors of protein or DNA synthesis. Late genes 
are not expressed until after DNA replication has begun [176]. The surge in GFP 
expression at 72 hours correlates with the plaque assay findings, and it may be that 
at this stage the virus is undergoing the final stages of replication.  The EEV form of 
the virus has been synthesised, exiting the cell to infect nearby tumour cells, and 
beginning early phase replication in these infected neighbouring cells. 
 
The results described in this chapter demonstrate an induction of several cytokines 
during JX-594 mediated tumour cell killing. The bystander immune effect of 
cytokines such as IL-6, IL-8 and IL-10 is still debatable, as most cytokines that 
promote inflammation may also support tumour proliferation. IL-6 is secreted by T 
cells and macrophages in response to IL-1 and TNF-β, and functions to stimulate 
an immune response. IL-6 has been shown to enhance the generation of CTL 
[177], up-regulate intracellular adhesion molecule 1 (ICAM-1) on endothelial cells 
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and both attract monocytes and skew them towards macrophage differentiation 
[178]. IL-6 has also been shown to be important in oncolytic virus treatment; in vivo 
blocking of IL-6 in a CRC (CT26) syngeneic BALB/c mouse model led to a reduced 
anti-tumour response by Sendai virus (anti-TReg mediated) [179]. On the other hand, 
IL-6 has been implicated in the aetiology of some cancers [180] and in an in vitro 
model, knockdown of IL-6, genetic ablation of the IL-6 gene, or treatment with a 
neutralizing IL-6 antibody was shown to retard Ras-driven tumorigenesis [181]. 
More recently, IL-6 has been found to promote prostate tumorigenesis and 
progression through autocrine cross-activation of insulin-like type I growth factor 
receptor (IGF-IR) [182].  
 
The effects of IL-8 are mediated through the binding of IL-8 to two cell-surface G 
protein–coupled receptors, CXCR1 and CXCR2, and the expression of IL-8 
receptors on cancer cells, endothelial cells, neutrophils, and tumour-associated 
macrophages suggests that the secretion of IL-8 from cancer cells may have a 
profound effect on the tumour microenvironment. IL-8 secreted from tumour cells 
may enhance the proliferation and survival of cancer cells through autocrine 
signalling pathways, and may activate endothelial cells in the tumour vasculature to 
promote angiogenesis, which in turn will induce a chemotactic infiltration of 
neutrophils into the tumour site. IL-8 can induce tumour-associated macrophages to 
secrete additional growth factors, which further affect the tumour microenvironment 
to increase the rate of tumour cell proliferation and invasion [183]. In more clinically 
relevant translations models, IL-8 signalling has also been shown to attenuate 
TRAIL- and chemotherapy-induced apoptosis in prostate cancer cells [184] but 
promotes tumour growth, metastasis, chemoresistance and angiogenesis in vitro 
and in vivo in colon cancer cell line models [185]; it also promotes tumour growth of 
HeLa cells overexpressing oncogenic Ras [186].  
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A variety of tumor cells secrete IL-10, which is generally considered an anti-
inflammatory cytokine as it inhibits immune priming and NK cell activity. It down-
regulates the expression of Th1 cytokines, MHC class II antigens, and co-
stimulatory molecules on macrophages, and is capable of inhibiting synthesis of 
pro-inflammatory cytokines such as IFN-γ, IL-2, TNFα and GM-CSF expressed by 
immune cells [187]. However, some studies have also revealed that IL-10 may have 
the pleotropic ability to stimulate anti-tumour innate and adaptive immunity [188]. In 
addition, IL-10 can favour tumor growth in vitro by stimulating cell proliferation and 
inhibiting cell apoptosis [189], and high systemic levels of IL-10 correlate with poor 
survival of some cancer patients.  This is not clinically conclusive, as this may just 
be due to the tumour grade and the converse has also been demonstrated [188, 
190]. The results displayed here show that in some cell lines in vitro, JX-594 
treatment decreases levels of IL-10 in the tumour microenvironment, which may 
have potentially beneficial effects on innate and adaptive immunity, and potentially, 
tumour proliferation. 
 
VEGF stimulates vasculogenesis and angiogenesis, and  VEGF expression in 
tumours correlates with invasiveness, vascular density, metastasis, recurrence, and 
prognosis. Anti-VEGF therapy (bevacizumab, a monoclonal antibody to VEGF) has 
been used in the treatment of metastatic CRC, non–small cell lung cancer 
(NSCLC), metastatic renal cell carcinoma (RCC) and glioblastoma (GBM). 
Bevacizumab has been shown to be promising and safe in the neo-adjuvant 
treatment of metastatic CRC in phase II trials [191] and effective in phase III trials in 
recurrent ovarian cancer [192], but not in adjuvant phase III trials [193]. The results 
in this chapter demonstrate a decrease in VEGF following JX-594 treatment, which 
otherwise increased over time in untreated cells. Breitbach et al. have 
demonstrated that VEGF treatment of human dermal endothelial cells (HDMECs) 
resulted in an increase in JX-594 output following 72 hours of treatment. This was 
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due to downstream signalling resulting in an increase in TK following VEGFR 
phosphorylation. Hence colorectal tumours, which produce high levels of VEGF, 
serve as a favourable targets for JX-594 therapy. Breitbach et al. have also 
demonstrated the anti-angiogenic properties of JX-594 in vivo. In mouse models, 
diffuse endothelial cell infection of subcutaneous 4T1 (breast cancer) tumours was 
demonstrated, with a concurrent reduction in tumour perfusion [194]. HCC is a 
hypervascular and VEGF-rich tumor type, and a phase I trial demonstrated dose-
dependent endothelial cell infection and transgene expression of JX-594 (in multiple 
tumour types) [134]. Moreover, in a phase II clinical trial treating 18 patients, higher-
dose JX-594 treatment was shown to disrupt tumour perfusion (5/8 patients), with 
no evident toxicity to normal blood vessels [194]. Liu et al. have also previously 
demonstrated reduction in serum VEGF following JX-594 treatment [76].  
 
The coupled response described in this chapter of the reduction in VEGF and IL-10 
is an interesting observation. Liu et al. observed that IL-10 was significantly co-
expressed with VEGF using an in vitro model of epithelial ovarian cancer. VEGF 
was found to interfere with DC maturation, and consequently the immature DCs 
secreted high levels of IL-10 in the tumour microenvironment, which induced Treg 
generation without antigen presentation in DCs [195]. 
 
Type I IFNs serve as an important part of the host’s anti-viral defence. The antiviral 
effect of IFNs is potent and rapid; IFNs are released almost instantly upon viral 
infection and then bind to receptors to activate signal transducer and activator of 
transcription (STAT) complexes, triggering expression of a series of IFN-responsive 
genes such as PKR, which convert cells to an antiviral state. Infection of CRC cell 
lines with JX-594 resulted in no measurable IFNα or IFNβ (see table 3-2). The large 
vaccinia genome codes for several immune evation proteins, with the B18R 
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proteins being important members of the virus’s arsenal against host anti-virus 
mechanisms. They act as decoy receptors to block the activity of type I IFNs from 
various species, inhibiting them from binding their cognate receptors and triggering 
an anti-viral response. The lack of measureable IFNs following JX-594 infection of 
CRC cell lines in these experiments may be explained by early expression of B18R, 
which may prevent detection of IFNs in vitro, even at 6 hours. 
 
The role of inflammation in cancer remains a matter for debate. Chronic 
inflammation and thus genotoxic stress can induce cancer initiation, and cancer 
promotion and progression by inducing cellular proliferation and enhancing 
angiogenesis and tissue invasion. A such, the development of HCC is related to the 
chronic inflammatory response generated by Hepatitis B and C viruses [196]. 
Inhibition of chronic inflammation with long-term use of anti-inflammatory drugs has 
a protective effect in patients with pre-malignant disease [197], as has been 
demonstrated in colorectal cancer, with a moderate chemopreventive effect of 
aspirin on adenomas in the large bowel [198]. However, intravesical BCG is 
effective in the treatment of superficial bladder cancer, and promotes inflammation 
at the site of disease, with an increase in detectable urinary IL-1, IL-2, IL-6, IL-8, IL-
10, IL-12, IL-18, IFNγ, macrophage colony stimulating factor, and TNF-α [52]. The 
induction of pro-inflammatory cytokines and the diminished anti-inflammatory 
cytokine activity induced by JX-594 treatment may have beneficial effects, 
particularly when coupled with the lytic activity of the virus. OVs, combined with 
targeting of cytokine signalling pathways, may have important implications in halting 
disease progression and attenuating tumour resistance to other chemotherapeutic 
and biological agents. The expression of virally-encoded GM-CSF provides further 
support for the importance of therapeutic inflammation in virotherapy, which will 
function to enhance innate immunity and subsequent anti-tumour memory 
(discussed in chapter 5). 
- 107 - 
 
This chapter describes the potential benefit of tumour cell killing following JX-594 
treatment; however it’s advantage over other conventional therapies may be related 
to its tumour-specificity. Work addressing this aspect of JX-594 therapy is shown in 
the following chapter. 
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 Chapter 4 
 
Results: JX-594 preferentially replicates in 
tumour cells ex vivo 
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4 JX-594 preferentially replicates in tumour cells ex vivo 
4.1 Introduction 
One particularly favourable characteristic of oncolytic viruses in their application as 
an emerging therapeutic modality is their selectivity for replication within cancerous 
cells. The resulting viral progeny when released from a cell consequently infect 
neighbouring cells, resulting in a rapid spread throughout a solid tumour. The 
insertion of genes of interest into the VV-TK locus also makes it a favourable 
candidate for gene therapy, selectively expressing potentially therapeutic genes in 
the tumour environment. The previous chapter has demonstrated viral replication in 
CRC cell lines; however, this does not address the issues of viral penetration into 
tumour tissue and tumour-specificity. Hence, an ex vivo system was developed, 
where surgically resected CRLM tumour and normal liver were infected with JX-594 
expressing GFP. 
 
4.2 JX-594 replicates in liver tumour, but not in matched normal 
liver tissue 
4.2.1 Tumour specific transgene (GFP) expression in precision-cut 
tissue slices 
The findings in chapter 3 so far have shown competent viral replication in tumour 
cell lines, which only presumably translate in vivo. In order to address this, and to 
demonstrate the difference between replication in liver tumour and normal tissue, a 
novel ex vivo system was used. Directly from the operating theatre, freshly resected 
liver tumour and matched normal tissue was sliced using a precision-cutting 
microtone (see section 2-13). In order to demonstrate tumour-specific replication, 
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JX-594-encoded GFP expression in the tissue slices was determined by confocal 
microscopy. GFP is under the control of a synthetic early/late promoter, thus its 
expression is in two phases – early, as the virus takes over the cell, and late, as the 
virus prepares for escape from the cell. Figure 4-1a shows the expression of GFP in 
tumour slices, but not in matched normal liver tissue slices. Although this illustrated 
the tumour-specificity of viral protein expression, the images were difficult to 
capture on confocal microscopy, due to the lack of a well defined focal point. 
Hence, a nuclear counterstain (DAPI) was then used (figure 4-1b), which enabled 
acquisition of higher quality images.  
 
Tumour specific replication was further demonstrated using tissue from a benign 
liver tumour, focal nodular hyperplasia (FNH). In figure 4-2, there was no GFP 
expression in the normal liver, nor the liver tumour (FNH). Hence, JX-594 appears 
to require malignant cells in order to efficiently replicate.  
 
As seen in figure 4-1 and 4-2, the observation of ‘speckles’ of green signal in the 
normal liver tissue was noted, and although this was likely to be due to 
autofluorescence, it was later investigated (see section 4.2.3). 
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Figure 4-1. CLSM images of precision cut tumour slices and tissue slices and 
modification of protocol. 
Freshly resected liver tumour and match normal tissue were collected directly from 
the operating theatre and embedded in agar. Using a precision-cut microtone, 
sections of tissue 250 µm in thickness were created, maintained in ‘fresh tissue 
culture medium’ for 96 hours, and infected with 0 and 107 pfu. Images were taken 
using the Nikon A1 confocal laser scanning microscope at 10x magnification. Figure 
a) shows the expression of GFP in the precision cut slices of CRLM but not 
matched normal liver tissue from the same patient. Figure b) depicts the addition of 
DAPI nuclear counterstain to the protocol. By selecting filters that only allow specific 
fluorescent wavelengths to pass through, images of nucleic acid staining (DAPI) 
and inherent tissue GFP fluorescence (FITC) can be detected in separate images, 
or combined.  
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Figure 4-2. No GFP expression in benign liver tumour 
Freshly resected liver tumour (FNH) and match normal tissue were collected 
directly form the operating theatre and embedded in agar. Using a precision-cut 
microtone, sections of tissue 250 µm in thickness were created, maintained in ‘fresh 
tissue culture medium’ for 96 hours, and infected with 0 and 107 pfu. Immediately 
prior to CFLM, tissue slices were stained with DAPI for 45 minutes and washed, 
and re-fixed in 1%PFA. Images were taken using the Nikon A1 confocal laser 
scanning microscope. There was no GFP expression in either the normal tissue or 
FNH.  
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4.2.2 Tissue Cores; optimising methodology 
The production of thin (250 µm thickness) tissue slices proved to be very time 
consuming, and the process of agar embedding prior to slicing caused some tissue 
damage and potentially compromised sterility - hence the tissue core method was 
adopted for all future experiments. Cylinders of liver and CRLM tumour tissue were 
created using a Tru-cut® biopsy needle to produce small sections/cylinders of tissue 
that can be grown in media for 96 hours. Firstly, it had to be determined that the 
cores maintained viability for the entire course of the assay. In order to do this, 
tissue cores were maintained in media, and alamer blue dye was added to the wells 
containing either normal liver or tumour core, and the fluorescence of the 
metabolised product (resorufin) determined as described in section 2.13. This 
assay was performed in two conditions; firstly using the same cores for the entire 
duration of the experiment (three 5mm cores per well) with fresh media replenished 
at each time point up to 120 hours (figure 4-3 a). In the second condition (figure 4-3 
b and c), separate cores were set up for each time point, and thus by 96 hours, the 
cores had no replenishing of media, which mimicked the experimental conditions 
applied to all future experiments. In both systems, the normal tissue maintained 
similar levels of metabolic activity up to 120 hours, whilst the tumour tissue did lose 
some activity by 96 hours in culture, which is likely to be due to the higher metabolic 
demand of the tumour cells. 
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Figure 4-3. Tissue viability using Alamer Blue  
Three cores of tissue per well in ‘fresh tissue medium’ was set up to test the viability 
of liver tissue and CRLM when maintained in culture. 25 µL of Alamer Blue dye was 
added to each well, and left to incubate for 1 hour at 37oC, media collected and 
fluorescence measured using a fluorescence plate reader. In figure a the same 
three cores were used for each time point, with fresh media replenished after 
alamer blue analysis. Figure a) shows the fluorescence signal in normal liver tissue 
cores from two separate patient samples, taken from opposite ends of the excised 
tissue mass, and data presented is the mean reading from cores taken from 
opposite ends of the tissue mass in two patients. In figures b (normal liver) and c 
(CRLM tumour), three cores per well were maintained in the same media for up to 
96 hours, with a different well at each time point (N=1). The detection of similar 
levels of fluorescence over time indicates the maintenance of tissue metabolic 
activity and thus viability. 
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4.2.3 Normal liver tissue expresses high auto-fluorescence 
Normal liver exhibits high background fluorescence, due to the fatty deposits which 
auto-fluoresce. In order to establish that the green signal seen in normal liver is due 
to auto-fluorescence and not due to GFP expression, a viral construct that does not 
express GFP was used (JX-594-YFP). Tissue cores from normal liver were treated 
with both JX-594-YFP and JX-594-GFP and the resulting fluorescence signals were 
similar for both (see Figure 4-4); hence, these ‘speckles’ can be regarded as non-
specific background auto-fluorescence. 
 
 
Figure 4-4. Confocal microscopy for auto-fluorescence of tissue cores treated 
with JX-594. 
Freshly-resected liver tissue from a single patient was collected immediately 
following resection and cylindrical cores of 5mm x 1mm were made using a Tru-
Cut® biopsy needle, and cultured in ‘fresh tissue culture medium’ infected with JX-
594-GFP and JX-594-YFP at either 0 and 107 pfu. At specified time points, 
supernatant was collected and tissue fixed in 1% PFA. Immediately prior to CFLM, 
tissue cores were stained with DAPI for 45 minutes and washed, and re-fixed in 1% 
PFA. Images were taken using the Nikon A1 confocal laser scanning microscope. 
 
 
0pfu% 107pfu%
24hr%
96hr%
Normal%Liver%JX95949eGFP%%
0pfu% 107pfu%
Normal%Liver%JX95949YFP%%
1200uM%
- 116 - 
4.2.4 Tumour specific transgene (GFP) expression in tissue cores 
Once it had been established that the viability of the tissue cores would be 
adequate to support viral infection, and that the green signal in the normal liver 
tissue was non-specific autofluorescence, the finalised protocol was performed in a 
total of 10 samples of CRLM tissue, each with matched normal liver. Cores were 
treated with JX-594-GFP for up to 96 hours in culture. Similar to the findings in the 
precision cut tissue slice system (figure 4-1), treatment of the liver tumour tissue 
cores with JX-594-GFP, resulted in an increase in GFP expression, which was not 
seen in the matched normal liver (figure 4-5 and 4-6). In 9 out of 10 CRLM samples, 
tumour-specific GFP expression was observed, and in the majority of cases, there 
was a pronounced increase in GFP expression between 48 and 72 hours, with 
maximal expression by 96 hours (see Appendix A for all 10 cases and table 4-1). 
There was an observed difference in the intensity of the GFP signal in various 
samples (as seen in 2 representative patients, figures 4-5 and 4-6), and this was 
subjectively quantified as displayed in table 4-1. In some cases (sample 4 and 8), 
there was a high GFP signal early at 24 hours, in comparison to the other tissue 
samples.   
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Figure 4-5. GFP expression in CRLM tumour cores – example 1 
Freshly-resected liver tumour and matched normal tissue were collected 
immediately following resection and cylindrical cores of 5mm x 1mm were made 
using a Tru-Cut® biopsy needle, and cultured in ‘fresh tissue culture medium’ 
infected with JX-594-GFP at either 0 or 107 pfu (figure a). At specified time points, 
supernatant was collected and tissue fixed in 1% PFA. Immediately prior to CFLM, 
tissue cores were stained with DAPI for 45 minutes and washed, and re-fixed in 
1%PFA. Images were taken using the Nikon A1 confocal laser scanning 
microscope. Figure b) shows the progression of GFP signal intensity in cores 
treated with 107 pfu JX-594-GFP. 
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Figure 4-6. GFP expression in CRLM tumour cores – example 2 
Freshly-resected liver tumour and matched normal tissue were collected 
immediately following resection and cylindrical cores of 5mm x 1mm were made 
using a Tru-Cut® biopsy needle, and cultured in ‘fresh tissue culture medium’ 
infected with JX-594-GFP at either 0 or 107 pfu (figure a). At specified time points, 
supernatant was collected and tissue fixed in 1% PFA. Immediately prior to CFLM, 
tissue cores were stained with DAPI for 45 minutes and washed, and re-fixed in 
1%PFA. Images were taken using the Nikon A1 confocal laser scanning 
microscope. Figure b) shows the progression of GFP signal intensity in cores 
treated with 107 pfu JX-594-GFP. 
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Patient Demographics Colorectal Liver Metastasis Normal Liver 
Details Age 
GFP 
24 hr 
GFP 
96 hr 
GFP 
24 hr 
GFP 
96 hr 
GH  72 ! !!! "# "# 
RC  66 ! !! "# "# 
TC 48 ! !! "# "# 
LF 77 !! ! "# "# 
JC 57 "# "# "# "# 
RP 69 ! !! "# "# 
JM 64 ! !! "# "# 
AM 78 !! !! "# "# 
MI 84 "# ! "# "# 
AB 53 ! !!! "# "# 
Table 4-1 Summary of GFP expression in patient samples  
A total of 10 patients with CRLM were recruited for sample collection. Matched 
normal and tumour tissue was available from all patients. The level of GFP 
expression by confocal microscopy at 24 hours and 96 hours was quantified 
subjectively. 
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4.2.5 GM-CSF expression in tissue cores treated with JX-594 
Genes encoding GFP and GM-CSF are within the same (disrupted TK) locus, and 
under the control of an early/late promoter. Hence, expression of both transgenes 
should be evident simultaneously, and GM-CSF expression would be expected to 
be higher in tumour tissue. At specific time points, when the tissue cores were 
transferred into 1% PFA for confocal microscopy, the supernatant was collected 
and stored for future ELISA. Figure 4-7 shows that GM-CSF in the tissue culture 
medium was found to increase significantly with viral treatment compared to 
untreated control by 48 hours in both normal and tumour tissue, and to a similar 
extent in both (around 200 pg/ml, p<0.05). However, after 48 hours, the levels of 
GM-CSF remained unchanged in the supernatant of the normal liver tissue cores, 
with no significant difference between treated (107 pfu) and untreated cores and 
between cores treated with 107 pfu at 24 and 72 p.i. In the liver tumour, there 
continued to be a significant increase in GM-CSF in treated (107 pfu) vs untreated 
cores at 72 and 96 hours, and there was a significant increase in GM-CSF from 24 
to 72 hours p.i. following treatment with 107 pfu. Although the average readings 
showed an overall increase in GM-CSF in the tumour vs normal tissue, there was a 
variable response evident in each experiment, particularly at 24 hours p.i. (figure 4-
7 c). By 96 hours p.i. (figure 4-7 d), most tumour cores had a higher level of GM-
CSF expression compared to normal liver tissue.  
 
In order to determine if the objective increase in GM-CSF correlated with subjective 
GFP expression, a single value of the increase in GM-CSF (ΔGM-CSF) from the 
baseline was calculated as: GM-CSFmax – GM-CSF0pfu, where GM-CSFmax is the 
maximal GM-CSF production at that particular time point and GM-CSF0pfu is the 
GM-CSF production from the untreated ‘control’ core. Although there was some 
coupling of GFP expression with increased GM-CSF expression (see table 4-2), the 
subjective grading of GFP expression by confocal microscopy did not significantly 
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correlate with the objective GM-CSF expression by ELISA (p>0.05, Spearman's 
rank correlation). 
 
 
Figure 4-7. GM-CSF production from tissue 
Freshly-resected normal liver tissue (a) and matched liver tumour (b) were collected 
immediately following resection; cylindrical cores of 5mm x 1mm were made using 
a Tru-Cut® biopsy needle, and cultured in ‘fresh tissue culture medium’ infected with 
JX-594-GFP at either 0, 106 or 107 pfu. At specified time points, supernatant was 
collected and GM-CSF production measured by ELISA. Figure c) and d) show 
individual patient results at 24 and 96 hours respectively. Experiments were 
performed in decuplicate (N=10); *p<0.05, **p<0.005, ***p<0.001. 
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Patient Demographics Colorectal Liver Metastasis Normal Liver 
Details Age 
GFP 
24 hr 
 
GFP 
96 hr 
ΔGM-CSF 
24 hr 
(pg/ml) 
ΔGM-CSF 
96 hr 
(pg/ml) 
ΔGM-CSF 
24 hr 
(pg/ml) 
ΔGM-CSF 
96 hr 
(pg/ml) 
GH 72 ! !!! 38 214 10 22 
RC 66 ! !! 41 153 43 0 
TC 48 ! !! 68 362 109 219 
LF 77 !! ! 219 12 127 15 
JC 57 "# "# 80 79 49 9 
RP 69 ! !! 72 138 4 118 
JM 64 ! !! 156 410 221 140 
AM 78 !! !! 68 33 180 118 
MI 84 "# ! 194 183 143 39 
AB 53 ! !!! 83 435 320 544 
Average 102 202 121 122 
Table 4-2 Summary of findings in patient samples  
A total of 10 patients were recruited for sample collection. Matched normal and 
tumour tissue was available from all patients. The level of GFP expression by 
confocal microscopy was quantified subjectively and the increase in GM-CSF was 
quantified objectively by ELISA. ΔGM-CSF = GM-CSFmax – GM-CSF0pfu, where GM-
CSFmax is the maximal GM-CSF production at that time-point and GM-CSF0pfu is the 
production of GM-CSF in the untreated core. 
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4.3 Infection of tissue cores with JX-595 does not result in a 
generalised inflammatory response 
The ability of JX-594 to induce a pro-inflammatory tumour microenvironment was 
described in chapter 3 using in vitro studies. In order to examine the effect in an ex 
vivo model, tissue cores were treated with 0, 106 and 107 pfu JX-594 for 24 to 96 
hours and the supernatants collected at specified time intervals for the 
cytokine/chemokine profile to be studied by ELISA. Following the findings of in vitro 
experiments, GM-CSF, VEGF, IL-6, IL-8 and IL-10 were studied, along with IFNα, 
IFNγ and TNFα. The dose/time response in GM-CSF has been described in section 
4.2. VEGF is known to be produced from CRC, and this finding was confirmed in 
the tumour tissue cores expressing higher levels than normal liver. However, there 
was no reduction in VEGF production as seen with the CRC cell lines (Figure 4-8). 
There was no consistent dose/time response after viral treatment in any of the other 
cytokines studied, aside from IL-10, which showed an increased production with 
escalating virus doses. This was only significantly increased in tumour cores at 24 
hours p.i., but not at later time points (data not shown). Production of IL-6 and IL-8 
from the cores did not show any response to viral infection, and were produced 
maximally within the first 24 hours, and reduced thereafter (data not shown). There 
was no difference in IL-6 and IL-8 production in liver tumour and normal liver 
samples. No consistently detectable IFNα, IFNγ and TNFα was found by ELISA 
(data not shown). Table 4-2 summarises the changes in cytokines in response to 
JX-594 treatment of tissue cores. 
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Figure 4-8. VEGF production in tissue cores treated with JX-594 
Freshly-resected normal liver tissue (a) and matched liver tumour (b) were collected 
immediately following resection; cylindrical cores of 5mm x 1mm were made using 
a Tru-Cut® biopsy needle, and cultured in ‘fresh tissue culture medium’ infected with 
JX-594-GFP at either 0, 106 or 107 pfu. At specified time points, supernatant was 
collected and VEGF production measured by ELISA. Experiments were performed 
in decuplicate (N=10). 
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 Effect upon infection of  ex vivo ‘tissue cores’ with JX-594 
 Tumour Normal 
GM-CSF !* (at all time points) !* (at 48 hours only) 
VEGF "# "# 
IL-6 "# "# 
IL-8 "# "# 
IL-10 "# "# 
IFNα  "# "# 
IFNγ "# "# 
TNFα "# "# 
 
Table 4-3. Summary of cytokine and chemokine profile following ex vivo 
treatment of CRLM tumour and normal liver ‘tissue cores’ with JX594 
Table summarises the overall cytokine profile of CRLM tumour and normal liver 
‘tissue cores’ infected with JX-594. Experiments were carried out in triplicate in all 
circumstances. 
* Significant (p<0.05) 
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4.4 Discussion 
There are several mechanisms that contribute to the tumour-selectivity of vaccinia 
replication (see Figure 1-3). The knockout of the TK gene results in the virus being 
replication-competent only in cells of high TK environment, as is characteristic of 
many cancer cells [199]. The activation of the EGFR/Ras/MAPK signal pathway 
which is inherent in most cancer cells also aids JX-594 replication, and the 
induction of JX-594 replication results in positive feedback due to the further 
activation of this pathway by VGF, which is an EGF-analogue. VGF binds onto 
EGFR on the cell surface, activating downstream pathways which further enhance 
the cell’s environment for vaccinia replication.  The inhibition of the anti-viral 
interferon response by another vaccinia-encoded protein, B18R, results in further 
enhancement of replication by binding IFN receptors on the tumour cell surface. 
Indeed, these mechanisms are all tumour specific, and make vaccinia an attractive 
platform for anti-tumour therapy. This is by no means an exhaustive list of the 
favourable characteristics of JX-594, and due to the large genome, there is scope 
for many gene therapy approaches to be investigated to further increase the 
efficiency of this agent.  
 
In chapter 3, replication in tumour cells was demonstrated by the plaque assay 
technique and by utilising GFP transgene. Plaque assays demonstrated increased 
replication by 72 hours p.i. which was supported by GFP expression by confocal 
microscopy in cell lines treated with JX-594-GFP. Indeed, these findings are 
supported by the ex vivo system, where the surge in GFP and significant increase 
in GM-CSF occurs between 48 and 72 hours. It is evident that the replication 
efficiency within the patient cohort is understandably variable, which may be due to 
several factors. The biology of the tumour cells will be different, as will the 
composition of the tissue core; some may have more immune cells and some may 
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have more necrotic debris rather than viable tumour. It is difficult to standardise for 
this, although this would not affect the primary aim; to determine tumour-specific 
replication. Indeed, information about the tumour biology may be useful, particularly 
with EGFR expression, and this should be addressed in future studies. 
 
Genes encoding both GM-CSF and GFP are inserted into the TK locus, and are 
both under the control of an early/late promoter; however, there was no significant 
correlation in the expression of these transgenes in the ex vivo system. At 48 hours 
p.i., there was little GFP seen in the majority of the JX-594 infected ex-vivo tumour 
tissue and none in the normal liver, but there was a significant increase in GM-CSF 
in both tumour and normal liver cores in response to virus. Hence the GM-CSF 
produced at this stage is likely to be from immune cells,  hepatocytes and colorectal 
tumour cells in response to JX-594 infection, rather than being solely translated 
from the JX-594 genome. By 72 hours p.i. however, GM-CSF expression continued 
to exhibit a dose-time dependant increase in tumour cores, but not in normal liver 
cores, and there was a concomitant surge in GFP expression between 48 and 72 
hours, in keeping with the in vitro findings. This would suggest that after 48 hours, 
late-phase JX-594 replication occurs in tumour tissue, but not in normal liver tissue. 
These findings of potential non-concomitant expression of GM-CSF and GFP, 
which are both driven by early/late promoters, may also lead one to question the 
efficacy of the two early/late promoters; GM-CSF driven by a synthetic promoter 
inserted into the TK gene locus and GFP by the p 7.5 early/late promoter, although 
the methodology required to investigate this is beyond the scope of this work.  
 
The preferential expression of GFP in tumour cells has been described in both ex 
vivo and in vivo systems in the literature, and the results displayed in this chapter 
are in keeping with published findings [136, 163]. Parato et al. described tumour-
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specific JX-594-derived GFP expression in ex vivo lung, colon, endometrial and 
renal cancers, with a 100-fold increase in viral amplification in colonic tumour vs 
normal colonic mucosa. Kirn et al. demonstrated similar tumour specificity in a 
similar ex vivo model. They collected fresh human colonic and liver tumour and 
adjacent normal tissue specimens which were sliced into approximately 2mm3 
pieces. These were placed on a medium-soaked Surgifoam sponge and vaccinia 
(WR backbone, B18R-ve and TK gene–ve) encoding GFP was then added directly to 
the specimen (at 1 x107 pfu) for  2 hours at 37 0C; the tissue specimen was then 
covered in media. At 48 hours, tumour-specific GFP was detected using 
fluorescence microscopy [100]. The literature only reports small numbers of these 
ex vivo systems, and not all tumour biopsies were accompanied by matched normal 
tissue, which has been addressed in our study. This ex vivo system addresses a 
few of the potential drawbacks of in vitro methodology. Although human cancer-
derived cell lines are the most widely used models to study the biology of cancer 
and for testing of new therapies, their use has been continuously questioned. 
Prolonged cell culture is more likely to induce secondary genomic changes. The 
immortalisation of these cell lines make them different in their biology to in vivo 
tumours, and they are not subject in normal culture conditions to other biological 
stresses such as hypoxia and nutrition depletion, and have no tumour architecture 
or 3D structure. This has been addressed to some extent - and the development of 
standardised protocols for authentication of cell lines and the establishment of the 
National Cancer Institute 60 (NCI-60) panel has helped to standardise findings 
between research groups [200]. The use of an ex vivo system, as described here, 
maintains tumour architecture and also allows for the interactions between the 
various cell types in the tumour, although this is obviously not dynamic and 
responsive to physiological stresses as it would be in vivo. Although the results 
displayed in the last two chapters display parallels between in vitro and ex vivo JX-
594 gene expression, there are stark differences in the cytokine and chemokine 
- 129 - 
profiles, which may be explained by enhanced replicative ability of JX-594 in vitro 
and the potential lack of tumour proliferation in ex vivo samples. Also, there may be 
restricted access to the tumour cells themselves in 3D models versus 2D in vitro 
models, due to penetration of the virus into a solid block of tissue; also, other cells 
may ‘mop up’ the virus. The immunosuppressive environment of tumours is well 
documented, and inherent immunosuppressive cytokines and cell populations may 
inhibit the cytokine response as seen in vitro.  
 
The major finding described herein of tumour-specific JX-594 transgene expression 
may be exploited not only in cancer therapy, but potentially in diagnostics, 
particularly in the ever-growing recognition of the role of sentinel lymph node 
excision during cancer surgery. Using an animal foot pad model of melanoma 
metastasis, and IT injection of a replication competent  HSV virus (NV1023), Brader 
et al. demonstrated 100% trafficking of virus to positron emission tomography 
(PET)-positive draining (popliteal and inguinal) lymph nodes [201]. Similarly in an in 
vivo model of breast cancer lymphatic metastasis in mice, IT injection of NV1066 
resulted in transit of viruses to draining axillary lymph nodes, which could be 
measured by in vivo fluorescent imaging with a sensitivity of 80% and a specificity 
of 96% [202]. Oncolytic viruses have been shown to not only penetrate into, but 
also to kill, lymph nodes metastases, as published using vaccinia virus in an 
orthotopic mouse model of metastatic triple negative breast cancer. Following IT 
injection, GLV-1h153 (Vaccinia, Lister strain, expresses GFP) could be tracked in 
metastatic lymph nodes after 48 hours, and following 5 weeks of treatment, all 
harvested lymph nodes showed no evidence of metastatic cells [126]. 
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The findings presented in this chapter demonstrating preferential replication of JX-
594 in tumour tissues makes it an ideal candidate for anti-tumour therapy. It limits 
toxicity and allows for targeted gene-therapy by manipulation of the viral genome. 
The expression of GM-CSF leads to potentially interesting consequences within the 
tumour micro-environment, with activation of innate immune effector cells aiding not 
only direct tumour lysis, but also the development of subsequent adaptive anti-
tumour memory via antigen presentation. Work investigating these questions is 
presented in the following chapter. 
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Chapter 5 
 
Results: Activation of Innate Immunity 
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5 Activation of Innate Immunity 
5.1 Introduction 
Because this chapter focuses on the activation of innate anti-tumour immunity by 
JX-594, a wider introduction to the innate immune system is given here.  Since 
Virchow’s description of the infiltration of leukocytes into tumours in the 1860s [203] 
the role of inflammation and the immune system in cancer has remained a 
controversial subject. It is becoming increasingly recognised that the immune 
system will play an important role in tumour progression and there is overwhelming 
evidence that immunity against transformed cells can develop to protect the host 
from cancer development [204]. Both the innate and adaptive immune systems will 
play a role in cancer cell recognition and destruction, and this chapter will 
concentrate on the role of innate anti-tumour immunity. 
 
5.1.1 The innate immune system 
The innate immune system is an evolutionarily primitive mechanism and  induces a 
response that remains unchanged irrespective of the frequency of exposure to the 
pathogenic antigen. Recognition between ‘self’ and ‘anti-self’ forms the first trigger 
of induction of this innate immune response and the cellular components 
responsible are phagocytes (macrophages, neutrophils, and dendritic cells), cells 
that release inflammatory mediators (mast cells, eosinophils, basophils) and natural 
killer cells [13].  
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5.1.1.1 Natural Killer Cells 
NK cells were first isolated in mice [205, 206], are defined as CD3-veCD56+ve 
lymphocytes and constitute approximately 10-20% of PBMCs. NK cells have 
evolved to recognize and kill abnormal (infected and malignant) host cells [207]. 
They are ‘educated’ early in their development in the bone marrow to distinguish 
between ‘self’ and ‘anti-self’ [208]. They can be sub-classified as CD56bright and 
CD56dim NK cells, with distinct activity. CD56dim  NK cells exist predominantly in the 
blood and sites of inflammation and are highly cytotoxic, whilst CD56bright NK cells 
make up the majority of lymph node NK cells, have little cytotoxic activity, and have 
a more immunoregulatory function, rapidly producing cytokines and chemokines 
[209].  
 
5.1.1.2 NK cell activation: receptor expression 
NK cells possess Fc (Fragment, crystallizable) receptors that bind IgG (eg FcγRIII / 
CD16). Thus, IgG-coated target cells are recognised and killed by a process called 
antibody-dependant cellular cytotoxicity (ADCC). CD56dim NK cells also display 
another recognition system which consists of killer-activating and killer-inhibiting 
receptors. These receptors detect molecules on the target cell surface and a ‘kill’ 
signal is then issued, which can be negated by an ‘anti-kill’ signal. Following 
infection or malignant transformation, cells lose expression of MHC class I 
molecules on their surface, and hence lose an inhibitory signal, causing activation 
of NK cell mediated killing. NK cell recognition of target cells is a balance between 
activatory (NKp30, NKp44, NKp46, NKG2D, DNAM-1, CD16) and inhibitory (killer-
cell immunoglobulin like receptors -KIR) signalling. DNAM-1 (DNAX accessory 
molecule-1) and NKG2D (NK group 2 member D) are major NK cell activating 
receptors, which transduce activating signals after binding their ligands CD155, 
CD112 and major histocompatibility complex class I-related chains A and B 
(MICA/B) [210]. 
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5.1.1.3 NK cell activation: cytokine response 
Innate responses involve soluble factors as well as the cellular component, and NK 
cells respond to signals from other immune cells, including dendritic cells, 
macrophages, and pathogen-infected tissue cells (see table 5-1). This signalling is 
mediated by the release of cytokines, which can activate NK cells, including type-I 
interferons (IFNα/β), IL-2, IL-10, IL-12, IL-15, and IL-18. NK cells also secrete 
cytokines that can activate immune responses, such as IFNγ, TNFα, GM-CSF and 
IL-13 [209, 211]. NK-derived IFNγ can stimulate DCs, inducing the production of IL-
12 activating T-cell ‘helper’ functions [208]. Helper T-cell may be classified into 
either Th1 and Th2, and secrete cytokines with differing roles. Th1-type cytokines, 
such as IFNγ, initiate a proinflammatory response responsible for killing intracellular 
parasites and for perpetuating autoimmune responses. However, excessive 
proinflammatory responses can lead to uncontrolled inflammation and thus Th2-
type cytokines (IL-4, IL-5,IL-10,  IL-13) function to counteract this. Table 5-1 shows 
a summary of the cytokines investigated during this work, with a brief summary of 
the source and function of these cytokines. 
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Table 5-1. Investigated cytokines involved in the innate immune system  
 
 
 
 
 
Cytokine Source Function 
IL-2 Th1 T-cells Activation of lymphocytes, NK cells and 
macrophages 
IL-6 Th2 T-cells and 
macrophages 
Activation of lymphocytes, differentiation of 
B cells, stimulating production of acute-
phase proteins 
IL-8 T-cells and macrophages Chemotaxis of neutrophils, basophils, DCs 
and T cells 
IL-10 Monocytes and 
Lymphocytes 
Inhibiting synthesis of pro-inflammatory 
cytokines 
TNFα Macrophages, NK cells, T-
cells, B-cells, and Mast cells 
Promotion of inflammation 
GM-CSF T-cells, macrophages, NK 
cells, and B-cells 
Promotion of the growth of granulocytes 
and macrophages 
IFNα 
IFNβ 
Virally infected cells, NK 
cells, B-cells and T-cells, 
pDCs (maximal IFNα), 
macrophages, fibroblasts, 
endothelial cells, osteoblasts 
 
Innate immune response against viral 
infection 
Resistance to virus 
IFNγ NK and NK-T cells, Th1 T-
cells, CD8+ve CTLs 
Innate and adaptive immunity against viral 
and intracellular bacterial infections  
Tumor control 
Activation of macrophages and inhibition of 
Th2 T-cells 
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5.1.1.4 NK cell degranulation and perforin-mediated killing 
Activated NK cells can be recognised by the expression of CD69 [212]. Upon 
activation, NK cells produce cytokines and cytotoxic granules containing perforin 
and granzyme (see figure 5-1). Perforin is a pore-forming molecule that enables 
granzymes to enter target cells. Granzymes are serine proteases which can induce 
apoptosis by cleaving caspase II [14, 213]. This process of release of antimicrobial 
cytotoxic molecules from secretory vesicles is referred to as ‘degranulation’ and 
‘degranulated’ cells may be characterized by the expression of cellular antigens 
CD107a/b. 
 
 
Figure 5-1. NK cell activity 
Tumour cells can, for example, lose MHC-I expression, and hence a ‘Kill’ signal is 
initiated, which leads to the release of cytolytic granzymes, which are packaged 
within endosomes in the NK cell cytoplasm. The release of perforin enzymes 
causes the tumour cell membrane to fuse with the endosome, and releases 
granzymes into the tumour cell, resulting in death by apoptosis. 
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5.1.2 Dendritic Cells 
Dendritic cells (DCs) are antigen presenting cells (APC), that are a key component 
of the innate immune system. DCs are derived from bone marrow progenitor cells, 
and exist in the mature (mDC) and immature (iDC) state [214]. iDCs constantly 
survey the surrounding environment, and usually become activated at the site of 
pathogenic entry (by ‘danger signals’) utilising pattern recognition receptors (PRR) 
such as the toll-like receptors (TLR). GM-CSF leads to recruitment and maturation 
of DCs, and thus improves antigen presentation by DC [215].  This is important in 
the context of oncolytic virotherapy, and the transfection of GM-CSF into several 
OVs such as HSV, MV and VV (including JX-594) has resulted in improved anti-
tumour immune responses [216]. Upon activation, DCs migrate to the draining 
lymph node, activating lymphocytes by presenting processed antigens via major-
histocompatibility-complex molecules. 
 
DCs form a group of antigen presenting cells (APCs) known as ‘professional’ APCs, 
which efficiently internalise an antigen, either by phagocytosis or by receptor-
mediated endocytosis, and display these antigens complexed with major 
histocompatibility complex (MHC) on their surfaces. T-cells are unable to recognise 
‘free’ antigen, but can recognize these complexes, leading to initiation of an 
adaptive response.  
 
 
5.1.3 Cross-talk 
NK cells and DCs play a synergistic role in the anti-tumour immune response. 
Direct tumour cytotoxicity of NK cells can release TAAs into the tumour micro-
environment, along with inflammatory cytokines and danger signals, thereby 
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activating DCs, including through IFN-γ and TNF-α dependant mechanisms. 
Reciprocally, DCs can activate NK cells through cytokines such as IL-12 and IFNα. 
[15] [217]. Cell-to-cell interactions play an important role in NK cell activation, and it 
has been demonstrated that contact-dependent interactions (using eg trans-well 
separation) between activated human NK cells and immature DCs provide a 
“control switch” for the immune system [217] [218].  
 
5.1.4 Liver-specific lymphocytes  
The immunological environment within the human liver is unique; it receives 
constant antigenic stimuli from gut-derived antigens, which does not result in 
inflammation. Up to 30–50% of all human hepatic lymphocytes are NK cells, which 
are preferentially located in the hepatic sinusoids [219]. Kuppfer cells, unique to the 
liver, secrete chemokines CCL2, CCL3 (MIP1α) and CXC-chemokine ligand 10 
(CXCL10), which attract NK cells into the liver [220]. However, Kuppfer cells have 
been shown to secrete high levels of IL-10 in response to gut-derived LPS, which 
can lead to decreased NK cell activation [219]. Tu et al. used a novel method to 
isolate lymphocytes from the liver, by perfusion of living donor liver lobes prior to 
transplantation (n=5). They found that the healthy human liver was a site of intense 
immunological activity, with activated lymphocytes compared to those from 
peripheral blood in the same donors. There were increased numbers of NK cells, 
which were in a higher state of activation (CD69; 80% vs 7% in PBMCs) and 
increased numbers of CD56+ve, CD4+ve and CD8+ve T cells [221]. 
 
The clinicopathological significance of tumor-infiltrating lymphocytes (TILs) is well 
recognised [222, 223] but typically, NK cells are found in only small numbers in 
advanced human neoplasms. In patients with multiple liver metastases from gastric 
and colonic primaries, fewer intratumoural CD56+ve cells were detected compared 
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to those with single metastases, and a reduced number of intrahepatic CD56+ve 
cells was observed in patients with metastases compared to those without [224]. 
Hence, this suggests that low NK cell numbers could result in the ‘escape’ of 
metastatic malignant cells from immune control within the liver. Within most human 
tumours, the phenotype of NK cells is immunosuppressive, with an overexpression 
of inhibitory receptors such as NKG2A, and an underexpression of activating 
receptors such as CD16, NKG2D, NKG2C and NKp30 [225]. 
 
5.1.5 Oncolytic viruses to activate innate anti-tumour immunity 
OVs may present an immunological ‘trigger’ to activate innate immune cells, 
particularly in the tumour microenvironment, where replication of OVs is most 
prolific. It has been demonstrated that iv VV therapy following colorectal cancer 
resection in humans resulted in enhanced NK cell function [226]. This chapter 
investigated the ability of JX-594 to activate human NK cells in vitro.  
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5.2 Phenotypic analysis of NK cells 
In order to select the NK cell population during flow cytometric analysis, the 
lymphocyte population is selected (or ‘gated’) using a forward –scatter (FSC) (cell 
mass) vs side-scatter (SSC) (cell density/granularity) box-plot. This relies on pattern 
recognition of known cellular properties to ‘gate’ around the population of interest. 
This ‘gate’ is applied onto a CD3 (PerCP) / CD56 (PE) histogram and NK cells are 
defined as the CD3–veCD56+ve cell population. The gating strategy is shown in 
Figure 5-2, with the ‘R4’ gate selecting the lymphocyte population. The significance 
of the R1, R2 and R3 gates will be discussed later. 
 
Figure 5-2. Selection of sub-population of immune cells within PBMCs  
Figure shows a box plot of Forward Scatter (FSC) versus side-scatter (SSC) (a). 
The gating strategy for all experiments is shown here. R1; all non-lymphocyte 
population, mainly consisting of monocytes, R2; All viable Monoctyes, R3; 
population shift following activation of monocytes with JX-594, R4; lymphocytes. In 
Figure 5-2 b, The R4 lymphocyte population has been selected and box-plot of CD3 
vs CD56 obtained. The NK cell population can be selected as the CD3-ve and 
CD56+ve population. 
 
 
 
 
 
 
R3#
R1#
R2#
R4# CD
56
#
CD3#
SS
C#
FSC#
NK# NK/T#
T/cells#B/cells#
a# b#
- 141 - 
5.3 JX-594 treatment of PBMCs leads to activation of NK cells 
In order to determine the effect of JX-594 on immune cells, first fresh whole blood 
was collected from healthy donors and patients undergoing resection for CRLM. 
PBMCs were isolated by density gradient centrifugation, treated in vitro with JX-
594-GM-CSF for 24 hours and flow cytometry used to determine the percentage of 
NK cells expressing CD69. Whole PBMCs were used, rather than isolated NK cells, 
as this is more comparable to the clinical scenario in vivo. Figure 5-3 shows the 
upregulation of CD69 in NK cells from healthy donors, and there is a significant 
increase in % of NK cells expressing CD69 compared to untreated controls 
following treatment with 0.1 pfu/cell JX-594-GM-CSF (15% vs 36%) or 1 pfu/cell JX-
594-GM-CSF (15% vs 34%). There was a marginally better overall response 
following treatment at 0.1 pfu/cell (p<0.01 vs untreated control) and treatment at 1 
pfu/cell (p<0.05 vs untreated control). The response following JX-594-GM-CSF 
treatment compared well to that following treatment with Reovirus (42% CD69 
expressing NK cells), which is known to be highly immunogenic. To determine 
whether a similar response was observed in patients with metastatic colorectal 
cancer, PBMCs from patients were also treated with JX-594 and a similar pattern of 
CD69 upregulation was observed (figure 5-4); however the response did not reach 
significance compared to untreated control (13%, 33% and 33% for 0 pfu/cell, 0.1 
pfu/cell and 1 pfu/cell respectively, p>0.05 in all cases).  Again, the response 
remained similar to that of Reovirus treated PBMCs (30%). In both healthy donors 
(figure 5-3b)  and patients (figure 5-4b), there was a viariable response, with some 
non-responders.  
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Figure 5-3. Treatment of whole healthy-donor-derived PBMCs with JX-594 in 
vitro results in NK cell activation as demonstrated by CD69 upregulation 
Fresh whole blood was sampled from healthy donors, PBMCs were isolated by 
centrifugation over lymphoprep gradient and PBMCs treated with JX-594 at 0, 0.1 
and 1 pfu/cell and Reovirus at 1 pfu/cell (positive control). The percentage of cells 
expressing CD69 was demonstrated by flow cytometry. Experiments were carried 
out between N=3 and N=14 and bars show the mean +/- SD * indicate significant 
reduction in viability; *p<0.05, **p<0.01. 
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Figure 5-4. Treatment of whole patient-derived PBMCs with JX-594 in vitro 
results in NK cell activation as demonstrated by CD69 upregulation 
Fresh whole blood was sampled from patients undergoing liver resection for CRLM, 
PBMCs were isolated by centrifugation over lymphoprep gradient and PBMCs 
treated with JX-594 at 0, 0.1 and 1 pfu/cell and Reovirus at 1 pfu/cell (positive 
control). The percentage of cells expressing CD69 was demonstrated by flow 
cytometry. Experiments were carried out between N=3 and N=8 and bars show the 
mean +/- SD. 
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5.4 JX-594 treatment does not lead to upregulation of activatory 
receptors on NK cells 
NK cells express activatory receptors, which when bound to ligands on potential 
target cells, can result in activation of the NK cells. Up-regulation of these activatory 
markers may lead to more potent NK cell cytotoxiocity, if the targets express 
appropriate ligands.  
 
Figure 5-5 shows that the majority of NK cells (>75%) from healthy donors (figure 5-
5 a and c) and patients with CRLM (figure 5-5 b and d) expressed NKG2D and 
DNAM. There was no significant increase in percentage of cells expressing these 
markers or the staining mean fluorescence intensity (data not shown) following 
treatment with JX-594. Potentially, there is a marginal decrease in NKG2D 
expression on NK cells from patients; however, the small number of samples (N=3) 
makes this difficult to confirm. Figure 5-6 shows that the majority of NK cells 
expressed the receptors NKp30 and NKp46, but not NKp44. There was no 
significant increase in percentage of cells expressing these markers or the mean 
fluorescence intensity (data not shown) following treatment with JX-594. There was 
a marginally decreased expression of NKp46 on NK cells from patients, although 
this was only in a single experiment . 
 
Thus, although there was an increase in surface CD69 expression on NK cells (and 
hence activation) following JX-594 treatment, there was no change in NK receptor 
expression. 
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Figure 5-5. JX-594 treatment in vitro does not upregulate activatory receptors 
NKG2D and DNAM-1 on NK cells 
Fresh whole blood was sampled from healthy volunteers (a and c) and patients 
undergoing liver resection for CRLM (b and d). PBMCs were isolated by 
centrifugation over lymphoprep gradient and treated with JX-594 at 0, 0.1 and 1 
pfu/cell. The percentages of cells expressing the activatory receptors NKG2D and 
DNAM-1 were determined by flow cytometry. Experiments were carried out in 
triplicate (N=3 donors) and bars show the mean + SD. 
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Figure 5-6. JX-594 treatment in vitro does not upregulate activatory receptors 
NKp30, NKp44 and NKp46 on NK cells 
Fresh whole blood was sampled from healthy volunteers (a, c and e) and patients 
undergoing liver resection for CRLM (b, d and f). PBMCs were isolated by 
centrifugation over lymphoprep gradient and treated with JX-594 at 0, 0.1 and 1 
pfu/cell. The percentages of cells expressing the activatory receptors NKp33, 
NKp44 and NKp46 were determined by flow cytometry. Experiments were carried 
out in triplicate (N=3) for healthy donors and a single experiment for patient sample 
(N=1) and bars show the mean + SD. 
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5.5 JX-594-treatment of PBMCs stimulates NK cell degranulation 
in response to CRC cell targets 
NK-cell mediated killing requires the release of granules, a process known as 
degranulation, which can be characterised in vitro by the expression of surface 
CD107. PBMCs from healthy donors and patients undergoing resection for CRLM 
were treated overnight with JX-594-GM-CSF. JX-594-GM-CSF treated PBMCs and 
untreated controls were co-cultured with near-confluent CRC cells (SW480 and 
SW620) and K562 cells, which served as a positive control (see section 2.12.1). 
Figure 5-7a) shows that untreated NK cells degranulated appropriately against 
K562 targets (42%), which responded positively (up to 56%, non-significant) to JX-
594 treatment. In figure 5-7b), PBMCs from healthy donors exhibited small increase 
in percentage of cell degranulating in response to JX-594 treatment without 
exposure to any CRC targets (12% following treatment with 1 pfu/cell JX-594). 
When exposed to SW480 and SW620 targets, untreated NK cells from both healthy 
donors and patients showed increased degranulation compared to no-target 
controls. When PBMCs from healthy donors were treated with 0.1 pfu/cell JX-594, 
NK cells from healthy donors degranulated against SW480 and SW620 targets, 
although there was no significant difference with virus (30% against SW480 and 
38% SW620, p>0.05 vs untreated control in both cases). However, following 
treatment with 1 pfu/cell JX-594, there was a significant increase in percentage of 
NK cells degranulating against SW480 cells, but not SW620 cells. Significantly, NK 
cells from patients treated with JX-594 exhibited a greater response than those 
from healthy donors (figure 5-7 c). There was a significant increase in percentage of 
NK cells degranulating against SW480 targets with 0.1 pfu/cell treatment (51%, 
p<0.005) and 1 pfu/cell treatment (42%, p<0.05), and against SW620 targets with 
0.1 pfu/cell treatment (50%, p<0.005) and 1 pfu/cell treatment (42%%, p<0.01). 
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Hence, these experiments show that JX-594 treatment may enhance NK cell 
degranulation against CRC tumour cells in patients. 
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Figure 5-7. JX-594-treatment increases NK cell degranulation against CRC 
targets. 
Fresh whole blood was sampled from healthy volunteers (a and b) and patients 
undergoing liver resection for CRLM (c). PBMCs were isolated by centrifugation 
over lymphoprep gradient, treated overnight with JX-594 at 0, 0.1 and 1 pfu/cell and 
in some cases Reovirus at 1 pfu/cell (as a potential positive control), and co-
cultured for 4 hours with SW480 and SW620 cell lines at an effector: target ratio of 
10:1 (b and c) with K562 targets as a positive control (a). CD107a/b expression was 
measured by flow cytometry within the gated NK cells. Experiments were carried 
out in triplicate (N=3 donors) and bars show the mean + SD. * indicate significant 
reduction in viability; *p<0.05, **p<0.01, **p<0.005. 
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5.6 JX-594-treatment of PBMCs activates NK cells to kill CRC 
cell targets, which is perforin/granzyme mediated. 
In order to determine if activated NK cells were able to kill tumour targets, and 
furthermore, to investigate the mechanism of killing, 51Cr-release assays were 
utilised (see section 2.12.2). PBMCs from healthy volunteers were treated overnight 
with JX-594 at 0, 0.1 and 1 pfu/cell. Near confluent CRC cell lines (SW480 and 
SW620) were labelled with 51Cr, and co-cultured with PBMCs at various 
effector:target ratios. Figure 5-8a) shows that at all effector/target ratios, PBMCs 
were cytotoxic against SW480 cells, and increased killing was seen at higher 
effector:target ratios and after treatment with JX-594. For example, at an effector to 
target ratio of 100:1, PBMCs treated with 0.1 pfu/cell JX-594-GM-CSF killed 44% of 
SW480 cells vs 24% in the untreated control (p<0.0001). A similar response was 
evident against SW620 cells; at a ratio of 100:1, cells treated with 0.1 pfu/cell JX-
594-GM-CSF killed 40% of SW480 cells vs 23% in the untreated control (p<0.01). 
At all effector:target ratios, against both SW480 and SW620 targets, a higher 
treatment dose of 1 pfu/cell did not result in a significant increase in killing 
compared to untreated control; at 100:1 effector:target ratio, 24% vs 30% against 
SW480 cells, and 23% vs 30% against SW620 cells. In order to determine if the 
mechanism of killing was perforin/granzyme mediated, the assay was repeated in 
the presence of ethylene glycol tetraacetic acid (EGTA) (N=2), a calcium chelator 
which blocks perforin-mediated killing (figure 5-8 c and d). EGTA blocked all killing 
from PBMCs irrespective of JX-594 treatment (at all effector:target ratios, but only 
data for 100:1 shown). A similar increase in PBMC-mediated killing was observed 
after JX-594 treatment in these experiments in the absence of EGTA. Hence, JX-
594 treatment can increase PBMC-mediated killing of CRC cells, which is mediated 
by perforin/granzyme. These findings, along with results of degranulation 
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experiments, support the role of NK cells in the JX-594 activated killing of CRC cell 
targets. 
 
 
Figure 5-8. JX-594-treated PBMCs kill CRC targets, in a perforin/granzyme 
dependant process. 
PBMCs were isolated from healthy volunteers, treated overnight with JX-594 at 0, 
0.1 and 1 pfu/cell, and co-cultured at various effector:target ratios for 4 hours with 
SW480 (a and c) and SW620 (b and d) cell lines which had been labelled with 51Cr 
(N=3). Chromium release from labelled CRC cells was measured to determine 
PBMC-mediated CRC cell killing. The assay was repeated in the presence of EGTA 
(c and d, N=2) to block perforin-mediated killing; data is shown at 100:1 
effector:target ratio only.  * indicate significant reduction in viability compared to 
untreated controls; * p<0.05, ** p<0.01, ***p<0.005, ****p<0.0001. 
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5.7 PBMCs/Lymphocytes do not support JX-594 replication 
The most commonly utilised route for delivery of JX-594 in the most recent trials is 
intravenous delivery. The results detailed in this chapter so far suggest that JX-594 
may be beneficial in activating innate anti-tumour immunity.  However, before 
suggesting this finding contributes to the therapeutic potential of JX-594, it was 
important to elucidate if the virus was capable of infecting and replicating within 
these immune effector cells. PBMCs were isolated from 5 healthy donors and 
treated with 0, 0.1 and 1 pfu/cell JX-594-GFP (N=2) or JX-594-GM-CSF (N=3) for 
24 and 48 hours. PBMCs treated with JX-594-GM-CSF were subjected to three 
cycles of freeze/thaw (cells and supernatant) to lyse the cells and release cell-
associated virus, and a plaque assay performed to examine replication; none was 
found (data not shown). In addition, PBMCs treated with JX-594-GFP were fixed in 
1% PFA and GFP expression in gated lymphocytes determined by flow cytometry. 
Figure 5-9 shows that JX-594-derived GFP was expressed in less than 2% of 
lymphocytes, suggesting that JX-594 does not exhibit any significant replication 
within lymphocytes, and possibly only early phase transcription/translation in a 
small number of cells. 
 
 
 
 
 
Figure 5-9. JX-594 does not replicate in gated lymphocytes 
PBMCs were isolated from healthy volunteers and treated with JX-594 at 0, 0.1 and 
1 pfu/cell for 24 and 48 hours. PBMCs were harvested and gated lymphocytes 
analysed by flow cytometry (N=2) to examine the expression of virally-derived GFP. 
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5.8 JX-594 treatment of PBMCs does not significantly decrease 
viability 
The lack of replicative ability of JX-594 within lymphocytes is important for its 
promotion as an intravenous agent; however, it must also be demonstrated that 
there is no toxicity to PBMCs. To address this, PBMCs from three healthy donors 
were treated with 0, 0.1 and 1 pfu/cell JX-594- GM-CSF for 24, 48 and 72 hours, 
and cell viability was determined using a Live/dead® PE-conjugated dye and flow 
cytometry (figure 5-10). There was a small decrease in viability in untreated cells 
over time (99% to 83%) as expected, but importantly, no increased loss in viability 
of lymphocytes was observed after treatment with JX-594.  
 
 
 
 
 
 
Figure 5-10. Viability of PBMCs following in vitro treatment with JX-594 
PBMCs from healthy volunteers were treated with JX-594 at 0, 0.1 and 1 pfu/cell for 
24, 48 and 72 hours. The entire cell population was selected (a) and cell viability of 
R4 lymphocytes was evaluated by Live/Dead® method (b). Data is presented as the 
mean +SD of N=3. 
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5.9 CD14+ve monocytes are required for JX-594 mediated 
activation of NK cells 
Based on the understanding of ‘cross-talk’ between various sub-populations within 
PBMCs, we next investigated whether the activation of NK cells was dependant on 
other PBMC cell populations. PBMCs from seven healthy volunteers and three 
patients undergoing resection for CRLM were isolated. Using magnetic beads, NK 
cells and CD14-ve PBMCs were isolated by negative selection (NK cells) and 
CD14+ve cells removed by positive selection (see figure 5-11). In all five donors, the 
three populations of cells (whole PBMCs, purified NK cells and CD14-ve PMBCs) 
were treated with JX-594-GM-CSF at 0 pfu/cell, 0.1 pfu/cell and 1 pfu/cell for 24 
hours and CD69 expression determined by flow cytometry. A reovirus positive 
control was used in experiments with whole PBMCs only, due to the small number 
of CD14-ve PBMCs and NK cells collected during the isolation procedure.  
 
Figure 5-12 shows that CD14+ve monocytes are required for activation of NK cells 
within PBMCs. Histograms a) and b) show that after removing the CD14+ve 
population (figure 5-12 b), there was no upregulation in CD69 expression on NK 
cells following JX-594 treatment; interestingly reovirus treatment still resulted in NK 
cell activation. In healthy donors (figure 5-12 c – e), the percentage of NK cells 
expressing CD69 within whole PBMCs increased from 6% to 33% following 
treatment of whole PBMCs with 0.1 pfu/cell JX-594-GM-CSF (p<0.05). In purified 
NK cells and CD14-ve PBMCs there was no appreciable increase in CD69 following 
treatment (NK cells; 3% to 8%, CD14-ve cells; 4% to 6%). In patients, a similar 
finding was observed, with an upregulation of NK cell CD69 expression in whole 
PBMCs following treatment with 0.1 pfu/cell JX-594-GM-CSF (7% vs 18%, p>0.05) 
but not with purified NK cells (13% vs 13%) or CD14-ve PBMCs  (3% vs 3%). 
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Figure 5-13 shows that JX-594 treatment of whole PBMCs not only resulted in 
CD69 upregulation on NK cells, but also downregulated CD14 expression on 
monocytes (R1 gate). There was a significant decrease in the percentage of 
PBMCs expressing CD14 following treatment with 1 pfu/cell compared to untreated 
PBMCs (38% vs 6%, p<0.005). A similar downregulation of CD14 was not evident 
following 1 pfu/cell Reovirus treatment. This CD14 downregulation was also evident 
following treatment of whole PBMCs from patients with CRLM, although the 
difference between untreated PBMCs and those treated with 1 pfu/cell JX-594 did 
not reach significance (18% vs 2%). The results thus indicate that JX-594 and 
Reovirus both activate NK cells, but via different mechanisms, with CD14+ve 
monocytes playing a significant role in the context of JX-594 treatment.  
 
Little is known about the interaction of PBMCs with oncolytic viruses, particularly 
with regards to the findings illustrated in figures 5-13 and 5-14 - the requirement of 
CD14+ve monocytes within a whole PBMC population for JX-594-driven innate 
immune activation. Here we demonstrate that JX-594 requires CD14+ve monocytes 
to activate NK cells, and that this interaction is associated with loss of monocyte 
CD14 expression. 
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Figure 5-11. Bead purification of NK cells and CD14-ve cells 
Figure shows representative images of the outcome of the bead purification of 
whole PBMCs (a and d) to isolate NK cells (b and e) and CD14-ve PBMCs (c and f). 
The NK cell (CD3-veCD56+ve) isolation protocol resulted in 80% purity as depicted by 
the box-plots b) and e), with a reduction in density of the R4-gated lymphocyte 
population (b), due to the loss of the CD3+ve and CD56-ve populations (e). The 
selection of the CD14-ve population is depicted by plot c) and histogram f), which 
shows the loss of the CD14+ve population in gate R1. 
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Figure 5-12, CD14+ve monocytes are required for JX-594 mediated activation 
of NK cells within whole PBMCs 
Fresh whole blood was sampled from healthy donors (a - e) and patients 
undergoing liver resection for metastatic CRC (f - h), and PBMCs were isolated by 
centrifugation over lymphoprep gradient; cell populations were separated using 
magnetic beads. Whole PBMCs (a, c and f), purified NK cells (d and g) and CD14-ve 
PBMCs (b, e and h) were treated with JX-594 at 0, 0.1 and 1 pfu/cell and, where 
indicated, Reovirus at 1 pfu/cell for 24 hours. Surface expression of CD69 was 
quantified by flow cytometry and data expressed as a histogram of CD69 
expression (a, b; representative histogram from a single patient) and % cells 
expressing CD69 (c – h). Experiments were carried out in 7 healthy donors and 3 
patients and data is presented as the mean +SD. * signifies significant difference, 
p<0.05. 
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Figure 5-13. Monocytes downregulate CD14 expression in response to JX-594 
infection in vitro 
PBMCs from healthy donors (a) and patients undergoing liver resection for 
metastatic CRC (b) were treated with JX-594 at 0, 0.1 and 1 pfu/cell and Reovirus 
at 1 pfu/cell for 24 hours. Percentage of cells in gate R1 expressing surface CD14 
was quantified by flow cytometry. Experiments were carried out in quintuplicate 
(N=5) data is presented as the mean +SD. * signifies significant difference; * 
p<0.05, ** P<0.01. 
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5.10 JX-594 treatment of PBMCs results in a ‘shift’ of the 
monocyte population, but not death 
During flow cytometric analysis, in addition to the finding of a downregulation of 
CD14 expression,  a ‘ left shift’ in the FCS vs SSC dot-plots of the apparent 
monocyte population was observed following JX-594 treatment, with some of the 
monocytes becoming smaller ($FSC) and more granular (!SSC). Hence, a careful 
gating strategy was developed to identify these sub-populations for future analyses 
(figure 5-14 a - d). Firstly, it was important to determine whether this change in size 
and granularity was due to a change in morphology, or cell death. A Live/Dead® 
assay and Active-Caspase 3 assay kit were used to determine PBMC death by flow 
cytometry. Histogram 5-14 e) shows that in the R1 gate, there was a small 
population of cells that were dead, although this did not increase significantly 
following JX-594 treatment (figure 5-14 f). Importantly, in gate R3 (‘shifted’ 
monocyte population) there were <10% dead cells, and this did not change with JX-
594 treatment. Figure 5-14 g) shows that no more than 2% of cells were positive for 
active caspase-3, and hence there was no appreciable JX-594-induced apoptosis. 
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Figure 5-14. JX-594 treatment results in a ‘shift’ in the apparent monocyte 
population, and the emerging cell population is viable. 
PBMCs from healthy volunteers were isolated and treated with JX-594 at 0, 0.1 and 
1 pfu/cell and Reovirus at 1 pfu/cell (comparision) for 24 hours. During flow 
cytometry, the gating strategy R2 and R3 (a – d) was used to separate the shifting 
cell population (R2 #R3)  following JX-594 treatment, and R1, the whole monocyte 
population. Viability of PBMCs was analysed by Live/Dead® assay (e; 
representative histogram, f; summary bar chart) and Active-Caspase 3 assay kit (g). 
Experiments were performed in 3 donors and bars show the mean + SD.  
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5.11 JX-594 treatment of PBMCs results in differentiation of 
monocytes towards an antigen presenting phenotype  
Once it had been established that the ‘shifted’ monocyte population of cells were 
not dead, the phenotype of these cells was characterised. PBMCs were isolated 
from three healthy donors and three patients undergoing resection for CRLM and 
treated for 24 hours with JX-594 at 0, 0.1 and 1 pfu/cell JX-594, and 1 pfu/cell 
Reovirus, harvested, and expression of CD14/CD11c/CD86/ClassIIDR/CD80 
determined by flow cytometry. Figures 5-15 to 5-20 show that monocytes treated 
with JX-594 differentiated towards an antigen-presenting phenotype. In figure 5-15, 
in the population of interest (R3 gate), there is an emergence of CD11c+ve cells in all 
three healthy donors (figure 5-15, b - d) following JX-594 treatment, but not 
Reovirus treatment. Although analyzing the cells within the R3 gate specifically 
studies the population of interest, it does not give any information on the dynamic 
shift of cells from gates R2 to R3; hence for all future analyses depicted in figures 5-
16 to 5-20, the cells within the whole non-lymphocyte R1 gate were anaylsed and 
all dot plots divided into quadrants based on CD14 expression and the expression 
of the investigated APC markers (CD11c/CD86/ClassIIDR/CD80). Figures 5-16 to 
5-19 show representative data for a single experiment, whilst figure 5-20 shows 
summary data. Figures 5-16 (representative donor), appendix C and figure 5-20 a) 
show that JX-594 treatment shifted monocytes towards a CD14-ve CD11c+ve 
phenotype, with an average increase from 37% (untreated) to 71% (1 pfu/cell) 
(p<0.005) in CD14-veCD11c+ve cells, a finding that was not observed following 
Reovirus treatment (p<0.001). A similar finding was observed in patients’ 
monocytes (figure 5-20 b), with an increase in CD14-veCD11c+ve cells from  26% to 
49% (p>0.05), which was again significantly different to Reovirus. In figure 5-17, 
appendix C and figure 5-20 c) and d) the shift towards a CD14-veCD86+ve phenotype 
following JX-594 treatment was demonstrated, with an average increase from 40% 
- 162 - 
(untreated) to 73% (1 pfu/cell) CD14-veCD86+ve cells (p<0.0001). This was also 
observed in patients’ monocytes (figure 5-20 d) (27% to 50%, p>0.05). Figure 5-18, 
appendix C and figure 5-20 e) and f), show the shift towards a CD14-veClassIIDR+ve 
phenotype following JX-594 treatment, with an average increase from 46% 
(untreated) to 80% (p<0.0001). Similarly, in patients’ monocytes (figure 5-20 f), 
there was a moderate increase in CD14-veClassIIDR+ve phenotype following 1 
pfu/cell JX-594 treatment (49% to 68%, p>0.05). There was no appreciable 
upreguation of CD80 on JX-594-treated monocytes (figure 5-19, figure 5-20 g and 
h, and appendix C).  
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Figure 5-15. Emergence of CD11c+ve cells in R3 gate following JX-594 
treatment  
PBMCs were isolated from three healthy donors (histograms b-d, each in a 
separate donor) and treated with 0, 0.1 and 1 pfu/cell JX-594, and 1 pfu/cell 
Reovirus control. Figure (a) is a representative dot plot showing the gating strategy. 
The upregulation of CD11c as an indicator of APC phenotype was measured by 
flow cytometry. Histograms b – d are gated on the ‘shifted’ R3 population. 
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Figure 5-16. JX-594 treatment of PBMCs alters monocyte phenotype, resulting 
in a new population of CD14-/CD11c+ cells  
PBMCs from three healthy donors were treated with JX-594 at 0, 0.1 and 1 pfu/cell 
and Reovirus at 1 pfu/cell (comparison) for 24 hours. PBMCs were harvested and 
CD14 and CD11c expression determined by flow cytometry of the non-lymphocyte 
population. Box plots are representative from one of three independent 
experiments,  and % cells in each quadrant are indicated. 
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Figure 5-17. JX-594 treatment of PBMC alters monocyte phenotype, resulting 
in a new population of CD14-/CD86+ cells  
PBMCs from three healthy donors were treated with JX-594 at 0, 0.1 and 1 pfu/cell 
and Reovirus at 1 pfu/cell (comparison) for 24 hours. PBMCs were harvested and 
CD14 and CD86 expression determined by flow cytometry. Box plots are 
representative from one of three independent experiments,  and % cells in each 
quadrant are indicated. 
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Figure 5-18. JX-594 treatment of PBMC alters monocyte phenotype, resulting 
in a new population of CD14-/ClassIIDR+ cells  
PBMCs from three healthy donors were treated with JX-594 at 0, 0.1 and 1 pfu/cell 
and Reovirus at 1 pfu/cell (comparison) for 24 hours. PBMCs were harvested and 
CD14 and ClassIIDR expression determined by flow cytometry. Box plots are 
representative from one of three independent experiments,  and % cells in each 
quadrant are indicated. 
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Figure 5-19. JX-594 treatment of PBMC does not alter monocyte phenotype 
towards CD14-/CD80+ cells  
PBMCs from three healthy donors were treated with JX-594 at 0, 0.1 and 1 pfu/cell 
and Reovirus at 1 pfu/cell (comparision) for 24 hours. PBMCs were harvested and 
CD14 and CD80 expression determined by flow cytometry. Box plots are 
representative from one of three independent experiments,  and % cells in each 
quadrant are indicated. 
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Figure 5-20. JX-594 treatment of PBMC alters monocyte phenotype, resulting 
in a new population antigen presenting-like cells  
PBMCs were isolated from healthy donors (a, c, e, g) and patients with CRLM (b, d, 
f, h) and treated with JX-594 at 0, 0.1 and 1 pfu/cell, and Reovirus at 1 pfu/cell 
(comparison) for 24 hours. PBMCs were harvested and CD14 and 
CD11c/CD86/ClassIIDR/CD80 expression on non-lymphocyte R1-gated cells 
determined by flow cytometry. Experiments were carried out in triplicate (N=3) and 
bars show the mean +SD * indicate significant upregulation of antigen; *p<0.05, 
**p<0.01, ***p<0.0005, ****p<0.0001. 
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5.12 JX-594 infects and begins early phase replication in 
monocytes 
The demonstration of a change in phenotype of monocytes may potentially be due 
to JX-594 infection and potentially replication within monocytes. It has been shown 
in section 5.7 that JX-594 does not replicate within PBMCs (by plaque assay) or 
lymphocytes (by GFP expression).  In a similar fashion, PBMCs from three healthy 
donors were treated with JX-594-GFP and GFP expression in the monocyte 
population (figure 5-21a, gate R1) determined by flow cytometry. Figure 5-21 shows 
that there was an upregulation in GFP production in monocytes following treatment 
with escalating doses of JX-594-GFP. After 24 hours (figure 5-21c), 75% of the 
monocytes in the R2 gate treated with JX-594-GFP expressed GFP, and after 48 
hours (figure 5-21c) this dropped to 18%, with the majority (69%) of the shifted 
monocytes in the R3 gate now expressing GFP.  
 
Figure 5-21. JX-594 will infect and begin early-phase replication in monocytes 
PBMCs were isolated from healthy donors and treated with JX-594-GFP at 0, 0.1 
and 1 pfu/cell for 24 hours. PBMCs were harvested and GFP expression (FITC) 
determined by flow cytometry. Experiments were carried out in duplicate (N=2). 
Figures (a) and (b) show representative dot plot and histogram respectively. 
Figures (c) and (d) show summary data at 24 hours and 48 hours respectively.  
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5.13 Cytokine profile of PBMCs treated with JX-594 
After demonstrating that JX-594 can activate NK cells within whole PBMCs, it was 
then determined if this activation was associated with an inflammatory cytokine 
response. Fresh blood was obtained from up to ten healthy donors and ten patients 
undergoing resection for CRLM by venepuncture, PBMCs isolated by density 
gradient centrifugation, and treated with 0, 0.1 and 1 pfu/cell JX-594-GM-CSF for 
24 (N=10) and 48 hours (N=3). Cell-free supernatant was collected and production 
of GM-CSF, IFNα, IFNβ, IFNγ, TNFα, IL2, IL-8, IL-10, RANTES and IL29 
determined by ELISA. Figure 5-22 shows the upregulation of GM-CSF and IFNα 
following 24 hours JX-594 treatment with PBMCs from healthy donors and patients. 
In healthy donors, compared to the untreated control, after 24 hours of treatment 
with 1 pfu/cell JX-594-GM-CSF, there was an increase in GM-CSF (12 pg/ml vs 63 
pg/ml) and IFNα (18 pg/ml vs 173 pg/ml), although these did not reach statistical 
significance. Compared to reovirus, JX-594 treatment of PBMCs for 24 hours led to 
a greater response in the production of GM-CSF (63 pg/ml vs 16 pg/ml, p>0.05) but 
not IFNα (173 pg/ml vs 1106 pg/ml, p<0.05). 
 
In PBMCs from patients with CRLM (Figure 5-22b and d) treated with 1 pfu/cell JX-
594-GM-CSF for 24 hours, there was a significant increase in GM-CSF (9 pg/ml vs 
86 pg/ml, p<0.05) but not IFNα (23 pg/ml vs 678 pg/ml, p>0.05).  
 
There was an upward trend in the production of IL-2 and IL-8 in both healthy 
donors’ and patients’ PBMCs following JX-594 treatment (data not shown), but 
there was no consistent trend in production of any of the other cytokines studied; 
IFNγ, TNFα, IL-10, RANTES, IL29 and IFNβ (see table 5-2 for summary).  
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Figure 5-22. GM-CSF and IFNα production following in vitro JX-594 infection 
of PBMCs 
PBMCs from healthy volunteers (a, c) and patients with CRLM (b and d) were 
treated with JX-594 at 0, 0.1 and 1 pfu/cell and Reovirus at 1 pfu/cell (positive 
control) for 24 hours. Supernatant was collected and cytokine expression quantified 
by ELISA. Experiments were and bars show the mean + SD. * indicates significant 
increase in cytokine production; *p<0.05. 
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5.14 Monocytes are required for modulation of an inflammatory 
response 
To further investigate the role of CD14+ve monocytes in NK cell activation, PBMCs 
from three healthy volunteers were sampled and NK cells and CD14-ve cells were 
isolated by negative selection, and CD14+ve cells removed by positive selection, to 
obtain CD14-ve PBMCs. (see figure 5-11). In all three donors, the four populations of 
cells (whole PBMCs, purified NK cells, CD14-ve cells and CD14+ve cells) were 
treated with 0 pfu/cell, 0.1 pfu/cell and 1 pfu/cell of JX-594-GM-CSF for 24 hours 
and cell-free supernatant was collected and inflammatory cytokines (GM-CSF, IFNα 
and IL8) analysed by ELISA. Data for whole PBMCs and CD14-ve cells is displayed 
in figure 5-23. There was no difference in production of GM-CSF in the four cell 
populations. In contrast, whole PBMCs were required for IFNα production, and 
removal of CD14+ve PBMCs inhibited IFNα production in response to JX-594. IL-8 
was produced in high quantities from CD14+ve monocytes, either pure or within 
whole PBMCs; similar findings were observed in experiments with patient blood 
(see table 5-2). 
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Figure 5-23. CD14+ve Monocytes potentiate an inflammatory reaction from 
PBMCs treated with JX-594 in vitro. 
Fresh whole blood was sampled from healthy donors, PBMCs were isolated by 
centrifugation over lymphoprep gradient, and cell populations separated using 
magnetic beads. Whole PBMCs and CD14-ve cells were treated with JX-594 at 0, 
0.1 and 1 pfu/cell for 24 hours. Supernatant was collected and levels of cytokine 
determines by ELISA. Experiments were carried out in triplicate (N=3) and bars 
show the mean + SD * p<0.05.  
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 Healthy Donors Patients 
 PBMC
s 
NK cells CD14-ve CD14+ve PBMCs NK 
cells 
CD14-
ve 
CD14+ve 
GM-CSF (24) ! ! ! ! ! ! ! ! 
GM-CSF (48) "# - - - - - - - 
IFNα (24) ! "# "# ! ! "# - - 
IFNα (48) "# - - - - - - - 
IL-8 (24) !! ! ! !! !! ! ! !! 
IL-8 (48) ! - - - "# - - - 
IFNγ (24) "# "# - - "# "# - - 
IFNγ (48) "# - - - "# - - - 
TNFα (24) "# - - - "# - - - 
TNFα (48) "# - - - "# - - - 
IL-10 (24) "# - - - "# - - - 
IL-10 (48) "# - - - - - - - 
RANTES (24) "# - - - "# - - - 
RANTES (48) "# - - - - - - - 
IL2 (24) ! - - - - - - - 
IL2 (48) ! - - - - - - - 
IL29 (24) $ - - - ! - - - 
IL29 (48) "# - - - - - - - 
IFNβ (24) "# - - - - - - - 
IFNβ (48) "# - - - - - - - 
Table 5-2. Summary of cytokine profile following in vitro treatment of 
components of PBMCs with JX-594 
Fresh whole blood was sampled from healthy volunteers, PBMCs were isolated by 
centrifugation over lymphoprep gradient and treated with JX-594 at 0, 0.1 and 1 
pfu/cell for 24 and 48 hours. Supernatant was collected and cytokine expression 
quantified by ELISA. Experiments were carried out in 8 to 10 donors for samples at 
24 hours, and 3 donors for samples at 48 hours.  
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5.15 Liver and Tumour derived NK cells are not activated by JX-
594 in vitro 
The liver is a highly vascular structure, and peripherally-activated NK cells following 
intravenous therapy are likely to infiltrate into the liver. However, it also important to 
investigate the effect of JX-594 on liver- and tumour- derived mononuclear cells 
(LMCs and TMCs respectively), particularly if intratumoural or transarterial delivered 
therapy is to be considered. Fresh surgical specimens immediately following 
resection were processed as detailed in section 2.13 and 2.14. LMCs and TMCs 
were isolated by centrifugation over lymphoprep gradient, and labelled with CD3-
PerCP and CD56-PE antibodies and analysed by flow cytometry. Isolation of LMCs 
and TMCs was initially performed with collagenase to aide dissociation of the 
tissue, which eased the process of passing the liver tissue through a 70 µm cell 
strainer. However, the resulting single cell suspension had excessive cellular 
debris. In addition, the liver tissue was also processed via lymphoprep gradient 
centrifugation, and although some hepatocyte- and tumour- bound mononuclear 
cells were lost in this process, a purer population was achieved (see figure 5-24); 
therefore, all future liver and tumour mononuclear cell isolation experiments were 
performed using this protocol. 
 
Figures 5-24 and 5-25 depict the gating strategy for LMCs and TMCs, and 
illustrates the difficulty in attaining pure and viable cell populations. Figure 5-25 b) 
shows that the normal liver is NK cell-rich (close to 30%, compared to 10% in 
peripheral blood), but the CRLM tumour deposit has fewer NK cells (8%).  
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Figure 5-24. Analysis of LMC and TMC isolation protocol 
Photomicrographs of the resulting single cell suspension when the LMC and TMC 
isolation protocol was performed with and without collagenase and lymphoprep 
gradient centrifuge is depicted in figure a). The optimised conditions (with 
lymphoprep, without collagenase) was selected based on the appearance of 
mononuclear cells and lack of cellular debris. Figure b) shows the flow cytometric 
analysis of immune mononuclear cells isolated without collagenase and with 
lymphoprep, and demonstrates the presence of CD3-veCD56+ve NK cells  (see 
section 2.14). 
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Figure 5-25. Depleted levels of NK cells in CRLM compared to normal liver 
Fresh surgical specimens immediately following resection were processed as 
detailed in section 2.6. Liver- (a, b) and Tumour- (c, d) mononuclear cells were 
isolated by centrifugation over lymphoprep gradient, and labelled with CD3-PerP 
and CD56-PE antibodies and analysed by flow cytometry. Figures (a) and (c) show 
FSc vs SSc and illustrate the lymphocyte population and figure (b) and (d) show 
identification of CD56+veCD3-ve NK cells within the LMC and TMC gate. 
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In figure 5-26, representative histograms (figure 5-26, a – c) and summary bar 
charts (figure 5-26, d – f) depict that NK cells from peripheral blood, but not normal 
liver or tumour could be activated by JX-594. Following Reovirus treatment, 
however, compared to untreated control, NK cells from normal liver (14% to 56% 
CD69 positive) and from CRLM tumour (28% to 60% CD69 positive) could be 
activated. This positive control with Reovirus was only performed in one patient due 
to availability of adequate quantities of LMCs and TMCs. It has been demonstrated 
earlier in this chapter that activation of NK cells in peripheral blood is associated 
with a downregulation of CD14 on monocytes, hence the % of CD14+ve cells in 
LMCs and TMCs was determined. In these patient samples, PBMCs had 
approximately 20% CD14+ve monocytes (figure 5-26, g and j) which was 
downregulated in response to JX-594 treatment. Within the liver, there was a higher 
percentage of CD14+ve cells, which did not show appreciable downregulation in 
response to JX-594 treatment, whilst in liver tumour, there were hardly any CD14+ve 
cells at all (<1%), and these did not respond to JX-594 treatment. 
 
The inflammatory cytokine production (GM-CSF, IFNα and IL-8) associated with JX-
594 treatment of LMCs and TMCs was investigated (figure 5-27). Following 24 
hours in culture, cell-free supernatant was collected and cytokine profile studied by 
ELISA. GM-CSF production was significantly higher following treatment of PBMCs, 
LMCs and TMCs with 1 pfu/cell JX-594. IFNα was only produced in small quantities 
in these samples (data not shown). IL-8 was produced in high quantities by  both 
LMCs and TMCs, which decreased moderately in response to JX-594 treatment. 
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Figure 5-26. Liver- and CRC tumour-derived NK cells are not activated by JX-
594. 
PBMCs were isolated from patients undergoing liver resection for metastatic CRC, 
and LMCs and TMCs isolated from fresh surgical specimens immediately following 
resection. PBMCs (a, d, g and j), LMCs (b, e, h and k) and TMCs (c, f, i and l) were 
treated with JX-594-GM-CSF at 0, 0.1 and 1 pfu/cell for 24 hours, and cell surface 
expression of CD14 and CD69 quantified by flow cytometry. Figures (a), (b) and (c) 
show representative histograms of CD69 expression on CD56+veCD3-ve NK cells, 
and figures (d), (e) and (f) show summary bar charts of CD69 expression on 
CD56+veCD3-ve NK cells; experiments were carried out in triplicate (N=3) and bars 
show the mean+SD. Figures (g), (h) and (i) show CD14 expression in the non-
lymphocyte population. Figures (j), (k) and (l) show the summary bar charts of 
CD14 expression on the non-lymphocyte population; experiments were carried out 
in triplicate (N=3) for PMBCs and LMCs, and N=1 for TMCs, and bars show the 
mean+SD. 
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Figure 5-27. Cytokine profile of LMCs and TMCs following JX-594 treatment 
Fresh whole blood was sampled from patients undergoing liver resection for 
metastatic CRC and PBMCs (a and d) were isolated by centrifugation over 
lymphoprep gradient. Fresh surgical specimens were obtained from the same 
patients immediately following resection and were processed as detailed in section 
2.6, and LMCs (b and e) and TMCs (c and f) were isolated by centrifugation over 
lymphoprep gradient. PBMCs, LMCs and TMCs were cultured for 24 hours +/- JX-
594 and supernatant collected and cytokine production determined by ELISA; (GM-
CSF N=3, IL8, N= 1 to 2). Bars show the mean + SD where indicated. * indicates 
significant increase in cytokine production; *p<0.05 **p<0.005. 
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5.16 Discussion 
The theory that the immune system can regulate tumourigenesis has been the 
subject of debate for over a century, and has gained more understanding as our 
knowledge of the immune system has developed. Burnett and Thomas’  
Immunosurveillance theory emerged, hailing adaptive immunity as the key player in 
preventing cancer development. This theory soon lost favour, with the 
demonstration of similar incidence of spontaneous and carcinogen-induced cancer 
in immunocompetent and nude mice with partial immunodeficiency, and an 
increased incidence of tumourigenesis in mice that lacked NK cells. The immuno-
editing and danger hypothesis soon became more accepted, and it is now accepted 
that an inflammatory microenvironment is a component of many tumours, and can 
facilitate both tumour growth and control. The previously described theory of 
immunosurveillance and its initial criticism lends itself as an important supportive 
argument for the role of NK cells. Further work has defined that in both 
immunocompetent and immunodeficient mice, IFNγ [32, 227, 228] and perforin 
[229-232] activities can (in various reports, independently) control tumor initiation, 
growth, and metastasis.  
 
The function of NK cells is determined by a balance between activating and 
inhibitory signals; hence before implicating NK cells as potential immunotherapy 
effectors against CRC, it must first be elucidated whether CRC cells display 
immunogenicity by expressing NK-activating receptor ligands. Zhang et al. have 
demonstrated a higher expression of CD155, CD112 and MHC class I chain-related 
(MIC) molecules (MICA/B) ligands in colon carcinoma tissues, and functional 
blocking of these ligands led to significant inhibition of NK cell cytotoxicity. Similar to 
findings in this chapter, they also observed reduced expression of DNAM-1 and 
NKG2D in NK cells of colon cancer patients compared to healthy donors, which 
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was explained by their finding of higher serum concentrations of sCD155 and 
sMICA/B (soluble ligands to NK cell surface activatory receptor proteins, which are 
secreted or shed from malignant cells) in CRC patients compared to healthy 
donors; sCD155 and sMICA/B may down-regulate DNAM-1 and NKG2D on NK 
cells [210]. Doubrovina et al. also showed that circulating sMIC in CRC cancer 
patients deactivates NK cell immunity by down-modulating NKG2D, and only 
NKG2D+ve NK cells were tumouricidal in vitro [233]. Thus CRC, despite immune 
evasion strategies, is a potentially immunogenic tumour, and lends itself as a target 
for NK cell-mediated killing. Results in this chapter demonstrate that NK cells from 
both healthy donors and patients with metastatic CRC can be activated by JX-594, 
demonstrated by the upregulation of CD69 on the surface of NK cells within JX-
594-treated PBMCs, which is an established activatory marker for NK cells [234]. 
The lack of significant upregulation compared to untreated control in patients may 
be partly explained by the lower numbers of subjects investigated, but also by the 
small number of patients who responded weakly to JX-594. These patients may 
have suppressed innate immunity due to the systemic consequence of malignancy, 
which may include over-expression and shedding of some of the soluble ligands as 
described above.  
 
A similar upregulation following JX-594 treatment as observed with CD69, was not 
seen with the activatory receptors NKG2D, DNAM-1, NKp30, NKp44 and NKp46. It 
is possible that there may be another undefined receptor and ligand pair that may 
have been upregulated following JX-594 treatment, which was not investigated in 
the experimental protocol. This is supported by the findings of Bhat et al., who 
showed that blocking NKp30, 44 and 46 in combination, and NKG2D and DNAM-1 
alone, inhibited the NK cell-mediated killing of pancreatic ductal adenocarcinoma 
cells, which was overcome by infection of the target cells with an oncolytic 
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parvovirus (H-1PV); this suggested that parvovirus may induce additional NK cell 
ligands on pancreatic ductal adenocarcinoma cells [235].  
 
Along with the activation of NK cells, the results in this chapter demonstrate that JX-
594 treated NK cells can degranulate and kill CRC cell targets by perforin/granzyme 
mediated cytotoxicity. A high level of degranulation was seen with NK cells in 
response to presentation to K562 cells (which express ligand for NKp30 [236]). 
Interestingly, although CD69 upregulation was greater in healthy donors compared 
to patients with CRLM, NK cells from patients exhibited greater degranulation; less 
virus was required for maximal degranulation, and degranulation was significant 
against the cell line more resistant to direct virus toxicity (SW620). In cytotoxicity 
studies, maximal killing was seen following treatment with 0.1 pfu/cell JX-594. 
Following 1 pfu/cell treatment, the response diminished, perhaps indicating that at 
this dose, although there is no demonstrated toxicity towards PBMCs, JX-594 may 
result in ‘defective’ NK cells which, although they can degranulate, do not kill 
efficiently - this is important to note when considering the optimal dose for trial 
therapy. There has been little published in the literature examining the activation of 
NK cells from patients with metastatic CRC by JX-594 in vitro, and the mechanistic 
findings detailed in this chapter are novel; hence few comparisons can be made 
with the published literature. During intravenous delivery of JX-594 in clinical trials, 
JX-594 has been found in the circulation shortly after IV or IT administration, with a 
second peak following a period of in vivo replication [77]. As JX-594 will be exposed 
to blood cells, it is important to determine whether blood cells become infected by 
JX-594. The results presented here suggest that JX-594 will not infect or kill 
lymphocytes, and that lymphocytes attracted to sites of viral replication and tumour 
cell destruction will not themselves be destroyed. Similarly, Parato et al. have also 
shown that PBMCs are resistant to JX-594 replication (virus-driven βgal activity), 
and are not susceptible to infection even in an activated state [163]. Breitbach et al. 
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have shown that NAbs were only detectable in 6/22 patients receiving IV JX-594 
and that there was no correlation between NAb titres and JX-594 replication, safety 
or antitumour activity [101].  
 
The requirement for CD14+ve cells for JX-594 activation of NK cells is a novel 
finding, although the described reduction in total number of CD14+ve cells following 
JX-594 treatment in vitro has been described in the literature [237]. This CD14-
dependant NK activation is not a phenomenon observed in reovirus-treated 
PBMCs, thus inferring a different mechanism of immune activation in these two 
OVs. CD14+ve monocytes may be the first to take up JX-594, leading to a cascade 
of events, including cell-to-cell interaction and cytokine production. 
 
The cytokine profile of PBMCs treated with JX-594 in vitro has been illustrated for 
the first time. JX-594 treatment leads to production of GM-CSF and IFNα, and to a 
lesser extent, IL-2 and IL-8. Interestingly, there was a viral dose-dependant 
expression of GM-CSF from PBMCs, and no demonstrable replication, with an 
initial increase at 24 hours in GM-CSF and IL-8 production which diminished at 48 
hours p.i. Taken together, these results lead us to postulate that GM-CSF was 
produced by immune cells in reaction to the initial viral exposure, or due to early-
phase replication of the virus which occurs independently of host-cell machinery. 
Support for the former comes from the demonstration of similar levels of GM-CSF 
production from isolated sub-populations of PBMCs; whole PBMCs, NK cells, 
CD14-ve cells and CD14+ve cells. The lack of IFNα production in CD14-ve PBMCs 
following JX-594 treatment and the lack of CD69 upregulation on NK cells, furthers 
our mechanistic understanding of innate immune activation by JX-594. However, 
further experiments, including transwell assays are required to further characterise 
this phenomenon. Although similar in vitro cytokine profiles have not been 
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published in the literature, cytokine profiles have been studied following in vivo 
therapy; Breitbach et al.  treated 22 patients with IV JX-594 and evaluated the 
cytokine profile. IFNγ, TNFα and IL-6 increased acutely in a dose-dependent 
manner (peak at 8 h and resolution at day 4). Levels of IL-10 were found to 
increase later, on days 4–8 [136]. The in vitro studies described in this chapter do 
not match this published in vivo cytokine profile, although they were only performed 
to a maximum of 48 hours. 
 
It is evident from the results discussed in this chapter that JX-594 will first infect 
monocytes and begin early-phase replication (with no new viral progeny, as 
demonstrated by plaque assay experiments). The lack of any demonstrated killing 
despite virally-expressed GFP within monocytes demonstrates the ability of PBMCs 
to prevent this highly-lytic virus from hijacking host cell machinery. These infected 
monocytes down-regulate CD14 expression, and attain an APC phenotype. The 
presentation of antigens by APCs is necessary for the induction of a memory T-cell 
response to a particular antigen. APCs include DCs, macrophages and B-cells, and 
activated APCs may be identified by the upregulation of CD86, CD11c and 
ClassIIDR [237, 238].  
 
It is interesting to note that, compared to untreated control, the increase in a CD14-
ve/CD11c+ve/CD86+ve/ClassIIDR+ve phenotype in patient-derived monocytes was not 
significant; this corresponded with a lack of significant increase in CD69 in NK cells 
from patients following JX-594 treatment. Hence, understanding the interaction of 
JX-594 with monocytes, and potentiating this, may be the key to enhancing 
immune-mediated anti-tumour outcomes following IV-delivered JX-594 therapy. 
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There is little in the literature describing this phenomenon of virus-induced 
monocytes shift towards APC. Hou et al. have described this shift to APC 
phenotype with several viruses, including Influenza A virus, VSV, and VV. They 
found that 18 hours of virus treatment induced monocytes to differentiate into CD16-
veCD83+ve mature dendritic cells, which did not require cell division (γ-irradiation on 
monocytes did not affect the conversion), but did require viral gene expression in 
the case of IAV [237]. We can only postulate that JX-594 induces a similar 
conversion of monocytes to DCs, but confirming this would require further studies to 
determine the exact identity of these cells. Future studies could involve treating 
isolated monocytes with JX-594 and incubating with NK cells, and trans-well 
experiments, to further characterised the ‘cross-talk’ involved in NK-cell activation 
by JX-594.  
 
Another interesting finding is that of high numbers of CD14+ve cells in the liver, 
which do not downregulate CD14 in response to JX-594 treatment. Although many 
of these may be macrophages/monocytes which do not respond to JX-594 in the 
same way as peripheral CD14+ve cells, some of these may be hepatocytes or 
Kupffer cells, both of which can express CD14 [239, 240]. Thus, the inability of JX-
594 to activate liver-derived NK cells may be due to the lack of an appropriate 
CD14+ve cell response. Similarly in the CRC tumour deposit from the liver, no 
CD14+ve cells were isolated, and concurrently, tumour-derived NK cells could not be 
activated by JX-594. The more general significance of CD14+ve immune cells has 
been reported in the literature; Kinouchi et al. have shown that infiltration of CD14+ve 
macrophages at the invasive front indicated a favourable prognosis in patients with 
metastatic CRC [241]. These findings are important in the context of understanding 
how to potentiate the effectiveness of JX-594 therapy, and future trials may need to 
evaluate the CD14+ve population. Future work examining chemo-attraction of 
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CD14+ve cells into the tumour environment, or even direct CD14+ve cell injection into 
tumours, may be worth considering. 
 
In addition to the lack of JX-594-responsive NK cells from the liver, the results in 
this chapter have demonstrated a reduction in the percentage of NK cells in tumour 
compared to normal liver and peripheral blood. However, the majority of these NK 
cells are in a higher state of activation (CD69+ve). This has been reported in the 
literature, with increased CD69, HLA-DR, and NKp44 expression [242] on NK cells 
derived from liver tumours. In the same study, liver-derived NK cells from patients 
with hepatic malignancy were less cytolytic compared to their peripheral 
counterparts, and were found to express less CD16 compared to peripheral NK 
cells (50% vs 90% of NK cells expressing CD16). The activation of NK cells is 
important in the context of metastatic CRC and it has been shown that metastatic 
spread of colorectal cancer is associated with decreased NK-cell activity, with 
overexpression of inhibitory receptors and defective expression of activatory 
receptors, and fewer NK cells in the tumour compared to normal tissue [225, 243]. It 
has been suggested that during surgery, manipulation of the affected organ may 
lead to tumour cell emboli, and NK cell clearance is a vital preventative mechanism 
against metastatic deposition. However, post-operative physiological stress can 
also lead to immune suppression. Tai et al. showed that in mice, perioperative 
administration of oncolytic parapoxvirus ovis (ORFV) and vaccinia virus reversed 
surgical stress-induced NK cell suppression, which correlated with a reduction in 
the postoperative formation of metastases. This was also demonstrated in human 
studies following pre-operative oncolytic vaccinia virus administration [226]. 
 
Oncolytic viruses can be designed to maximise ‘good’ inflammation to promote 
immune-mediated anti-tumour therapy alongside direct tumour cell killing. Hence, 
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compared to current conventional treatments, oncolytic virotherapy may have the 
particular benefit of providing disease control via activation of an innate response 
which may in turn induce an long-term adaptive T-cell memory response to keep 
tumours in check. The results presented in this chapter further our mechanistic 
understanding of the action of JX-594 and present another attractive anti-tumour 
characteristic of JX-594 - the potential to induce effective antigen presentation of a 
tumour antigen for adaptive anti-tumour immune priming. 
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6 Conclusion and future work 
JX-594 is a double-stranded, enveloped, lytic DNA virus with a large capacity for 
foreign DNA. It is easy to manipulate genetically, has rapid replication and spread, it 
is motile, does not integrate into host DNA, and it is safe in animal models and 
primates [244]. JX-594 is highly immunogenic and produces a strong anti-tumour 
cytotoxic T-Lymphocyte (CTL) response [245]. The tumour-specificity of JX-594 is 
achieved by deletion of the TK gene, rendering it incapable of replication in TK-
deficient (normal) cells; the insertion of GM-CSF into the TK locus enhances its 
immunogenicity. Despite the use of this OV in phase I and early phase II trials, 
there is little in the literature about the mechanism by which the virus functions, 
particularly the immunogenic actions of the virus. The work detailed in this thesis 
investigates the consequences of JX-594 treatment on CRC and PBMCs, and the 
mechanisms by which it achieves its anti-tumour outcome. 
 
The results displayed in the thesis demonstrate the ability of JX-594 to kill CRC 
tumour cells in vitro and replicate whilst doing so, inducing an inflammatory tumour 
microenvironment in its wake. Through the use of MTT and Live/Dead® assays, the 
loss of metabolic activity and viability of CRC cell lines in vitro is demonstrated, 
which is more pronounced in cells with increased surface EGFR expression. In all 
cell lines, the cytolytic effects of JX-594 became more pronounced following a 72-
hour incubation period, demonstrating that the virus initiates a ‘slow-kill’ of the CRC 
cell lines treated. Through the demonstration of an increased expression of active 
caspase-3, it is elucidated that the mechanism of CRC cell-killing is in part due to 
activation of the apoptotic pathway, with the more susceptible cell lines also 
displaying a higher quantity of active caspase-3. Alongside the killing, it is evident 
that JX-594 can replicate within these CRC cell lines, as demonstrated by the 
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plaque assay technique and the expression of a virally-encoded protein; GFP, with 
increased replication in the more susceptible cell lines. The use of confocal 
microscopic determination of GFP expression on cell lines demonstrated the bi-
phasic replication of JX-594, with a clear burst of transgene products after 48 hours 
infection. 
 
In addition to the tumour-specific cytotoxicity and replicative ability of JX-594, there 
are also inflammatory changes induced within the tumour microenvironment.  The 
encoded GM-CSF is expressed with a dose-time response following treatment of 
CRC cell lines with JX-594 up to 72 hours, following which there is reduction in GM-
CSF expression due to death of the tumour cells by 96 hours. At this late stage of 
the assay, there is also a reduction in the quantity of VEGF expression with 
increased treatment doses of the virus. A pro-inflammatory microenvironment 
following JX-594 treatment is achieved not only by the expression of GM-CSF, but 
also by upregulation of IL-6 and downregulation of Il-10, however there was no 
discernible upregulation of IL-28, RANTES, IFNα or IFNβ. The slower death of the 
cell lines induced by JX-594 compared to other OVs may be beneficial in the 
context of the induction of a pro-inflammatory environment particularly for encoded 
replication-dependant proteins such as GM-CSF. 
 
In order to verify the in vitro findings in more clinically relevant model, an ex vivo 
system is adopted. Fresh liver tissue from CRLM and adjacent normal liver is 
collected immediately following resection, from which ‘cores’ of tissue are made and 
maintained in culture for up to 96 hours (n=10). Tumor-specific replication is shown 
by the preferential expression of GFP in JX-594-GFP-treated CRLM cores, but not 
in cores of normal liver. Similarly, the expression of GM-CSF in CRLM cores 
continues to increase after 48 hours, in keeping with the in vitro findings of a bi-
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phasic burst of transgene expression, whereas in normal liver this is not the case. 
Unlike in the in vitro system, treatment of CRLM cores with JX-594 is not 
associated with a generalised inflammatory response.  
 
The description of the generation of a pro-inflammatory tumour microenvironment 
as a beneficial characteristic of JX-594 is a controversial one, as there remains a 
debate as to the role of inflammation in cancer. JX-594 can influence the cells of 
the immune system both locally and peripherally.  The tumour-specific expression 
of GM-CSF will attract immune cells into the tumour tissue where they will be 
exposed to the virus and the melee of cytokines and TAAs following viral-mediate 
cell death. As the favoured route of administration of the virus is via intravenous 
infusion, the virus will also be in contact with immune cells peripherally. NK cells 
remain the only immune cell type whose presence within the tumour 
microenvironment has not been shrouded with the controversy of the pro- and anti- 
tumourgenic debate. Hence, the influence of JX-594 treatment on NK cell activity is 
the focus of this thesis’ investigation into the immunogenicity of JX-594. It is 
demonstrated that JX-594 treatment of PBMCs in vitro leads to an activation of NK 
cells as demonstrated by an increase in CD69 expression on the NK cell surface, 
and an increased de-granulation against tumour cell lines. These activated and de-
granulated NK cells are also shown to cytotoxic against CRC cell line targets, as 
determined by 51Cr-release assays, which also reveal the mechanism of killing to be 
perforin/granzyme mediated. Importantly, it is also demonstrated that JX-594 is not 
cytotoxic against PBMCs in vitro, and JX-594 will not replicate in PBMCs. There is 
little cytokine activity observed following JX-594 treatment of PBMCS; with a dose-
dependant increase in GM-CSF and a modest increase in IFNα. 
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Mechanistically, it is revealed here that JX-594 requires CD14+ve monocytes in 
order to activate NK cells; when these are removed by bead selection, then JX-594 
treatment of the remaining (non-CD14+ve) population results in no CD69 
upregulation on NK cells. It is also shown that JX-594 will preferentially infect 
monocytes, and begin early-phase replication, without killing. In addition to the 
upregulation of CD69 on NK cells in a whole PBMC population, JX-594 treatment 
also results in a downregulation of CD14 expression on the non-lymphocyte 
population, resulting in a shift of these cells to a smaller, more granular phenotype. 
Following flow cytometric analysis, this new shifted cell population is characterized 
as a CD14-ve/ CD86+ve/ClassIIDR+ve/CD11c+ve APC-like phenotype. This observation 
is particularly important when considering the long-term implications of JX-594 
therapy and the potential generation of a memory response against new tumour 
burden, as these new APC-like cells have the potential to induce effective antigen 
presentation of a tumour antigen, resulting in adaptive anti-tumour immune priming. 
This may, however, be reliant on the infiltration of peripherally-activated immune 
cells into the tumour, as NK cells derived from within the normal liver and the CRLM 
did not show the same activatory response when treated with JX-594, with no 
associated downregulation of CD14 expression. 
 
Future work should be focused on further examining this proposed mechanism of 
immune cell activation further, and determining the exact mechanism by which 
CD14+ve cells can influence innate immune activation; through cell-to-cell contact or 
cytokine messaging. It is clear that the presence of CD14+ve cells is required for JX-
594-mediated NK cell activation, but more cytokine analysis is required, including 
intra-cellular IFNs and GM-CSF analysis, and trans-well assays. It would also be 
interesting to characterize the response of nodal mononuclear cells/NK 
cells/monocytes to JX-594 treatment. The lack of an activatory response on NK 
cells within LMCs and TMCs needs further clarification, along with if/how this can 
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be overcome, and further analyses of the potential shift towards APC in monocytes 
from LMCs. The tissue core model developed here has potential for further 
refinement and may also be used to determine JX-594-induced killing of CRLM 
tumour cells, and sparing of normal liver cells. 
 
Ultimately, the effects of JX-594 in vivo needs to be investigated; either though an 
animal model or a human trial, to confirm the in vitro and ex vivo findings of this 
thesis. This needs to be performed in subjects with not only disseminated disease 
(as in the majority of the trials performed so far), but also in early disease, as this 
would provide more information on particularly the immune-mediated effects of JX-
594 on cancer cells that have not undergone excessive transformation and thus 
escaped from immune surveillance. A proposal for a functionally significant animal 
model would ideally involve an animal model with CRC and time-dependant liver 
metastasis, injecting the primary colorectal tumour with JX-594 along with IV 
infusion. This presents a multitude of possibilities for analysis: the treated and 
untreated animals can be compared for survival and generation of liver metastases; 
following sacrifice, colonic tissue can be analysed for tumour-specific replication, 
death and immune response; nodal tissue can be gathered for analysis of nodal 
infiltration of JX-594 and the presence of TAA-specific APCs; and liver tissue can 
be analysed for JX-594 infiltration into any developing metastatic tumours. 
 
The field of oncolytic virotherapy is promising, and holds potential to develop into a 
novel adjunct to current therapeutic modalities. It is not the intention of this thesis to 
suggest that it is a magic bullet, but rather that it does provide a new modality for 
therapy that may provide further treatment options for patients and clinicians.  
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8 List of Abbreviations 
5-FC 5-Fluorocytosine 
5-FU 5-Fluorouracil  
ADCC Antibody-Dependent Cell-Mediated Cytotoxicity 
AFP Alpha-Feto Protein 
AIDS Aquired Immuno-Deficiancy syndrome 
ANOVA Analysis Of Variants 
APC Atigen Presenting Cell 
ATP Adenosine tTri-phosphate  
BCG Bacillus Calmette-Guerin 
CD Cluster of Differentiation 
CDC Complement-Dependant Cytotoxicity 
CEA Carcino-Embryogenic Antigen 
CEV Cell-associated Enveloped Virus 
CIK Cytokine-Induced Killer cells 
CLSM Confocal Laser Scanning Microscopy 
CMC Carboxymethylecellulose 
CRC Colorectal Carcinoma 
CRLM Colorectal Liver Metastases 
CT Computed Tomography 
CTL Cyto-toxic T Lymphocyte 
DAMP Damage-Associated Molecular Patterns  
DC Dendritic Cells  
DFI Disease Free Interval 
DMEM Dulbecco's Modified Eagle Medium 
DMSO Dimethyl Sulphoxide 
DNA Deoxyribonucleic acid  
EBV Epstein-Barr Virus 
EDTA Ethylenediaminetetraacetic acid 
EEV Extra-cellular Enveloped Virus 
EGF Epidermal Growth Factor 
EGFR Epidermal Growth Factor Recepter 
EGTA Ethylene Glycol Tetraacetic Acid 
ELISA Enzyme Linked Immunoabsorbent Assay 
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FACS Fluorescence Activated Cell Sorting 
FCS Foetal Calf serum 
FITC Fluorescein Isothiocyanate 
FNH Focal Nodular Hyperplasia 
FSC Forward scatter 
GAG Glucosaminoglycans 
GFP Green Fluorescent Protein 
GMCSF Granulocyte-Macrophage Colony Stimulating Factor 
HBSS Hanks' Buffered Salt Solution 
HBV Hepatitis B Virus 
HCC Hepatocellular Carcinoma 
HCV Hepatitis C Virus 
HLA Human Leukocyte Antigen 
HPV Human Papiloma Virus  
HSV Herpes Simplex Virus 
HTLV  Human T-cell Leukemia Virus Type I  
HU Hounsefield Units 
ICAM Intracellular Adhesion Molecule 
IDO Indolemine Dioxygenase 
IEV Intracellular Enveloped Virus 
IFN Interferon  
IGF Insulin-like Growth Factor 
IL Interleukin  
IMV Intracellular Mature Virus 
IT Intra-tumoural  
ITR Inverted Terminal Repeats 
IV Intra-venous  
Kras Kirsten rat sarcoma 
LIVP Lister strain from the Institute of Viral Preparations 
LMC Liver Mononuclear Cells 
LPS Lipopolysaccharide 
LV Leocovorin  
MACS Magnetic-Activated Cell Sorting 
MAPK Mitogen-Activated Protein Kinase 
MHC Major Histocompatibility 
MOI Multiplicity of Infection 
MTD Maximum Tolerated Dose 
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MTT Microculture Tetrazolium Test  
MV Measles Virus  
MVA Modified Vaccinia virus Ankara 
NAb Neutralising Antibodies 
NDV Newcastle Disease Virus 
NK Natural Killer  
NSCLC Non-Small Cell Lung Cancer 
OS Overall Survival 
OV Oncolytic Virus 
p.i. Post-infection  
PAMP Pathogen-Associated Molecular Patterns 
PARP Poly ADP-Ribose Polymerase  
PBMC Peripheral Blood Mononuncleocytes 
PBS Phosphate Buffered Saline 
PET-CT Positron Emission Tomography -CT 
PFA Paraformaldehyde 
PFU Plaque-forming units 
PKR Protein Kinase R 
PRR Pattern Recognition Receptors  
PSA Prostate-specific antigen 
RANTES 
Regulated upon Activation, Normal T-cell Expressed and 
Secreted 
RB Retinoblastoma protein 
RECIST Response Evaluation Criteria in Solid Tumors 
RNA Ribosenucleic Acid 
RPMI Roswell Park Memorial Institute 
RT Room Temperature 
SD Standard Deviation 
SEM Standard Error of the Mean 
SIRS Systemic Inflammatory Response Syndrome 
SSC Side scatter  
TAA Tumour Associated Antigens 
TGF Transforming Growth Factor  
Th1 T helper 1  
TILs Tumour Infiltrating Lymphocytes 
TK Thymidine Kinase 
TLR Toll-Like Receptor 
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TMC Tumour Mononuclear Cells 
TRAIL Tumour necrosis factor-Related Apoptosis-Inducing Ligand 
TSA Trichostatin  
UK United Kingdom 
UPR Unfolded Protein Response  
USA United States of America 
UVB Ultraviolet B  
VCO Vaccinia Colon Oncolysate 
VEGF Vascular Endothelial Growth Factor 
VGF Vaccinia Growth Factor 
VMCL Vaccinia Melanoma Cell Lysate 
VMO Vaccinia Melanoma Oncolysate 
VSV Vesicular Stomatitis Virus 
VV Vaccinia Virus 
WCC White Cell Count 
WR Western Reserve 
WT Wild Type  
YFP Yellow-Fluorescent Protein 
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9 Appendix A. Details of cell lines 
HCT116: Epithelial cell line derived from adult male. Microsatelite unstable, near 
diploid and tumorigenic in mice [246].  
LoVo: Epithelial cell line derived from adult male, colon (from metastatic site: 
colon); grade IV; Dukes' type C [247]. Microsatelite unstable, near diploid and 
tumourigenic in nude mice [248]. 
SW480: Epithelial cell line derived from 51 year old Caucasian male with colorectal 
adenocarcinoma Duke’s B.  Near diploid, and is tumorigenic in Mice [246]. 
SW620: Epithelial cell line derived from 51-yr old Caucasian male (as above, 
SW480) with Duke’s C colorectal adenocarcinoma.  Hyperdiploid, and tumorigenic 
[249]. 
K562: human chronic myeloid leukaemia. These are easily killed by natural killer 
(NK) cells as they lack the MHC complex required to inhibit NK activity. 
Vero: These originate from isolated kidney epithelial cells extracted from an African 
green monkey. They are interferon-deficient; unlike normal mammalian cells, they 
do not secrete type 1 interferons when infected by viruses. 
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10 Appendix B: GFP expression in ‘Tissue Cores 
 
Figure 10-1. Tumour specific transgene (GFP) expression. CRLM, N=1 
 
 
Figure 10-2. Tumour specific transgene (GFP) expression. CRLM, N=2 
 
 
0pfu% 1pfu%
24hr%
96hr%
Normal%Liver%
0pfu% 1pfu%
Liver%Tumour%
1200uM%
0pfu% 107pfu%
24hr%
96hr%
Normal%Liver%
0pfu% 107pfu%
Liver%Tumour%
1200uM%
- 215 - 
 
Figure 10-3. Tumour specific transgene (GFP) expression. CRLM, N=3 
 
 
Figure 10-4. Tumour specific transgene (GFP) expression. CRLM, N=4 
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Figure 10-5. Tumour specific transgene (GFP) expression. CRLM, N=5 
 
 
Figure 10-6. Tumour specific transgene (GFP) expression. CRLM, N=6 
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Figure 10-7. Tumour specific transgene (GFP) expression. CRLM, N=7 
 
 
Figure 10-8. Tumour specific transgene (GFP) expression. CRLM, N=8 
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Figure 10-9. Tumour specific transgene (GFP) expression. CRLM, N=9 
 
 
Figure 10-10. Tumour specific transgene (GFP) expression. CRLM, N=10 
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11 Appendix C: Upregulation of CD86, CD11c and ClassIIDR 
following JX-59 infection in vitro 
 
Figure 11-1. Upregulation of CD14+veCD11c+ve phenotype following JX-594 
treatment in three healthy donors 
 
Figure 11-2. Upregulation of CD14+veCD86+ve phenotype following JX-594 
treatment in three healthy donors 
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Figure 11-3. No upregulation of CD14+veCD80+ve phenotype following JX-594 
treatment in three healthy donors 
 
 
 
Figure 11-4. Upregulation of CD14+veCIIDR+ve phenotype following JX-594 
treatment in three healthy donors 
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CD14/CIIDR((Donor(3)(
JX594(
0pfu/cell(
JX594(
0.1pfu/cell(
JX594(
1pfu/cell(
Reo((
1pfu/cell(
45.1%(
267.0(
26.9%(
260.4(
19.3%(
6.7(
8.8%(
10.2(
CD14(
Cl
as
s(I
I(D
R(
R1(
50.7%(
389.2(
32.7%(
362.1(
14.9%(
7.4(
1.8%(
16.3(
26.6%(
497.2(
42.2%(
837.9(
30.3%(
7.4(
0.8%(
8.0(
80.1%(
375.9(
4%(
331.4(
15.6%(
6.9(
0.4%(
5.2(
CD14/CIIDR((MI)(
JX594(
0pfu/cell(
JX594(
0.1pfu/cell(
JX594(
1pfu/cell(
Reo((
1pfu/cell(
35.2%( 20.8%(
38.8%( 5.2%(
63.3%( 6.4%(
29.6%( 0.7%(
60.2%( 0.2%(
39.5%( 0.04%(
24.2%( 12.9%(
62.5%( 0.3%(
CD14(
CI
ID
R(
CD14/CIIDR((RP)(
JX594(
0pfu/cell(
JX594(
0.1pfu/cell(
JX594(
1pfu/cell(
Reo((
1pfu/cell(
70.5%(
274.2(
4.6%(
232.0(
22.3%(
5.9(
2.7%(
6.7(
CD14(
CI
ID
R(
80.6%(
303.4(
2.9%(
311.3(
16.4%(
6.3(
0.2%(
8.9(
71.3%(
341.2(
4.3%(
503.8(
23.8%(
5.9(
0.6%(
9.7(
81.7%(
299.4(
0.3%(
239.6(
18.0%(
6.6(
0.1%(
10.0(
CD14/CIIDR((GS)(
JX594(
0pfu/cell(
JX594(
0.1pfu/cell(
JX594(
1pfu/cell(
Reo((
1pfu/cell(
42.6%(
230.4(
11.0%(
207.4(
42.4%(
6.5(
4.0%(
13.2(
CD14(
CI
ID
R(
48.1%(
257.1(
4.6%(
334.7(
46.9%(
7.2(
0.4%(
13.3(
26.6%(
282.4(
9.0%(
417.6(
63.5%(
5.8(
0.9%(
13.1(
62.9%(
251.8(
0.8%(
395.9(
36.3%(
7.7(
0.1%(
5.1(
CD14/CIIDR((Donor(2)(
JX594(
0pfu/cell(
JX594(
0.1pfu/cell(
JX594(
1pfu/cell(
Reo((
1pfu/cell(
58.3%(
218.9(
12.6%(
279.3(
17.5%(
9.1(
11.7%(
8.1(
CD14(
Cl
as
s(I
I(D
R(
R1(
58.2%(
264.9(
22.0%(
381.2(
18.6%(
8.2(
1.1%(
16.2(
44.0%(
318.5(
18.8%(
454.6(
35.6%(
7.1(
1.6%(
10.9(
85.1%(
264.3(
2.0%(
395.2(
12.6%(
10.1(
0.3%(
17.1(
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12 List of Suppliers 
 
AbD Serotec Endeavour House, Langford Business 
Park, Langford Lane, Kidlington, Oxon, 
OX5 1GE, UK 
Adams Healthcare Lotherton Way Garfotch, Leeds, West 
Yorkshire, LS25 2JY 
Alere Ltd. 
 
 
Alere Limited, Pepper Road, Hazel 
Grove, Stockport, Cheshire, SK7 5BW, 
UK 
Alpha Laboratories Ltd. 
 
40 Parham Drive, Eastleigh, Hampshire, 
SO50 4NU, UK 
ATCC Queens Road , Teddington, Middlesex, 
TW11 0LY , UK 
AXIS Shield Axis-Shield PoC AS, Kjelsåsveien 161, 
P.O. Box 6863 Rodeløkka, NO-0504, 
Oslo, Norway 
BD Biosciences The Danby Building, Edmund Halley 
Road, Oxford Science Park, Oxford, 
OX4 4DQ, UK 
BD Falcon Supplied by Scientific Laboratory 
Supplies 
Care Fusion Eurosurgical, Merrow Business Park, 
Surrey, Guildford, GU4 7WA, UK 
 
Corning Costar  Distributed by Sigma Aldrich Ltd. 
Dako Distributed by Alere Ltd. 
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Dupont Windham Road, Chilton Industrial 
Estate, SUDBURY, Suffolk, CO10 2XD, 
UK. 
Fisher Scientific UK Ltd. Bishop Meadow Road, Loughborough, 
Leicestershire, LE11 5RG, UK. 
Gibco Supplied by Life technologies Ltd. 
Grant Instruments Grant Instruments (Cambridge) Ltd, 
Shepreth, Cambridgeshire, SG8 6GB, 
UK. 
Greiner Bio-One Ltd. Brunel Way, Stroudwater Business 
Park, GL10 3SX, UK 
 
Invitrogen Supplied by Life Technologies 
Life Technologies Ltd 3 Fountain Drive, Inchinnan Business 
Park, Paisley PA4 9RF, UK 
Lorne Laboratories Lorne Laboratories Limited Unit 1 
Danehill Cutbush Park Industrial 
Estate Lower Earley Reading RG6 4UT 
 
Mabtech Box 1233, SE-131 28 Nacka Strand, 
Sweden 
Miltenyi Biotec Ltd. Almac House, Church Lane, Bisley, 
Surrey, GU24 9DR, UK 
Molecular Devices UK Unit 660 665, Eskdale Road, 
Wokingham, Berkshire, RG41 5TS, 
UK 
NIKON 5-21, Katsushima 1-chome, Shinagawa-
ku, Tokyo 140-0012, Japan 
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NHS Supplies Valley Point Valley Drive, Rugby , 
Warwickshire CV21 1TN, UK 
NuAire Inc. 2100 Fernbrook Lane N Plymouth, MN 
55447, USA 
Nunc® Distributed by Fisher Scientific 
PBL Interferon source 131 Ethel Rd West, Suite 6, Piscataway, 
NJ 08854, USA. 
Perkin Elmer Kelvin Close, Birchwood Science Park, 
Risley, Warrington, Cheshire WA3 7PB, 
UK 
 
 
 
Pharmingen See BD Biosciences 
R & D Systems Europe Ltd. 19 Barton Lane, Abingdon Science 
Park, Abingdon,OX14 3NB, UK 
Sanyo Sanyo Gallenkamp Plc., Monarch Way, 
Belton Park, Loughborough, LE11 5XG, 
UK 
 Sigma-Aldrich Ltd. Sigma Chemical Company, Fancy 
Road, Poole, Dorset, BH17 7NH, UK 
Swann-Morton Supplied by NHS Supplies 
Thermo Fisher Scientific Unit 5, The Ringway Centre, Edison Rd., 
Basingstoke, Hampshire, RG21 6YH, 
UK 
Weber Scientific 2732 Kuser Road, Hamilton, NJ 08691, 
USA 
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